

VOLUME 8

PAGES 1177 - 1342

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

BEFORE THE HONORABLE PHYLLIS J. HAMILTON, JUDGE

PLANNED PARENTHOOD	)	
FEDERATION OF AMERICA, INC.	)	
AND PLANNED PARENTHOOD	)	
GOLDEN GATE,	)	
	)	
PLAINTIFFS,	)	
	)	
VS.	)	NO. C 03-4872 PJH
	)	
JOHN ASHCROFT, ATTORNEY	)	MONDAY, APRIL 12, 2004
GENERAL OF THE UNITED	)	
STATES, IN HIS OFFICIAL	)	SAN FRANCISCO, CALIFORNIA
CAPACITY,	)	
	)	
DEFENDANT.	)	
	)	

REPORTER'S TRANSCRIPT OF PROCEEDINGS

APPEARANCES:

FOR PLAINTIFFS:	BINGHAM MCCUTCHEON LLP
	THREE EMBARCADERO CENTER
	SAN FRANCISCO, CALIFORNIA 94111-4003
BY:	BETH H. PARKER, ATTORNEY AT LAW
	DEBORAH ADLER, ESQUIRE
	PLANNED PARENTHOOD FEDERATION OF
	AMERICA
	434 W. 33RD STREET.
	NEW YORK, NEW YORK 10001
BY:	EVE C. GARTNER, ESQUIRE

(APPEARANCES CONTINUED ON NEXT PAGE)

REPORTED BY:	DIANE E. SKILLMAN, CSR 4909
	OFFICIAL COURT REPORTER

DIANE E. SKILLMAN, OFFICIAL COURT REPORTER, USDC (415) 552-5393

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

PLANNED PARENTHOOD FEDERATION OF  
AMERICA  
1780 MASSACHUSETTS AVENUE, N.W.  
WASHINGTON, D.C. 200036  
BY: HELENE T. KRASNOFF, ESQUIRE

FOR INTERVENOR OFFICE OF THE CITY ATTORNEY  
PLAINTIFFS CITY 1390 MARKET STREET, SUITE 1008  
AND COUNTY OF SAN FRANCISCO, CALIFORNIA 94102  
SAN FRANCISCO: BY: KATHLEEN SUZANNE MORRIS,  
ALEETA MARIE VAN RUNKLE,  
DEPUTY CITY ATTORNEYS

FOR DEFENDANT: U.S. DEPARTMENT OF JUSTICE  
20 MASSACHUSETTS AVENUE, N.W. ROOM 7128  
WASHINGTON, D.C. 20530  
BY: MARK THOMAS QUINLIVAN  
W. SCOTT SIMPSON,  
KAIJA MARIE CLARK,  
ASSISTANT U.S. ATTORNEYS

1 MONDAY, APRIL 12, 2004

8:30 A.M.

2

3

P R O C E E D I N G S

4

5

6

7

8

9

THE COURT: ALL RIGHT. GOOD MORNING. BEFORE WE GET STARTED WITH THE FIRST WITNESS, I DO WANT TO GO OVER WITH YOU MY RULINGS ON THE VARIOUS DIFFERENT OBJECTIONS THAT YOU ALL SUBMITTED TO US LAST WEEK. I REVIEWED ALL OF THE ARTICLES AND STUDIES OVER THE WEEKEND AND THE TRANSCRIPTS. WE HAVE FOUR MATTERS THAT ARE PENDING.

10

YES? IS THERE A QUESTION?

11

MS. PARKER: NO.

12

13

14

15

16

17

THE COURT: WE HAVE FOUR MATTERS PENDING. ONE IS THE ADMISSIBILITY OF THE STUDIES BY DRS. DREY AND CHASEN. ONE IS THE ARTICLE BY DR. SPRANG. AND THEN, THERE ARE TWO REQUESTS TO STRIKE TESTIMONY. ONE, I BELIEVE, PORTION IS THE TESTIMONY OF DR. WESTHOFF, AND THE OTHER IS THE TESTIMONY OF DR. DOE. STARTING FIRST WITH THE ARTICLES --

18

19

20

MS. PARKER: YOUR HONOR, WE HAVE LOOKED AT THAT ISSUE OVER THE WEEKEND, AND WE WOULD BE WILLING TO WITHDRAW OUR MOTION TO HAVE THOSE ARTICLES COME INTO EVIDENCE.

21

22

THE COURT: YOU WISH TO WITHDRAW YOUR MOTION TO HAVE ANY --

23

24

MS. PARKER: OF THE DREY AND CHASEN ARTICLES PUT INTO EVIDENCE.

25

THE COURT: WHAT ABOUT THE SPRANG ARTICLE? ARE YOU

1 WITHDRAWING YOUR MOTION FOR THAT?

2 MR. SIMPSON: YES, YOUR HONOR.

3 THE COURT: OKAY. I CERTAINLY WISH YOU WOULD HAVE  
4 TOLD ME. I SPENT A GREAT DEAL OF MY TIME OVER THE WEEKEND --

5 MR. SIMPSON: WELL, YOUR HONOR, I'M SORRY. OUR  
6 WITHDRAWAL IS BASED ONLY ON PLAINTIFFS' WITHDRAWAL. I BELIEVE  
7 OUR DISCUSSION ON FRIDAY WAS THAT THE ONLY BASIS FOR BRINGING  
8 IN THE SPRANG ARTICLE WOULD BE IF THE COURT WERE GOING TO GRANT  
9 PLAINTIFFS' MOTION. I HAD NOT PLANNED TO WITHDRAW OUR REQUEST.

10 IN FACT, IF THE COURT IS INCLINED TO GRANT IT,  
11 THAT'S CERTAINLY FINE WITH US.

12 THE COURT: NO, I WAS NOT INCLINED TO GRANT IT.

13 INTERESTING. ALL RIGHT.

14 NOW, WITH REGARD, THEN, TO THE DEPOSITIONS, THE  
15 FIRST ONE WAS DR. DOE'S TESTIMONY REGARDING THE EFFICACY OF THE  
16 DIGOXIN AS OPPOSED TO THE SAFETY OF THE DIGOXIN. THE DEFENSE  
17 ARGUING THAT ITS CROSS WAS LIMITED TO ONLY QUESTIONS ABOUT THE  
18 SAFETY.

19 I HAVE READ YOUR PAPERS. I DO AGREE WITH THE  
20 DEFENSE THE QUESTIONS REGARDING THE EASE OF THE PROCEDURE ARE  
21 NOT TANTAMOUNT TO QUESTIONS ABOUT THE EFFICACY OF CAUSING FETAL  
22 DEMISE. I DID READ THE TRANSCRIPT OF DR. DOE IN ITS ENTIRETY  
23 ON THIS SUBJECT, AND IT SEEMS TO ME THE DEFENDANTS ARE PARSING  
24 IT A LITTLE BIT TOO FINALLY.

25 I THINK A FAIR ARGUMENT COULD BE THAT ASKING HIM

1 QUESTIONS ABOUT THE USE OF DIGOXIN AT ALL COULD GIVE RISE TO  
2 QUESTIONS ABOUT SAFETY AND EFFICACY. SIMILARLY, I THINK THAT  
3 ASKING QUESTIONS ABOUT THE DREY STUDY, THAT THE DREY STUDIES  
4 WHICH WERE AIMED TOWARDS ASSESSING EFFICACY AND SAFETY COULD  
5 OPEN THE DOOR.

6 BUT, MORE SIGNIFICANTLY, I THINK THAT THERE WAS A  
7 QUESTION ASKED BY THE DEFENSE COUNSEL AT PAGE 453, LINES NINE  
8 THROUGH 14, ESSENTIALLY THAT THE QUESTION WAS:

9 "IF A DOCTOR ENSURED FETAL DEMISE BY USING  
10 DIGOXIN OR KCL WOULD THAT PHYSICIAN BE IN VIOLATION  
11 OF THE ACT."

12 WHILE I CERTAINLY THINK THAT FAIRLY OPENS THE DOOR  
13 TO QUESTIONS ABOUT WHETHER OR NOT USING DIGOXIN DOES, INDEED,  
14 ENSURE FETAL DEMISE, WHICH IS A CONTESTED ISSUE IN THIS CASE.  
15 SO I AM DENYING THE MOTION TO STRIKE DR. DOE'S TESTIMONY. I  
16 BELIEVE THE REDIRECT WAS APPROPRIATE GIVEN THE NATURE OF CROSS.

17 AND WITH REGARD TO DR. WESTHOFF'S TESTIMONY, THE  
18 OBJECTION, AS I UNDERSTAND IT, HAD TO DO WITH ALSO THE QUESTION  
19 OF DIGOXIN. PLAINTIFFS HAD AGREED THAT, INDEED, THE QUESTION  
20 AND ANSWER AT PAGE 819, LINE 20, THROUGH 820, LINE 5 SHOULD,  
21 INDEED, BE STRICKEN.

22 AND THE REAL TESTIMONY WAS IN THE ENSUING 20 LINES  
23 OR SO, WHETHER OR NOT THE DECLARATION WAS SUFFICIENT.

24 I FIND THE DECLARATION IS SUFFICIENT SUCH THAT THOSE  
25 QUESTIONS SHOULD REMAIN. AND WITH RESPECT TO THE SPECIFIC

1 LINES AT 12 THROUGH 14 AND 17 THROUGH 20 ON PAGE 820, THAT THE  
2 DEFENDANT OBJECTED TO WITH REGARD TO THE ACTUAL FACTS OF WHAT  
3 OCCURRED ON THAT SPECIFIC OCCASION THAT DR. WESTHOFF HAD USED  
4 DIGOXIN I FIND THAT THOSE LINES SHOULD BE INCLUDED JUST AS THAT  
5 ENTIRE PORTION IS, BECAUSE IT'S PURELY FACTUAL DATA.

6 IT IS PURELY FACTUAL DATA DESCRIBING WHAT OCCURRED  
7 ON THE ONE TIME THAT SHE DID USE IT. I AM DENYING THE DEFENSE  
8 REQUEST TO STRIKE DR. WESTHOFF'S TESTIMONY, AS WELL.

9 ALL RIGHT. SINCE YOU NO LONGER -- NEITHER SIDE  
10 WANTS THE ARTICLES IN, WE ARE READY TO GO.

11 MS. GARTNER: I THINK WE WILL PROBABLY DISCUSS THE  
12 SAME ISSUE.

13 I THINK, YOUR HONOR, WE WANTED TO DISCUSS WITH YOU  
14 WHAT YOUR HONOR HAD IN MIND WITH RESPECT TO CLOSING ARGUMENTS  
15 ON FRIDAY. YOU SUGGESTED ON THE FIRST DAY THAT YOU WOULD  
16 ENTERTAIN THOSE. I THINK BOTH SIDES WOULD LIKE TO PRESENT  
17 CLOSING ARGUMENTS. BUT WE WANTED TO TALK ABOUT HOW THAT WOULD  
18 FIT IN WITH DR. CHASEN'S TESTIMONY AND HOW MUCH TIME YOUR HONOR  
19 WAS PREPARED TO GIVE US.

20 THE COURT: HOW MUCH TIME DO YOU ANTICIPATE THAT DR.  
21 CHASEN WILL TAKE ON FRIDAY?

22 MR. SIMPSON: ACTUALLY, YOUR HONOR, OUR DESIRE TO  
23 PRESENT CLOSING ARGUMENT IS BASED ONLY ON PLAINTIFFS' DESIRE TO  
24 DO SO. WE ACTUALLY DON'T THINK CLOSING ARGUMENT IS NECESSARY,  
25 BUT CERTAINLY IF PLAINTIFFS ARE GOING TO PRESENT CLOSING

1 ARGUMENT WE WOULD WANT TO DO SO, AS WELL.

2 THE COURT: WELL, ACTUALLY, I AM A LITTLE INTERESTED  
3 IN HEARING WHAT YOUR OVERALL PERSPECTIVE IS ON THE EVIDENCE. I  
4 KNOW YOU HAVE HEARD IT ALL BEFORE BECAUSE YOU HAVE TAKEN THE  
5 DEPOSITIONS AND YOU KNOW WHAT THE WITNESSES ARE GOING TO  
6 TESTIFY TO.

7 I WOULD LIKE TO HEAR, AFTER IT'S ALL IN, WHAT YOU  
8 BELIEVE THAT THE EVIDENCE BEFORE THE COURT HAS SHOWN. SO I  
9 WOULD LIKE TO HAVE CLOSING ARGUMENTS.

10 THE QUESTION IS WHETHER OR NOT YOU CAN DO THEM ON  
11 FRIDAY OR WHETHER OR NOT WE NEED SOME OTHER TIME. DO YOU THINK  
12 THAT DR. CHASEN WILL TAKE THE ENTIRE DAY?

13 MS. PARKER: NO, YOUR HONOR. I THINK DR. CHASEN'S  
14 DIRECT EXAMINATION WILL PROBABLY TAKE TWO HOURS IS MY BEST  
15 GUESS AT THIS TIME.

16 THE COURT: AND DOES CROSS TAKE A SIMILAR AMOUNT OF  
17 TIME?

18 MR. SIMPSON: I SUPPOSE SO, YOUR HONOR. I BELIEVE  
19 IT TOOK ALL DAY IN NEW YORK.

20 MS. GARTNER: THEY HAVE A MORE SPREAD OUT DAY. AND  
21 READING THE TRANSCRIPT, THERE IS A LOT MORE QUESTIONS BY THE  
22 COURT AND A LOT MORE OBJECTIONS. IT TAKES MUCH LONGER FOR ALL  
23 THE WITNESSES IN NEW YORK.

24 THE COURT: DO YOU WANT TO GIVE YOUR ARGUMENTS,  
25 ASSUMING WE HAVE A FULL DAY ON FRIDAY? WE CAN GO TO

1 4:00 O'CLOCK AND TAKE A LUNCH BREAK. WE CAN FINISH WITH DR.  
2 CHASEN, LIKE WE DID LAST MONDAY, AND THEN TAKE A LUNCH BREAK  
3 AND COME BACK AND GIVE YOUR ARGUMENTS, AN HOUR OR SO EACH, I  
4 WOULD IMAGINE YOU WOULD NEED.

5 WOULD YOU LIKE TO DO THAT OR WOULD YOU LIKE TO COME  
6 BACK ON MONDAY?

7 MR. SIMPSON: WE WOULD MUCH RATHER STAY ON FRIDAY.

8 THE COURT: YOU WOULD MUCH RATHER HAVE A LONGER DAY  
9 ON FRIDAY?

10 MS. GARTNER: YES, YOUR HONOR. I THINK MANY OF US  
11 WOULD LIKE TO GO HOME.

12 THE COURT: ALL RIGHT. I AM CERTAINLY WILLING TO DO  
13 THAT ON FRIDAY SO WE CAN CONCLUDE THE MATTER.

14 I DO WANT YOU ALL TO ADDRESS ONE OF THE ISSUES THAT  
15 I AM STILL THINKING ABOUT FROM THE PRETRIAL BRIEFS THAT YOU  
16 GAVE ME ON THE DEFERENCE ISSUE. YOU ALL HAVE THOROUGHLY  
17 BRIEFED THE ISSUE, SO I DON'T EXPECT THAT I WILL HEAR A LOT  
18 ABOUT THAT, ALTHOUGH YOU CAN CERTAINLY ARGUE WHATEVER -- YOU  
19 CAN ARGUE WHATEVER YOU WISH TO FRIDAY, BUT I AM NOT ASKING YOU  
20 TO SUBMIT ANY FURTHER BRIEFING.

21 BUT I WOULD LIKE THE DEFENDANT, HAVING REVIEWED YOUR  
22 PROPOSED FINDINGS OF FACT AND CONCLUSIONS OF LAW OVER THE LAST  
23 WEEK, I AM A LITTLE PUZZLED BY THE POSITION ADVANCED BY THE  
24 DEFENSE ON THE -- WITH REGARD TO HOW THE COURT IS TO VIEW THE  
25 CONGRESSIONAL RECORD IN THE CASE.



1           IN YOUR -- I BELIEVE IT WAS IN THE BRIEF ON  
2 DEFERENCE, THE DEFENSE HAS TAKEN THE POSITION THAT ESSENTIALLY  
3 THE TRIAL RECORD SUPPLEMENTS THE CONGRESSIONAL FINDINGS. AND I  
4 AM JUST A LITTLE BIT CONFUSED ABOUT HOW THAT REALLY IS SUPPOSED  
5 TO WORK, BECAUSE YOU -- BOTH SIDES HAVE ARGUED THAT THE  
6 CONGRESSIONAL FINDINGS AREN'T ADMISSIBLE EXCEPT THAT THE COURT  
7 MAY JUDICIALLY NOTICE THE RECORD. BUT IS NOT TO ACCEPT IT FOR  
8 THE TRUTH OF THE MATTER ASSERTED.

9           SO I AM NOT LOOKING AT THE CONGRESSIONAL RECORD FOR  
10 THE TRUTH OF WHAT IS CONTAINED THEREIN, YET I AM LOOKING AT THE  
11 EVIDENCE THAT HAS BEEN PRESENTED BEFORE ME, FOR THE TRUTH OF  
12 WHAT IS PRESENTED, I AM NOT EXACTLY SURE HOW WHAT HAPPENS HERE  
13 SUPPLEMENTS A RECORD THAT I AM ONLY NOTICING.

14           AND YOU ALL HAVE NOT EXPLAINED THAT. SO MAYBE YOU  
15 CAN GIVE THAT SOME THOUGHT AND ADDRESS IT ON FRIDAY IN YOUR  
16 CLOSING ARGUMENTS, BECAUSE WHILE I FOUND YOUR BRIEFS ON THE  
17 AMOUNT OF DEFERENCE FOR CONGRESS INTERESTING AND SOMEWHAT  
18 HELPFUL, NEITHER SIDE, I BELIEVE, ADEQUATELY ADDRESSED THE  
19 INTERPLAY BETWEEN THE FINDINGS BEFORE CONGRESS AND THE FINDINGS  
20 THAT THE COURT WILL MAKE AS I WOULD FOLLOWING ANY BENCH TRIAL  
21 IN THIS CASE.

22           I AM NOT EXACTLY SURE. WE HAVE THESE TWO PARALLEL  
23 TRACKS, BUT I AM NOT EXACTLY SURE THEY ARE REALLY EVEN  
24 PARALLEL. OKAY?

25           ANOTHER QUESTION I WOULD LIKE YOU TO ADDRESS, AS

1 WELL, IS SIMPLY THE QUALITY OF THE RECORD BEFORE -- THE QUALITY  
2 OF THE EVIDENCE OF THE RECORD BEFORE CONGRESS VERSUS THE  
3 QUALITY OF THE EVIDENCE THAT HAS BEEN PRESENTED HERE IN COURT.

4 I MEAN, I HAVE LOOKED AT IT AND IT SEEMS TO BE  
5 SIMILAR IN MANY RESPECTS. SOME OF THE SAME DOCTORS TESTIFIED  
6 BEFORE CONGRESS HAS TESTIFIED HERE. SOME OF THE SAME MATERIAL  
7 THAT THEY HAVE REFERRED TO IS ESSENTIALLY WHAT CONGRESS WAS --  
8 INDEED, CONGRESS FACED ESSENTIALLY THE SAME KIND OF RECORD THAT  
9 THE COURT HAS.

10 SO I WOULD LIKE SOME COMMENT ON THAT, AS WELL. AND  
11 AS THE WEEK GOES ON IF OTHER QUESTIONS COME UP I WILL TELL YOU  
12 AND YOU WILL HAVE A LITTLE TIME TO THINK ABOUT IT BEFORE YOUR  
13 ARGUMENTS ON FRIDAY. OKAY?

14 ANY OTHER QUESTIONS OR THINGS WE SHOULD ADDRESS?

15 MR. QUINLIVAN: YES, YOUR HONOR.

16 MS. VAN RUNKLE: YOUR HONOR, I WANTED TO LET THE  
17 COURT KNOW THE CITY DOES PLAN ON PRESENTING CLOSING ARGUMENT.

18 THE COURT: SURE. YOU MAY.

19 MR. SIMPSON: YOUR HONOR, THE COURT SAID "ONE HOUR  
20 PER SIDE"?

21 THE COURT: WELL, WHAT I WAS THINKING OF -- WE WILL  
22 HAVE THE AFTERNOON. WE WILL TAKE THE LUNCH BREAK, AND I WOULD  
23 LIKE TO GET THE ARGUMENTS IN. ASSUMING WE FINISH WITH DR.  
24 CHASEN BY NOON, IF WE START AT 8:30 PERHAPS WE CAN, OR SOMETIME  
25 THEREABOUT, SAY BETWEEN ONE AND FOUR FOR CLOSING. THAT IS

1 THREE HOURS. THE CITY AND COUNTY OF SAN FRANCISCO HAS NOT  
2 REALLY PARTICIPATED TO A GREAT EXTENT AND HAS NOT REQUESTED  
3 ADDITIONAL TIME FOR ADDITIONAL WITNESSES. AND SO I WOULD  
4 CERTAINLY LIKE TO AFFORD THEM SOME OPPORTUNITY TO PARTICIPATE  
5 BY MAKING A CLOSING STATEMENT.

6 SO WHAT I WOULD LIKE IS TO PERHAPS AFFORD EACH OF  
7 YOU AN HOUR AND YOU AN HOUR.

8 IF YOU THINK THAT THAT IS NOT REALLY ENOUGH, THEN  
9 MAYBE YOU CAN TALK ABOUT IT AND SEE IF YOU CAN SPLIT UP A  
10 THREE-HOUR CHUNK OF TIME. OKAY?

11 MR. QUINLIVAN.

12 MR. QUINLIVAN: YES, JUST ONE MINOR MATTER, YOUR  
13 HONOR. I JUST WANTED TO ALERT THE COURT THAT ON THURSDAY OF  
14 THIS WEEK WE WILL BE JOINED BY PREEYA NORONHA, WHO IS A  
15 CO-COUNSEL IN THIS CASE FROM THE NEBRASKA CASE.

16 AND MS. NORONHA WILL BE EXAMINING DR. ANAND ON  
17 THURSDAY.

18 THE COURT: YES, ALL RIGHT. ARE YOU READY WITH YOUR  
19 NEXT WITNESS, MS. CLARK?

20 MS. CLARK: THE DEFENSE CALLS DR. ELIZABETH  
21 SHADIGIAN.

22 DR. ELIZABETH M. SHADIGIAN  
23 CALLED AS A WITNESS FOR THE DEFENDANT, HAVING BEEN DULY SWORN,  
24 TESTIFIED AS FOLLOWS:

25 THE WITNESS: I DO.

1 THE CLERK: PLEASE TAKE THE STAND.

2 PLEASE STATE YOUR NAME FOR THE COURT.

3 THE WITNESS: MY NAME IS DR. ELIZABETH SHADIGIAN.

4 THE CLERK: SPELL YOUR LAST NAME.

5 THE WITNESS: S-H-A-D-I-G-I-A-N.

6 THE CLERK: THANK YOU.

7 DIRECT EXAMINATION

8 BY MS. CLARK:

9 Q. GOOD MORNING, DR. SHADIGIAN.

10 A. GOOD MORNING.

11 Q. COULD YOU PLEASE TELL THE COURT WHAT YOU DO FOR A LIVING?

12 A. YES. I'M A FACULTY MEMBER AT THE UNIVERSITY OF MICHIGAN IN  
13 THE SCHOOL OF MEDICINE, AND I'M A PHYSICIAN, AN OBSTETRICIAN  
14 GYNECOLOGIST THAT TAKES CARE OF PREGNANT WOMEN AND WOMEN WHO  
15 AREN'T PREGNANT FOR THEIR GYNECOLOGICAL NEEDS.

16 Q. HOW LONG HAVE YOU BEEN AT THE UNIVERSITY OF MICHIGAN?

17 A. I WILL BE COMPLETING MY 10TH YEAR AT THE UNIVERSITY OF  
18 MICHIGAN IN JUNE OF 2004.

19 MS. CLARK: MAY I APPROACH, YOUR HONOR?

20 THE COURT: YES.

21 BY MS. CLARK:

22 Q. I'VE JUST SHOWN YOU WHAT HAS BEEN MARKED AS DEFENDANT'S  
23 EXHIBIT A-6. IS THIS A COPY OF YOUR C.V.?

24 A. YES, IT IS.

25 Q. DID YOU CREATE IT?

1 A. YES, I DID.

2 Q. DOES IT ACCURATELY REFLECT YOUR EDUCATION, WORK EXPERIENCE  
3 AND PUBLICATIONS?

4 A. YES, IT DOES.

5 MS. CLARK: DEFENDANT MOVES TO ADMIT INTO EVIDENCE  
6 DEFENDANT'S EXHIBIT A-6.

7 THE COURT: ANY OBJECTION?

8 MS. PARKER: NO.

9 MS. KRASNOFF: NO OBJECTION.

10 THE COURT: ADMITTED.

11 THE CLERK: A-6 INTO EVIDENCE.

12 (DEFENDANT'S EXHIBIT A-6  
13 WAS RECEIVED IN EVIDENCE.)

14 BY MS. CLARK:

15 Q. DR. SHADIGIAN, WILL YOU EXPLAIN BRIEFLY YOUR EDUCATIONAL  
16 BACKGROUND?

17 A. YES. I WENT TO PURDUE UNIVERSITY FOR UNDERGRADUATE  
18 EDUCATION AND RECEIVED A BACHELOR OF SCIENCE DEGREE IN  
19 CHEMISTRY.

20 AND THEN, I WENT ON TO THE JOHNS HOPKINS SCHOOL OF  
21 MEDICINE AND RECEIVED MY MEDICAL DEGREE IN 1990. AND THEN,  
22 RECEIVED POSTGRADUATE TRAINING AT AN OBSTETRICS AND GYNECOLOGY  
23 RESIDENCY PROGRAM IN BALTIMORE CALLED FRANKLIN SQUARE HOSPITAL  
24 CENTER, AS WELL AS THE JOHNS HOPKINS HOSPITAL.

25 Q. DO YOU HAVE ANY BOARD CERTIFICATIONS?

1 A. YES.

2 Q. WHAT ARE THOSE CERTIFICATIONS?

3 A. I AM BOARDED IN OBSTETRICS AND GYNECOLOGY.

4 Q. AND ARE YOU LICENSED TO PRACTICE MEDICINE IN MICHIGAN?

5 A. YES, I AM.

6 Q. AND WAS IT IMMEDIATELY AFTER YOUR RESIDENCY THAT YOU CAME

7 TO WORK AT THE UNIVERSITY OF MICHIGAN?

8 A. YES. I BECAME A FACULTY MEMBER BASICALLY RIGHT AFTER

9 RESIDENCY.

10 Q. WHAT WAS YOUR INITIAL POSITION?

11 A. I WAS CLINICAL ASSISTANT PROFESSOR OF OBSTETRICS AND

12 GYNECOLOGY.

13 Q. AND WHAT IS YOUR POSITION NOW?

14 A. I'M CLINICAL ASSOCIATE PROFESSOR OF OBSTETRICS AND

15 GYNECOLOGY.

16 Q. DOES THAT MEAN YOU HAVE BEEN PROMOTED SINCE YOU HAVE BEEN

17 AT THE UNIVERSITY OF MICHIGAN?

18 A. YES, IN 2002 I WAS PROMOTED.

19 Q. DR. SHADIGIAN, COULD YOU PLEASE EXPLAIN WHAT YOU DO AS A

20 CLINICAL ASSOCIATE PROFESSOR AT THE UNIVERSITY OF MICHIGAN,

21 FIRST WITH RESPECT TO YOUR CLINICAL PRACTICE?

22 A. YES. BASICALLY, I DO THREE THINGS AT THE UNIVERSITY OF

23 MICHIGAN. ONE IS ACTUALLY TAKE CARE OF WOMEN IN TERMS OF MY

24 SCOPE OF PRACTICE IN OBSTETRICS AND GYNECOLOGY. SO THAT IS THE

25 CLINICAL CARE PIECE.

1 I ALSO TEACH MEDICAL STUDENTS AND RESIDENTS, AND I  
2 ALSO DO RESEARCH IN VARIOUS SUBJECTS.

3 Q. COULD YOU DESCRIBE THE KINDS OF PATIENTS THAT YOU TREAT?

4 A. YES, I CERTAINLY CAN. I HAVE A BROAD RANGE OF PRACTICE.  
5 I'M A GENERALIST. I DO HIGH RISK OBSTETRICS, SO I TAKE CARE OF  
6 WOMEN WITH DIFFERENT MEDICAL DISEASES IN PREGNANCY SUCH AS HIGH  
7 BLOOD PRESSURE, DIABETES, CERTAIN CONNECTIVE TISSUES DISORDERS  
8 OR RHEUMATOLOGICAL DISORDERS.

9 I TAKE CARE OF TWIN PREGNANCIES, AND I TAKE CARE OF  
10 NORMAL LOW RISK PREGNANCIES, AS WELL. I DO PRENATAL CARE OF  
11 THESE WOMEN, AS WELL AS THEIR DELIVERY AND POSTPARTUM OR  
12 AFTERCARE AFTER A PREGNANCY.

13 AND, IN ADDITION, I DO GENERALIST GYNECOLOGY, SO I  
14 TAKE CARE OF PATIENTS WITH CHRONIC PELVIC PAIN. I OPERATE ON  
15 WOMEN WHO NEED CERTAIN SURGICAL PROCEDURES. IN ADDITION, I DO  
16 FAMILY PLANNING, SUCH AS DISCUSS WITH WOMEN IF THEY WANT TO  
17 AVOID PREGNANCY WHAT OPTIONS THEY HAVE. AND ALSO JUST DO WELL  
18 WOMEN GYNECOLOGICAL CARE.

19 Q. APPROXIMATELY HOW MANY BABIES HAVE YOU DELIVERED IN THE  
20 LAST YEAR?

21 A. PROBABLY BETWEEN 100 AND 150.

22 Q. HOW MANY OF THOSE ARE VAGINAL DELIVERIES?

23 A. PROBABLY ABOUT EIGHTY PERCENT OF THEM.

24 Q. AND TWENTY PERCENT BY CESAREAN SECTION?

25 A. YES.

1 Q. AND HAVE YOU EVER VAGINALLY DELIVERED BABIES IN A BREECH  
2 PRESENTATION?

3 A. YES, I HAVE.

4 Q. WHEN WAS THE LAST TIME YOU DID THAT?

5 A. PROBABLY ABOUT TWO MONTHS AGO.

6 Q. CAN YOU BRIEFLY DESCRIBE A VAGINAL DELIVERY WHEN THERE IS A  
7 BREECH PRESENTATION?

8 A. YES. FIRST WE ASSESS WHAT PART OF THE BABY IS COMING DOWN,  
9 SO IF IT IS ACTUALLY THE FEET OR THE BOTTOM OR ONE FOOT OR TWO  
10 FEET AND WHERE THE FEET ARE WITH RESPECT TO THE BOTTOM.

11 AND THEN, WE GO AHEAD AND DELIVER THE PRESENTING  
12 PART. SO IF IT'S THE BOTTOM, WE WILL DELIVER THAT, AND THEN WE  
13 BRING THE FEET OUT. WE DELIVER UP TO ABOUT THE NAVEL AND THEN  
14 WE PULL THE BABY GENTLY DOWN IN A TOWEL, AND THEN WE REACH UP  
15 AND PUT OUR FINGERS DOWN THE HUMERUS OR UPPER ARM AND BASICALLY  
16 HOOK NEAR THE ELBOW THE BABY'S ARM AND HAVE IT COME OUT.

17 AND THEN, WE ROTATE THE BABY AND BRING OUT THE OTHER  
18 ARM. AND THEN, ONCE THE HEAD IS DELIVERED, ONCE THE -- EXCUSE  
19 ME -- THE SHOULDERS ARE DELIVERED, THEN WE WOULD GO AHEAD AND  
20 PROCEED TO DELIVER THE BABY'S HEAD. AND BASICALLY WE WANT TO  
21 DEFLEX OR TIP DOWN THE HEAD TO REDUCE THE DIAMETER OF THE  
22 BABY'S HEAD COMING OUT.

23 Q. ARE MOST OF THE PATIENTS THAT YOU SEE, ARE MOST OF THEM  
24 REFERRALS TO YOU?

25 A. SOME ARE REFERRALS BUT SOME ARE PATIENTS. I HAVE BEEN



1 THERE FOR 10 YEARS NOW, SO I HAVE A LOT OF WOMEN I HAVE  
2 FOLLOWED FOR MANY YEARS.

3 Q. DO YOU EVER REFER PATIENTS TO MATERNAL FETAL MEDICINE  
4 SPECIALISTS?

5 A. YES, I DO.

6 Q. WHAT KIND KINDS OF PATIENTS DO YOU REFER TO MFM'S?

7 A. THERE ARE SOME WOMEN WITH MORE SEVERE MEDICAL PROBLEMS,  
8 SUCH AS COMPLICATED CARDIAC DISEASE, WOMEN WHO MAY HAVE  
9 TRIPLETS OR QUADS, AND THREE OR FOUR BABIES INSIDE.

10 IN ADDITION, THERE ARE CERTAIN CONNECTIVE TISSUE  
11 DISORDERS LIKE SEVERE LUPUS, WHICH I WOULD REFER BECAUSE OF  
12 THEIR SPECIALIZED TRAINING AS WELL AS WOMEN WHO ARE HIV  
13 POSITIVE.

14 Q. DR. SHADIGIAN, YOU MENTIONED THAT YOU PROVIDE FAMILY  
15 PLANNING TO YOUR PATIENTS. WHAT KIND OF FAMILY PLANNING DO YOU  
16 PROVIDE TO THEM?

17 A. BASICALLY I PROVIDE THE FULL RANGE OF FAMILY PLANNING, SO  
18 ANYWHERE FROM EXPLAINING HOW NATURAL FAMILY PLANNING WORKS,  
19 OFFERING THEM BARRIER CONTRACEPTIVES SUCH AS DIAPHRAGMS AND  
20 CONDOMS, THROUGH BIRTHS CONTROL PILLS, INTRAUTERINE DEVICES AND  
21 STERILIZATION.

22 Q. DOCTOR, ARE THERE OCCASIONS WHEN CARING FOR A PATIENT YOU  
23 HAVE NEEDED TO TERMINATE A PREGNANCY?

24 A. YES, THERE HAVE BEEN.

25 Q. AND IN THOSE INSTANCES HAVE YOU EVER NEEDED TO TERMINATE A

1 PREGNANCY WHERE THE FETUS WAS ALIVE? THAT THE TERMINATION --  
2 EXCUSE ME -- WAS NECESSARY TO TREAT A MATERNAL HEALTH  
3 CONDITION?

4 A. YES, I HAVE.

5 Q. WHAT REASONS HAVE YOU NEEDED TO TERMINATE A PREGNANCY?

6 A. THERE IS A WIDE VARIETY OF REASONS. ONE EXAMPLE MIGHT BE  
7 AN INFECTION IN THE MOTHER'S UTERUS OR AROUND THE BABY CALLED  
8 CHORIOAMNIONITIS. THERE ARE OTHER MEDICAL DISORDERS LIKE  
9 PREECLAMPSIA WHEN THERE IS HIGH BLOOD PRESSURE AND SWELLING IN  
10 THE WOMAN AS WELL AS PROTEIN IN THE URINE THAT MAY NECESSITATE  
11 AN EARLIER BIRTH.

12 AND THEN, THERE MAY BE SOME OTHER SITUATIONS WHERE A  
13 WOMAN MAY HAVE CANCER AND NEED TO INITIATE CHEMOTHERAPY AND THE  
14 BABY IS A FAR ENOUGH ALONG TO BE DELIVERED TO HELP CARE FOR THE  
15 MOTHER.

16 Q. DR. SHADIGIAN, HAVE YOU EVER DIAGNOSED FETAL ANOMALIES IN  
17 THE PREGNANT WOMEN THAT YOU HAVE TREATED?

18 A. YES.

19 Q. WHAT KINDS OF FETAL ANOMALIES HAVE YOU DETECTED?

20 A. AGAIN, A WIDE VARIETY IN THE LAST 14 YEARS. SOME THINGS  
21 ARE GENETIC LIKE TRISOMY 21, OR 18 OR 13. TURNER'S SYNDROME IS  
22 ANOTHER EXAMPLE OF A KIND OF GENETIC PROBLEM.

23 AND THEN, THERE ARE ACTUAL STRUCTURAL PROBLEMS, SO  
24 THINGS LIKE HAVING THE BOWELS OUTSIDE THE BABY, SUCH AS  
25 ENCEPHALOCELE OR GASTROSCHISIS ARE OTHER EXAMPLES OF ANOMALIES.

1           IN ADDITION, I HAVE TAKEN CARE OF A MOTHER WITH  
2 CONJOINED TWINS, WHICH IS WHERE INSTEAD OF TWO BABIES ARE  
3 SEPARATED THEY WERE CONNECTED BOTH AT THE CHEST WALL AND  
4 ABDOMEN, AS WELL.

5 Q. THROUGH YOUR TRAINING AND BACKGROUND AND YOUR CLINICAL  
6 EXPERIENCE, HAVE YOU BECOME FAMILIAR WITH DIFFERENT METHODS OF  
7 TERMINATING PREGNANCY?

8 A. YES, I HAVE.

9 Q. WHAT METHODS HAVE YOU UTILIZED TO TERMINATE PREGNANCY?

10 A. THE FULL RANGE OF METHODS ARE -- OR WHAT I WOULD USE  
11 GENERALLY, SOME THINGS ARE AS COMMON AND SIMPLE AS A CESAREAN  
12 SECTION DONE EARLIER THAN USUAL. AND OTHER WOULD BE PROCEDURES  
13 SUCH AS D&C'S, D&E'S, WHICH IS DILATION AND EVACUATION AND ALSO  
14 MEDICAL INDUCTION OF PREGNANCY. I SHOULD SAY OF LABOR AND  
15 PREGNANT.

16 Q. TAKING THE D&C FIRST, WHAT DO YOU MEAN BY "D&C"?

17 A. THE LETTERS D&C, THE ACRONYM STAND FOR DILATION AND  
18 CURETTAGE, WHICH IS THE FRENCH WORD "TO SCRAPE." AND SO THAT  
19 MEANS DILATING OR OPENING THE CERVIX OF A WOMAN AND THEN GOING  
20 AHEAD AND REMOVING THE CONTENTS OF THE UTERUS BY SHARP OR  
21 SUCTION CURETTAGE.

22 Q. AND WHAT IS YOUR EXPERIENCE WITH D&C -- WITH D&C'S GOING  
23 BACK TO MEDICAL SCHOOL?

24 A. IN MEDICAL SCHOOL I OBSERVED SEVERAL D&C'S ON LIVE BABIES  
25 FOR TERMINATION OF PREGNANCY THAT WERE ELECTIVE. HOWEVER, I

1 DIDN'T DIRECTLY PARTICIPATE BY HOLDING INSTRUMENTS. INSTEAD, I  
2 TOOK MY TRAINING IN THAT ON BABIES THAT HAD ALREADY DIED.

3 Q. AND APPROXIMATELY D&C'S HAVE YOU DONE IN YOUR CAREER?

4 A. I'M SURE IT IS IN THE HUNDREDS RANGE.

5 Q. AND DO YOU CONTINUE TO PERFORM D&C'S IN YOUR CURRENT  
6 PRACTICE?

7 A. YES, I DO.

8 Q. NOW, NEXT, TURNING TO THE D&E, WHAT DO YOU MEAN BY "D&E" OR  
9 DILATION AND EVACUATION?

10 A. THE WAY I USE THAT TERM IS GENERALLY WHEN THEY ARE IN THE  
11 SECOND-TRIMESTER OF PREGNANCY WHERE USUALLY LAMINARIA OR  
12 OSMOTIC DILATORS ARE USED THE DAY BEFORE THE PROCEDURE TO OPEN  
13 THE CERVIX OF THE WOMEN, AND GENERALLY THAT IS PLACED AS GENTLY  
14 AS POSSIBLE WITH THE LAMINARIA PLACED BEING INSIDE THE CERVIX,  
15 SOMETIMES WITH TRACTION ON THE CERVIX AND SOMETIMES WITHOUT.

16 AND THEN, THE NEXT DAY IN THE OPERATING ROOM A WOMAN  
17 IS TAKEN TO THE OPERATING ROOM, A SPECULUM IS PLACED IN THE  
18 VAGINA. THE LAMINARIA ARE REMOVED, AND THEN A DEVICE IS  
19 DECIDED UPON WHICH TO PUT TRACTION ON THE CERVIX TO STRAIGHTEN  
20 THE CERVIX ANGLE WITH THE REST OF THE UTERUS OUT, AND THEN WITH  
21 A SERIES OF INSTRUMENTS THE BABY IS DISARTICULATED OR REMOVED  
22 IN PIECES WITH CERTAIN KINDS OF FORCEPS. AND THEN, THE FLUID  
23 IN THE MEMBRANES AND THE PLACENTA IS ALSO REMOVED. AND  
24 SOMETIMES WE USE ULTRASOUND GUIDANCE FOR THIS PROCEDURE, AS  
25 WELL.

1 Q. COULD YOU PLEASE EXPLAIN TO THE COURT YOUR EXPERIENCE IN  
2 PERFORMING D&E'S?

3 A. YES. FIRST AS A STUDENT I WATCHED QUITE A FEW D&E'S  
4 BECAUSE I WAS INTERESTED IN FINDING OUT HOW THEY WERE PERFORMED  
5 AND WHY THEY ARE PERFORMED ON DIFFERENT KINDS OF WOMEN IN  
6 DIFFERENT SITUATIONS.

7 AND THEN, AS A MEDICAL STUDENT, ESPECIALLY AS A  
8 RESIDENT, I ACTUALLY MADE IT A POINT TO LEARN HOW TO DO THIS  
9 PROCEDURE PROPERLY. AND I TRIED TO PARTICIPATE IN AS MANY AS I  
10 POSSIBLY COULD AS A RESIDENT BECAUSE I KNEW THIS WAS MY WINDOW  
11 OF OPPORTUNITY TO LEARN.

12 SO I PROBABLY PARTICIPATED IN 30 TO 50 AS A RESIDENT  
13 OVER FOUR YEARS.

14 Q. AND APPROXIMATELY HOW MANY TIMES IN YOUR CAREER HAVE YOU  
15 PERFORMED A D&E PROCEDURE?

16 A. TOTAL NUMBER OF TIMES PROBABLY 60 TO 70.

17 Q. AND HAS THIS ALWAYS INVOLVED DISMEMBERMENT OF THE FETUS?

18 A. YES.

19 Q. IN THE D&E PROCEDURES THAT YOU HAVE PERFORMED OR  
20 PARTICIPATED IN, HAVE THOSE FETUSES BEEN ALIVE OR DEAD?

21 A. THE ONES I ACTUALLY HELD THE INSTRUMENTS AND ACTUALLY DID  
22 THE ACTUAL PROCEDURE THE BABY HAD BEEN DEAD.

23 Q. AND WHEN YOU OBSERVED AT ONE OF THOSE OBSERVATIONS,  
24 OBSERVATIONS OF D&E'S PERFORMED ON LIVE FETUSES?

25 A. YES, MANY WERE.

1 Q. IS THE EXTRACTION PART OF THE D&E PROCEDURE THAT YOU  
2 PERFORM WHEN THE FETUS HAS DIED DIFFERENT FROM THE D&E  
3 PROCEDURE PERFORMED ON A LIVE FETUS?

4 A. THE ACTUAL TECHNIQUE IS THE SAME, BUT THE WAY THE BABY'S  
5 DISARTICULATED, PULLED APART, WOULD PROBABLY BE SOMEWHAT EASIER  
6 WITH A DEAD BABY THAN IT WOULD BE ON A LIVE BABY.

7 Q. AND WOULD THAT DEPEND ON HOW LONG THE BABY HAS BEEN DEAD  
8 FOR?

9 A. YES, IT WOULD.

10 Q. UP TO WHAT GESTATIONAL AGE HAVE YOU OBSERVED A D&E ON A  
11 LIVING FETUS?

12 A. BETWEEN 20 AND 22 WEEKS.

13 Q. NEXT, TURNING TO THE INDUCTION PROCEDURE. IN GENERAL  
14 TERMS, WHAT DO YOU MEAN BY "MEDICAL INDUCTION"?

15 A. MEDICAL INDUCTION OF LABOR IS WHEN CERTAIN MEDICINES ARE  
16 GIVEN EITHER ORALLY, THROUGH THE MOUTH, VAGINALLY, OR EVEN  
17 INSTILLED INTO THE AMNIOTIC FLUID AROUND THE BABY THAT WILL  
18 MAKE THE BODY HAVE CONTRACTIONS AND EXPEL THE BABY  
19 PHYSIOLOGICALLY.

20 Q. WHAT IS YOUR EXPERIENCE WITH THE INDUCTION METHOD OF  
21 TERMINATION?

22 A. WELL, AS A STUDENT I ACTUALLY ROTATED AT SOMETHING CALLED  
23 THE FRANCIS SCOTT KEY MEDICAL CENTER OR THE COUNTY MEDICAL  
24 CENTER, AND THEY DID QUITE A FEW INSTILLATION MEDICAL INDUCTION  
25 PROCEDURES BECAUSE THEY ACTUALLY DID THE MOST NUMBER IN

1 BALTIMORE, SO I GOT DIRECT OPPORTUNITY TO SEE WHAT THEIR  
2 PROTOCOLS WERE, TO ACTUALLY TALK TO WOMEN UNDERGOING THE  
3 PROCEDURES. SO I OBSERVED SEVERAL DURING THAT TIME. PROBABLY  
4 TEN TO TWENTY OF THOSE AT THE FRANCIS SCOTT KEY.

5 AND THEN, DURING RESIDENCY IS WHEN THINGS SHIFTED  
6 SOMEWHAT. AND INSTEAD OF JUST INSTILLATION, WE ALSO SHIFTED  
7 OVER TO MORE PROSTAGLANDINS. SO, OF COURSE, WE HAVE USED  
8 OXYTOCIN OR PITOCIN FOR MANY YEARS FOR INDUCTIONS OF LABOR.

9 Q. DO YOU CURRENTLY USE THE MEDICAL INDUCTION FOR TERMINATION  
10 OF PREGNANCIES?

11 A. YES, I DO.

12 Q. AND HOW FREQUENTLY DO YOU USE THAT METHOD?

13 A. DEPENDS ON THE CLINICAL SITUATION, BUT AS THE NEED ARISES  
14 SOMETIMES ON A WEEKLY BASIS WE NEED TO INDUCE WOMEN'S LABORS  
15 BECAUSE OF MEDICAL PROBLEMS OR PROBLEMS WITH THE BABY.

16 Q. CURRENTLY, WHAT AGENT OR AGENTS DO YOU USE WHEN PERFORMING  
17 AN INDUCTION FOR TERMINATION OF PREGNANCY?

18 A. THE MOST COMMON TWO MEDICATIONS WE USE ARE THE MISOPROSTOL,  
19 WHICH IS ONE OF THE PROSTAGLANDINS THAT WE HAVE BEEN TALKING  
20 ABOUT, AND THE OTHER ONE IS OXYTOCIN.

21 Q. IS OXYTOCIN IS A PROSTAGLANDIN?

22 A. NO, IT IS NOT. IT IS A SEPARATE CATEGORY OF MEDICATION.

23 Q. AND JUST TO BE CLEAR -- YOU TOUCHED ON THIS -- HOW ARE  
24 THOSE AGENTS, THE MISOPROSTOL AND OXYTOCIN, ADMINISTERED TO THE  
25 WOMEN?

1 A. THE MISOPROSTOL IS GIVEN EITHER ORALLY TO A WOMAN OR  
2 INTRAVAGINALLY, THE WAY WE USE IT. AND THEN, THE OXYTOCIN IS  
3 AN IV DRIP.

4 Q. WHEN YOU SAY AN "IV DRIP," IS THIS DIFFERENT THAN  
5 INSTILLATION?

6 A. YES. IT MEANS AN INTRAVENOUS GOING TO A WOMEN'S VEIN WITH  
7 A MIXTURE OF SOME KIND OF SALINE SOLUTION PLUS THE MEDICATION  
8 ITSELF: OXYTOCIN.

9 Q. AND FOR APPROXIMATELY HOW LONG HAVE YOU BEEN PERFORMING  
10 INDUCTIONS WITH PROSTAGLANDINS AND OXYTOCIN?

11 A. FOR MY ENTIRE CAREER OF PRACTICE, WITH ONE OR BOTH.  
12 FOURTEEN YEARS, APPROXIMATELY.

13 Q. WHEN WAS THE LAST TIME YOU PERFORMED AN INDUCTION USING AN  
14 INSTILLATION METHOD?

15 A. PROBABLY THE LAST TIME I SAW INSTILLATION METHODS WERE WHEN  
16 I WAS A RESIDENT.

17 Q. SO, APPROXIMATELY WHAT YEAR?

18 A. IN THE EARLY '90'S. AND IN MEDICAL SCHOOL IN THE LATE  
19 '80'S.

20 Q. AND WHEN THERE IS AN INSTILLATION, CAN YOU EXPLAIN WHERE  
21 THE INSTILLATION -- WHERE THE INJECTION IS INSTALLED INTO THE  
22 WOMAN?

23 A. SO GENERALLY, IT IS VERY SIMILAR TO AN AMNIOCENTESIS.  
24 INSTEAD OF FLUID BEING DRAWN OFF FROM AROUND THE BABY, INSTEAD  
25 MEDICATIONS WOULD BE INJECTED AROUND THE BABY INTO THE AMNIOTIC



1 FLUID.

2 Q. DO YOU CONSIDER INDUCTIONS WITH THE USE OF PROSTAGLANDINS  
3 AND OXYTOCIN DIFFERENT IN ANY MATERIAL WAY FROM THE  
4 INSTILLATION METHODS?

5 A. WELL, BECAUSE THE WOMEN'S UTERUS IS NOT PUNCTURED WITH A  
6 NEEDLE, IT IS A DIFFERENT PROCESS. AND SO ONE MIGHT ASSUME  
7 THAT THERE MIGHT BE DIFFERENT COMPLICATIONS AND DIFFERENT  
8 AMOUNTS OF MEDICATIONS USED, FOR EXAMPLE.

9 Q. HAVE YOU USED THE MEDICAL INDUCTION PROCEDURE WHEN THE  
10 FETUS IS PREVIABILITY?

11 A. YES, I HAVE.

12 Q. AND HAVE YOU USED THE MEDICAL INDUCTION PROCEDURE WHEN THE  
13 FETUS IS POSTVIABLE?

14 A. YES.

15 Q. WHAT DO YOU UNDERSTAND "PREVIABLE" TO MEAN?

16 A. GENERALLY, YOU SAY "PREVIABLE" IS ANY TIME BEFORE A BABY  
17 CAN SURVIVE OUTSIDE THE MOTHER'S UTERUS. SO IN CURRENT,  
18 GENERAL PRACTICE FOR NEONATAL PRACTICE WE USUALLY SAY VIABILITY  
19 IS AT APPROXIMATELY 23 WEEKS GESTATION.

20 Q. DO YOU CURRENTLY PERFORM MORE INDUCTIONS THAN D&E'S?

21 A. YES, I DO.

22 Q. WHY IS IT THAT YOU'VE HAD THE OCCASION TO PERFORM MORE  
23 INDUCTIONS THAN D&E'S IN YOUR PRACTICE?

24 A. IN GENERAL, THE WAY IT'S SET UP AT UNIVERSITY OF MICHIGAN,  
25 WE GET TRANSFERS OF VERY SICK WOMEN. AND I TAKE CALL WITH THE

1 RESIDENTS. WE CALL IT "SUPERVISORY CALL" AT NIGHTTIMES. SO  
2 WHENEVER THERE IS TRANSFERS OF SICK WOMEN, MANY OF THEM -- I  
3 WOULD SAY IN A YEAR WE HAVE A FEW IN THE LATE SECOND-TRIMESTER  
4 WHO ARE QUITE SICK. MANY MORE IN THE THIRD-TRIMESTER WHO ARE  
5 SICK AND, IN FACT, NEED TO BE DELIVERED.

6 AND BECAUSE WE HAVE A VERY HIGH LEVEL NEONATAL UNIT  
7 WE GET TRANSFERS ALL SOUTHERN MICHIGAN AND NORTHERN OHIO TO OUR  
8 INSTITUTION.

9 Q. AND WHAT DOES THAT HAVE TO DO WITH WHETHER OR NOT YOU  
10 PERFORM INDUCTION MORE THAN D&E?

11 A. THE DATA HAS SHOWN THAT IN THE LATE SECOND-TRIMESTER OF 20  
12 WEEKS AND ABOVE THAT ACTUAL MEDICAL INDUCTION'S A SAFER  
13 PROCEDURE FOR WOMEN RATHER THAN THE DILATATION AND EVACUATION.

14 SO WHEN WE ARE PRESENTED WITH PATIENTS WHO HAVE  
15 MEDICAL PROBLEMS IN THE LATE SECOND-TRIMESTER, IT HAS BEEN OUR  
16 HABIT BECAUSE OF THE SAFETY DATA TO USE MEDICAL INDUCTION OF  
17 LABOR RATHER THAN D&E TO END A PREGNANCY.

18 Q. DR. SHADIGIAN, FOCUSING ON YOUR EXPERIENCE WITH PREGNANCY  
19 TERMINATIONS WHILE IN MEDICAL SCHOOL, AND IN YOUR RESIDENCE,  
20 DID YOU MAKE A SPECIAL EFFORT -- YOU HAVE ALREADY TOUCHED ON  
21 THIS, BUT DID YOU MAKE A SPECIAL EFFORT TO LEARN ABOUT  
22 PREGNANCY TERMINATION?

23 A. YES, I DID.

24 Q. WHY DID YOU MAKE THAT SPECIAL EFFORT?

25 A. I KNEW IT WAS SOMETHING THAT WAS REALLY COMMON FOR WOMEN TO

1 CHOOSE TO HAVE AN ABORTION, THAT IN THE FIRST OR  
2 SECOND-TRIMESTER WOMEN ELECTIVELY DECIDE TO HAVE AN ABORTION.  
3 AND THEY ALSO DECIDE BECAUSE OF PROBLEMS WITH THE BABY AND  
4 PROBLEMS WITH THEIR OWN HEALTH. SO I WANTED TO MAKE SURE I  
5 UNDERSTOOD ALL OF THE RAMIFICATIONS THAT MAKING THOSE DECISIONS  
6 WOULD HAVE ON A WOMAN.

7 AND BECAUSE ABOUT 43 PERCENT OF WOMEN HAVE AN  
8 ABORTION BY THE TIME THEY ARE AGE 45, I KNEW I WOULD HAVE A LOT  
9 OF WOMEN IN MY PRACTICE WHO HAD HAD ABORTIONS. AND SO I NEEDED  
10 TO KNOW HOW TO TAKE BEST CARE OF THEM, BOTH DURING THE TIME  
11 THEY ARE MAKING IMPORTANT DECISIONS AND AFTERWARDS, AND THEN IN  
12 THE LONG RUN.

13 Q. WHILE YOU WERE IN BALTIMORE TRAINING, AT WHAT INSTITUTIONS  
14 DID YOU WORK WHERE ABORTION SERVICES WERE PROVIDED?

15 A. AT THE JOHNS HOPKINS HOSPITAL I WAS A MEDICAL STUDENT AND  
16 FRANCIS SCOTT KEY MEDICAL CENTER, THE COUNTY HOSPITAL, AS WELL.

17 Q. AND --

18 A. AND ONE MORE THING. DID YOU ASK ME JUST FOR MEDICAL SCHOOL  
19 OR MEDICAL SCHOOL AND RESIDENCY?

20 Q. WELL, I WAS WONDERING DURING YOUR TRAINING JUST AT WHAT  
21 INSTITUTIONS DID YOU WORK WHERE ABORTION SERVICES WERE  
22 PROVIDED?

23 A. AND ALSO FRANKLIN SQUARE HOSPITAL, AS WELL.

24 Q. WHAT KINDS OF PATIENTS DID YOU SEE AND TREAT?

25 A. BASICALLY, THE FULL RANGE OF PATIENTS THAT THEY WOULD HAVE

1 AT THAT INSTITUTION, SO BOTH ELECTIVE TERMINATIONS, AS WELL AS  
2 WOMEN WHO WERE SICK AND WOMEN WHO HAD BABIES WITH ANOMALIES.

3 Q. DID YOU SEE WOMEN WITH TEEN PREGNANCIES, IN PARTICULAR?

4 A. YES. IN FACT IN MY RESIDENCY WE HAD THE UNFORTUNATE BUT  
5 NEEDED SERVICE OF PROVIDING PREGNANCY CARE AND LABOR AND  
6 DELIVERY CARE TO A HIGH PERCENTAGE OF TEEN WOMEN. IN FACT,  
7 BALTIMORE HAD AND STILL HAS ONE OF THE HIGHEST TEEN PREGNANCY  
8 RATES IN THE COUNTRY.

9 AND SO THAT WAS ONE OF THE THINGS THAT WE ESPECIALLY  
10 TOOK CARE OF WERE TEENS.

11 Q. WAS THE INDUCTION METHOD OF TERMINATION OF PREGNANCY, WAS  
12 THAT FREQUENTLY USED AT THE JOHNS HOPKINS MEDICAL CENTER?

13 A. YES, IT WAS.

14 Q. NOW, I WOULD LIKE TO ASK YOU SOME QUESTIONS ABOUT YOUR  
15 TEACHING RESPONSIBILITIES. COULD YOU PLEASE GENERALLY DESCRIBE  
16 YOUR TEACHING RESPONSIBILITIES AT THE UNIVERSITY OF MICHIGAN?

17 A. THERE ARE BASICALLY FOUR SETS OF STUDENTS AND/OR RESIDENTS  
18 THAT I TEACH. ONE ARE UNDERGRADUATE STUDENTS WHERE I GUEST  
19 LECTURE IN WOMEN'S STUDIES COURSES, PSYCHOLOGY COURSES,  
20 SOCIOLOGY COURSES AND GRADUATE-LEVEL TEACHING IN THE NURSE  
21 MIDWIFERY PROGRAM AS WELL AS IN CERTAIN PSYCHOLOGY PH.D. THESIS  
22 I HAVE BEEN ON.

23 AND THEN, IN THE MEDICAL STUDENTS I LECTURE ON  
24 INTERPERSONAL VIOLENCE ISSUES, INCLUDING DOMESTIC VIOLENCE,  
25 SEXUAL ASSAULT, CHILD ABUSE AND ELDER ABUSE. I RUN A

1 SECOND-YEAR COURSE IN THIS.

2 THE THIRD YEAR I TEACH THE STUDENTS ROTATING THROUGH  
3 OUR DEPARTMENT IN OB/GYN BY BOTH HANDS-ON LEARNING AND  
4 TEACHING, AS WELL AS GIVING LECTURES EVERY SIX WEEKS IN BOTH  
5 BREAST-FEEDING AND MORE COMPLICATED DOMESTIC VIOLENCE ISSUES.

6 AND, THEN, FINALLY I RUN A FOURTH-YEAR MEDICAL  
7 STUDENT ELECTIVE CALLED "PRIMARY CARE OB/GYN" WHERE SENIOR  
8 STUDENTS GET TO PICK DIFFERENT TOPICS THEY ARE INTERESTED IN  
9 AND UNDERSTAND THEM FROM BOTH CLINICAL AND DIDACTIC ANGLES,  
10 BASICALLY.

11 AND THOSE ARE THE STUDENT AREAS. AND THEN, THE  
12 RESIDENTS I TEACH -- THE MOST TIME I TEACH ARE ACTUALLY OB/GYN  
13 RESIDENTS THAT WE HAVE IN OUR PROGRAM.

14 AND THEN, I HAVE HAD THE OCCASION ON AN ONGOING  
15 BASIS TO TEACH FAMILY PRACTICE RESIDENTS AND INTERNAL MEDICINE  
16 AND PEDIATRIC RESIDENTS, AS WELL.

17 Q. AND WITH THE RESIDENTS, WHAT KINDS OF THINGS DO YOU TEACH  
18 TO THE RESIDENTS?

19 A. JUST THE FULL RANGE OF WHAT I DO IN THE OFFICE SETTING AND  
20 IN THE INPATIENT SETTING, I WILL DISCUSS WITH THE RESIDENTS.  
21 BUT HOW IT SORT OF WORKS WHERE I AM SET UP IS THAT IT FEELS  
22 THAT IF YOU ARE A WOMAN COMING TO MY OFFICE IT FEELS LIKE A  
23 PRIVATE OFFICE. THAT YOU JUST SEE ME MOST OF THE TIME IN THE  
24 OFFICE.

25 SOMETIMES I WILL HAVE A STUDENT WITH ME, SOMETIMES I

1 WON'T. BUT THEN WITH THE RESIDENTS I AM DOING MORE INPATIENT  
2 WORK, MEANING SUPERVISING GYN PROCEDURES, LABOR AND DELIVERY  
3 PROCEDURES. AND THEN, SOMETIMES PEOPLE CONSULT ME, ESPECIALLY  
4 WOMEN WHO HAVE BEEN ABUSED, BECAUSE THAT IS MY OTHER AREA OF  
5 INTEREST.

6 Q. AND DO YOU SUPERVISE RESIDENTS IN PERFORMING PREGNANCY  
7 TERMINATIONS?

8 A. IF THE BABY HAS ALREADY DIED AND IT'S MY OWN PATIENT I  
9 WOULD HAVE HER COME TO THE OPERATING ROOM AFTER I'VE CONSENTED  
10 HER, AND ONE OF THE RESIDENTS WOULD SCRUB IN AND ASSIST ME IN  
11 MOST PROCEDURES.

12 AND, IN ADDITION, IF I AM ON CALL, SUPERVISORY CALL,  
13 AND SOMEONE IS TRANSFERRED IN AND THEY NEED TO HAVE A MEDICAL  
14 INDUCTION OF LABOR, THEN I WOULD SUPERVISE THE RESIDENTS IN  
15 THAT CASE, AS WELL.

16 Q. DOCTOR, DO YOU ALSO TEACH ABOUT ABORTION COMPLICATIONS?

17 A. YES, I DO.

18 Q. AND WHO DO YOU TEACH?

19 A. WELL, IT WOULD DEPEND AT THE TIME, BUT MANY TIMES WOMEN ARE  
20 READMITTED AFTER HAVING A TERMINATION OF PREGNANCY, FOR  
21 WHATEVER REASON, WITH A FEVER, WITH HEMORRHAGING, WITH OTHER  
22 COMPLICATIONS THAT ARE COMMON, AND WE NEED TO GO BACK AND DO  
23 ANOTHER PROCEDURE, SO A CURETTAGE OR SCRAPING TO GET THE REST  
24 OF THE PLACENTA OUT.

25 SO THERE IS THE HANDS-ON KIND OF TEACHING WHEN THE

1 WOMEN IS READMITTED.

2 AND THEN, THERE HAS BEEN OTHER OCCASIONS WHEN I HAVE  
3 BEEN ASKED TO SPEAK IN FRONT OF DIFFERENT GROUPS TO TALK ABOUT  
4 ABORTION COMPLICATIONS BECAUSE OF THE PAPER I HAVE WRITTEN.

5 Q. WHAT KINDS OF GROUPS ARE THOSE THAT YOU'VE LECTURED TO  
6 ABOUT ABORTION COMPLICATIONS?

7 A. I HAVE LECTURED TO DIFFERENT GROUPS OF ACOG, THE AMERICAN  
8 COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS. I HAVE GIVEN GRAND  
9 ROUNDS IN MEDICAL INSTITUTIONS. AND THEN, ANY GROUPS THAT HAVE  
10 ASKED ME TO COME, AND IF I CAN PUT THEM ON MY SCHEDULE I HAVE  
11 GONE AHEAD AND LECTURED TO DIFFERENT GROUPS.

12 Q. WHAT KINDS OF ABORTION COMPLICATIONS HAVE YOU TREATED IN  
13 YOUR PRACTICE?

14 A. THE MOST COMMON ONES ARE INFECTIONS AFTER AN ABORTION  
15 PROCEDURE, RETAINED PLACENTA, MEANING THAT THERE IS STILL SOME  
16 KIND OF PLACENTA OR DIFFERENT PARTS OF THE BABY THAT CAN BE  
17 LEFT INSIDE. AND THEN, THERE ARE OTHER THINGS THAT I DO  
18 ATTRIBUTE TO ABORTION, SUCH AS WOMEN WHO HAVE HAD EARLY BIRTHS  
19 IN ANOTHER PREGNANCY AND WOMEN WHO HAVE PLACENTA PREVIA, FOR  
20 EXAMPLE.

21 Q. I WOULD NOW LIKE TO TOUCH ON YOUR RESEARCH  
22 RESPONSIBILITIES. IN WHAT AREAS HAVE YOU PERFORMED RESEARCH  
23 AND WRITING?

24 A. MY TWO BIGGEST AREAS OF RESEARCH ARE ON VIOLENCE AGAINST  
25 WOMEN, SO I HAVE DONE DIFFERENT STUDIES AND THEN PUBLISHED THEM

1 ON ISSUES AROUND VIOLENCE AGAINST WOMEN. AND ALSO ON ABORTION  
2 COMPLICATIONS. ONE THING THAT I AM SORT OF SUBSPECIALIZED IN  
3 IS SOMETHING CALLED "SYSTEMATIC REVIEW," SO THAT WHEN WE LOOK  
4 AT PUBLICATIONS PREVIOUSLY PUBLISHED IN PEER REVIEWED JOURNALS  
5 I TRY TO TAKE NOT JUST ONE OR TWO ARTICLES AND SYNTHESIZE THEM,  
6 BUT DO A WHOLE LITERATURE SEARCH AND GATHER ALL THE ARTICLES ON  
7 A CERTAIN TOPIC AND THEN TRY TO MAKE SENSE OF WHAT THEY SHOW IN  
8 AGGREGATE.

9 SO I HAVE DONE THAT ON BOTH ISSUES AROUND VIOLENCE  
10 AGAINST WOMEN AND ISSUES AROUND ABORTION COMPLICATIONS.

11 Q. HOW DOES YOUR RESEARCH IN THE AREAS OF DOMESTIC VIOLENCE  
12 RELATE TO YOUR OB/GYN PRACTICE?

13 A. AGAIN, VIOLENCE AGAINST WOMEN IS A VERY COMMON PROBLEM,  
14 BOTH IN THE UNITED STATES AND WORLDWIDE. SO I KNEW WHEN I WAS  
15 A RESIDENT, A MEDICAL STUDENT THAT I WOULD SEE A LOT OF WOMEN  
16 WHO HAVE BEEN ABUSED.

17 AND SO, AGAIN, TO TAKE THE BEST CARE OF WOMEN I CAN,  
18 I NEED TO BE ABLE TO UNDERSTAND THEIR PERSONAL SITUATION IN  
19 TERMS OF: IS IT SAFE AT HOME? HAVE THEY POSSIBLY BEEN  
20 ASSAULTED AS A GIRL OR AS A YOUNG WOMAN, BECAUSE I AM GOING TO  
21 BE OPERATING ON THEM AND I AM GOING TO BE SOMEONE THAT THEY  
22 REALLY NEED TO TRUST.

23 AND IF THEY CAN'T TRUST THAT I CARE ABOUT THOSE VERY  
24 INTIMATE AND SCARY AREAS OF THEIR LIVES, THEN IT IS GOING TO BE  
25 HARD FOR THEM TO TRUST ME ABOUT THE MEDICAL THINGS.



1                   SO I THINK THEY GO TOGETHER. AND THAT IS PART OF  
2 WHY I WANTED TO KNOW ABOUT ABORTION, BECAUSE, AGAIN, IT IS ONE  
3 OF THESE VERY INTIMATE AND PERSONAL AREAS WHERE, YOU KNOW,  
4 WOMEN NEED TO HAVE A LOT OF SUPPORT IN THEIR PHYSICIAN.

5 Q. HAVE YOU WRITTEN ANY ARTICLES ABOUT THE LONG-TERM  
6 COMPLICATIONS OF ABORTION?

7 A. YES, I HAVE.

8 Q. WHAT IS THAT ARTICLE?

9 A. IN JANUARY OF 2003, MYSELF AND TWO OTHER CO-AUTHORS FROM  
10 UNIVERSITY OF NORTH CAROLINA GOT PUBLISHED AN ARTICLE LOOKING  
11 AT THE LONG-TERM, BOTH PHYSICAL AND PSYCHOLOGICAL,  
12 COMPLICATIONS OF ABORTION, CALLED "A REVIEW OF THE EVIDENCE,"  
13 WHICH IS, AGAIN, ONE OF THE SYSTEMATIC REVIEWS.

14 Q. WAS THAT PEER REVIEWED?

15 A. YES, IT WAS.

16 Q. ARE YOU A JOURNAL REVIEWER FOR ANY PUBLICATIONS?

17 A. YES.

18 Q. WHICH JOURNALS?

19 A. I HAVE BEEN ASKED TO BE JOURNAL REVIEWER FOR MANY. SOME  
20 EXAMPLES ARE THE GREEN JOURNAL, WHICH IS ONE OF THE MAJOR  
21 OB/GYN JOURNALS CALLED OBSTETRICS AND GYNECOLOGY. AND THEN,  
22 THE AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,  
23 THE MAYO CLINIC PROCEEDINGS, THE FEMALE PATIENT AND SEVERAL  
24 OTHERS.

25 Q. DO YOU BELONG TO ANY PROFESSIONAL ORGANIZATIONS?

1 A. YES, I DO. PROBABLY THE ONE THAT IS MOST IMPORTANT TO ME  
2 AND THE ONE I AM MOST INTIMATELY INVOLVED IN IS THE AMERICAN  
3 COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS.

4 IN ADDITION, I'M PART OF MANY OTHER ORGANIZATIONS,  
5 AS WELL.

6 Q. ARE YOU ALSO A MEMBER OF AAPLOG?

7 A. YES. AAPLOG IS THE AMERICAN ASSOCIATION OF PRO-LIFE  
8 OBSTETRICIANS AND GYNECOLOGISTS. AND, IN FACT, IS A PART OF  
9 ACOG, THE MAIN GROUP. IT'S A SPECIAL INTEREST GROUP OF ACOG.

10 Q. ARE YOU A FELLOW OF ACOG?

11 A. YES, I AM.

12 Q. BRIEFLY, WHY DID YOU DECIDE TO SPECIALIZE IN OBSTETRICS AND  
13 GYNECOLOGY?

14 A. WELL, WOMEN ARE NEAR AND DEAR TO MY HEART, I GUESS POSSIBLY  
15 BECAUSE I AM ONE, TOO. BUT JUST I WAS FASCINATED BY THE  
16 BREADTH OF WHAT WE DO TO TAKE CARE OF WOMEN, BOTH ON THE  
17 OBSTETRICAL END AND THE GYNECOLOGICAL END.

18 AND THAT I LIKED BEING ABLE TO FOLLOW WOMEN OVER  
19 TIME AND GIVE THEM TIME TO GET TO KNOW ME PERSONALLY AND SO I  
20 COULD HELP THEM WITH MAJOR LIFE DECISIONS AND BE A SOUNDING  
21 BOARD FOR MEDICAL INFORMATION, TOO.

22 Q. TURNING TO THE PARTIAL-BIRTH ABORTION PROCEDURE, WHAT DO  
23 YOU UNDERSTAND THE PARTIAL-BIRTH ABORTION PROCEDURE TO BE?

24 MS. KRASNOFF: OBJECTION, FOUNDATION.

25 THE COURT: SUSTAINED.

1 THE WITNESS: IN SHORT --

2 THE COURT: JUST A MOMENT.

3 THE WITNESS: OH, I'M SORRY.

4 THE COURT: SHE'LL ASK YOU A DIFFERENT QUESTION.

5 BY MS. CLARK:

6 Q. DR. SHADIGIAN, HAVE YOU HEARD THE TERM "PARTIAL-BIRTH  
7 ABORTION"?

8 A. YES, I HAVE.

9 Q. AND WHAT DO YOU UNDERSTAND "PARTIAL-BIRTH ABORTION" TO  
10 MEAN?

11 MS. KRASNOFF: OBJECTION, FOUNDATION. SHE'S NOT  
12 BEEN QUALIFIED TO TESTIFY ABOUT THAT AREA.

13 THE COURT: YOU HAVEN'T EVEN TOLD US YET WHAT YOU  
14 ARE OFFERING HER TO TESTIFY ABOUT.

15 MS. CLARK: I CAN JUMP TO THAT. YOUR HONOR,  
16 DEFENDANT OFFERS DR. SHADIGIAN AS AN EXPERT IN OBSTETRICS AND  
17 GYNECOLOGY, PREGNANCY TERMINATION AND ABORTION COMPLICATIONS.

18 THE COURT: ALL RIGHT. AND DO YOU HAVE AN  
19 OBJECTION?

20 MS. KRASNOFF: WE WOULD LIKE TO VOIR DIRE ON  
21 PREGNANCY TERMINATION.

22 THE COURT: AND NOT ABORTION COMPLICATIONS?

23 MS. KRASNOFF: NO, YOUR HONOR.

24 THE COURT: ALL RIGHT. YOU MAY DO SO.

25 MS. KRASNOFF: AS THEY RELATE TO SPECIFIC METHODS,

1 PERHAPS. BUT NOT --

2 THE COURT: OPPOSING COUNSEL IS GOING TO ASK A FEW  
3 QUESTIONS BEFORE I DETERMINE WHAT AREAS YOU ARE COMPETENT TO  
4 TESTIFY AS AN EXPERT IN.

5 VOIR DIRE EXAMINATION

6 BY MS. KRASNOFF:

7 Q. GOOD MORNING, DR. SHADIGIAN. I AM HELENE KRASNOFF. WE MET  
8 AT YOUR DEPOSITION.

9 IN YOUR CAREER, YOU HAVE PERFORMED BETWEEN 20 AND 40  
10 PREVIABILITY ABORTIONS WHERE THE FETUS WAS ALIVE AT THE  
11 BEGINNING OF THE PROCEDURE; IS THAT CORRECT?

12 A. THAT'S APPROXIMATELY CORRECT, YES.

13 Q. AND YOU TESTIFIED ON DIRECT THAT YOU PERFORMED TERMINATIONS  
14 OF PREGNANCY WEEKLY, BUT THOSE ARE NOT PREVIABLE; IS THAT  
15 CORRECT?

16 A. CORRECT.

17 Q. ACTUALLY, ON PREVIABLE FETUSES YOU PERFORM ABOUT TWO OR  
18 THREE PER YEAR; IS THAT CORRECT?

19 A. THAT'S CORRECT.

20 Q. AND EACH AND EVERY ONE OF THOSE IS BY THE INDUCTION METHOD;  
21 IS THAT CORRECT, WHERE THE FETUS IS ALIVE?

22 A. WHERE THE FETUS IS ALIVE, THAT'S CORRECT.

23 Q. IN FACT, YOU HAVE NEVER PERFORMED A D&E PROCEDURE ON A LIVE  
24 FETUS; IS THAT CORRECT?

25 A. THAT IS CORRECT.

1 Q. AND YOU HAVE NEVER PERFORMED A HYSTEROTOMY ON A LIVE FETUS;  
2 IS THAT CORRECT?

3 A. NOT THAT I CAN RECALL.

4 Q. SO YOUR ONLY EXPERIENCE PERFORMING D&E'S ARE ON FETUSES  
5 THAT HAVE ALREADY DEMISED; IS THAT CORRECT?

6 A. YES, EXCEPT FOR WHEN I WAS OBSERVING OTHERS DOING D&E'S ON  
7 LIVE BABIES.

8 Q. SO YOUR ONLY EXPERIENCE ACTUALLY PERFORMING THEM YOURSELF;  
9 IS THAT CORRECT?

10 A. THAT IS CORRECT.

11 Q. AS A FACULTY MEMBER AT THE UNIVERSITY OF MICHIGAN OVER THE  
12 PAST 10 YEARS, YOU HAVE ONLY SUPERVISED OR PARTICIPATED IN  
13 BETWEEN 10 AND 20 D&E'S WHERE THE FETUS HAD DEMISED; IS THAT  
14 CORRECT?

15 A. THAT IS CORRECT.

16 Q. SO, IF YOU AVERAGE THAT OUT THAT SUPERVISION WITH A DEMISED  
17 FETUS HAPPENS BETWEEN ZERO AND TWO TIMES EACH YEAR; IS THAT  
18 CORRECT?

19 A. THAT IS CORRECT.

20 Q. AND THE LATEST GESTATIONAL AGE AT WHICH YOU HAVE ACTUALLY  
21 PERFORMED A D&E ON A DEAD FETUS AT THE UNIVERSITY OF MICHIGAN  
22 IN THE PAST 10 YEARS IS AT 17 OR 18 WEEKS; IS THAT CORRECT?

23 A. THAT IS CORRECT.

24 Q. AND ISN'T IT TRUE THAT SOME D&E'S MAY REQUIRE SURGICAL  
25 SKILLS BEYOND YOUR PRACTICE SUCH THAT YOU WOULD REFER THOSE TO

1 THE MATERNAL FETAL MEDICINE SPECIALISTS?

2 A. THAT IS CORRECT.

3 Q. TURNING TO INTACT D&E, YOU YOURSELF HAVE NEVER PERFORMED AN

4 INTACT D&E; IS THAT CORRECT?

5 A. THAT IS CORRECT.

6 Q. AND YOU HAVEN'T SUPERVISED ANYONE ELSE PERFORMING AN INTACT

7 D&E, HAVE YOU?

8 A. THAT IS CORRECT.

9 Q. YOU HAVEN'T OBSERVED AN INTACT D&E ABORTION BEING

10 PERFORMED; IS THAT CORRECT?

11 A. NOT LIVE, THAT'S CORRECT. I HAVE NOT SEEN ONE LIVE; THAT

12 IS CORRECT.

13 Q. AND YOU HAVEN'T BEEN TAUGHT THE INTACT D&E PROCEDURE, HAVE

14 YOU?

15 A. THAT IS CORRECT.

16 Q. AND YOU HAVEN'T TAUGHT IT TO ANY MEDICAL STUDENTS OR

17 RESIDENTS, EITHER, HAVE YOU?

18 A. THAT IS CORRECT.

19 Q. AND YOU HAVE NEVER DISCUSSED INTACT D&E WITH ANY PHYSICIAN

20 WHO PERFORMS INTACT D&E, HAVE YOU?

21 A. THAT IS CORRECT.

22 Q. AND YOU DON'T ACTUALLY PERSONALLY KNOW ANY PHYSICIAN WHO

23 PERFORMS INTACT D&E, DO YOU?

24 A. PROBABLY NOT.

25 Q. AND YOU HAVEN'T DISCUSSED THE INTACT D&E PROCEDURE WITH ANY

DIANE E. SKILLMAN, OFFICIAL COURT REPORTER, USDC (415) 552-5393

1 OTHER PHYSICIAN AT THE UNIVERSITY OF MICHIGAN, WHETHER HE OR  
2 SHE PERFORMS INTACT D&E OR NOT?

3 A. THAT IS CORRECT.

4 Q. AND PRIOR TO DECEMBER 22, 2003, YOU NEVER DONE A LITERATURE  
5 SEARCH ABOUT INTACT D&E ABORTIONS, HAD YOU?

6 A. THAT IS CORRECT.

7 MS. CLARK: YOUR HONOR I AM JUST GOING TO OBJECT.  
8 WE HAVEN'T SOUGHT TO QUALIFY HER AS AN EXPERT ON THE TECHNIQUE  
9 OF THE D&X PROCEDURE, SO I THINK IT IS OUTSIDE THE SCOPE AND  
10 NOT PARTICULARLY RELEVANT.

11 THE COURT: COUNSEL, THIS IS VOIR DIRE. THIS IS  
12 VOIR DIRE. SHE CAN ASK THOSE KINDS OF QUESTIONS.

13 BY MS. KRASNOFF:

14 Q. AND AT THAT TIME BACK IN DECEMBER, YOU ALSO HADN'T DONE A  
15 LITERATURE SEARCH FOR THE PURPOSE OF COMPARING THE SAFETY OF  
16 SECOND-TRIMESTER ABORTION PROCEDURES; IS THAT CORRECT?

17 A. THAT IS CORRECT.

18 Q. SO IT WASN'T UNTIL AFTER YOU WERE CONTACTED TO TESTIFY IN  
19 THIS CASE THAT YOU PERFORMED THE LITERATURE REVIEWS WHICH FORM  
20 THE BASIS OF THE OPINIONS YOU ARE GOING TO OFFER TODAY; IS THAT  
21 CORRECT?

22 A. THAT IS CORRECT.

23 Q. AND, IN FACT, IT WAS BECAUSE OF THAT UNFAMILIARITY THAT IT  
24 TOOK YOU MORE THAN 35 HOURS FROM THE TIME YOU WERE CONTACTED  
25 UNTIL YOUR EXPERT REPORT WAS PREPARED TO PREPARE IT; IS THAT

1 RIGHT?

2 A. I DON'T KNOW WHAT YOU MEAN.

3 Q. I COULD SHOW YOU SOMETHING THAT MIGHT REFRESH YOUR  
4 RECOLLECTION.

5 DR. SHADIGIAN, I HAVE SHOWN YOU AN INVOICE FOR THE  
6 TIME SPENT ON THIS CASE. DOES THAT REFRESH YOUR RECOLLECTION  
7 ABOUT THE TIME YOU SPENT PREPARING YOUR EXPERT REPORT?

8 A. I BELIEVE YOU ASKED THE QUESTION -- YES. BUT YOU ASKED A  
9 QUESTION ABOUT IF IT WAS JUST ALL SPENT ON LITERATURE SEARCH, I  
10 THOUGHT.

11 Q. OH, I'M SORRY. DID YOU NOT SPEND 35 HOURS OF WORK FROM  
12 WHEN YOU WERE FIRST CONTACTED UNTIL YOU SIGNED YOUR EXPERT  
13 REPORT ON JANUARY 16TH?

14 A. THAT IS CORRECT.

15 Q. AND YOU HADN'T PREVIOUSLY, PRIOR TO DECEMBER, DONE ANY  
16 RESEARCH RELATED TO THESE METHODS OF ABORTION IN THE  
17 SECOND-TRIMESTER; IS THAT RIGHT?

18 A. NOT FORMAL, YES.

19 MS. KRASNOFF: YOUR HONOR, PLAINTIFFS BELIEVE THAT  
20 DR. SHADIGIAN DOES NOT MEET THE STANDARD LAID OUT BY THE COURT  
21 LAST WEEK ON BEING ABLE TO TESTIFY ABOUT HOW INTACT D&E  
22 ABORTIONS ARE PERFORMED. SHE HAS NEVER PERFORMED, SUPERVISED,  
23 OBSERVED, TAUGHT, BEEN TAUGHT OR EVEN SPOKEN TO ANY PHYSICIAN  
24 WHO PERFORMS THAT PROCEDURE.

25 WE DO NOT OBJECT TO DR. SHADIGIAN BEING QUALIFIED AS

DIANE E. SKILLMAN, OFFICIAL COURT REPORTER, USDC (415) 552-5393



1 AN EXPERT IN OBSTETRICS AND GYNECOLOGY, GENERALLY. AND WE DO  
2 NOT OBJECT TO HER SPEAKING GENERALLY ABOUT HER RESEARCH IN THE  
3 COMPLICATIONS RELATED TO ABORTION. AS THEY RELATE TO SPECIFIC  
4 PROCEDURES, SUCH AS INTACT D&E, WE BELIEVE THERE IS NO BASIS  
5 FOR THAT.

6           HOWEVER, AS THE COURT PERMITTED LAST WEEK WITH DR.  
7 SPRANG, WE DON'T OBJECT TO HER PROVIDING EXPERT OPINION ON THE  
8 SAFETY OF INTACT D&E BASED ON HER GENERAL EXPERTISE IN OB/GYN,  
9 NOR HER BRIEFLY SETTING FORTH HER UNDERSTANDING OF THE  
10 PROCEDURE IN ORDER TO OFFER THOSE OPINIONS THAT ARE BASED ON  
11 EXTERNAL SOURCES ONLY.

12           BUT HER TESTIMONY REGARDING HOW INTACT D&E ABORTIONS  
13 ARE PERFORMED, WE SUBMIT, WOULD THUS NOT BE FOR THE TRUTH OF  
14 HOW THAT PROCEDURE IS, BUT RATHER THAT THOSE ARE THE BASES OF  
15 HOW SHE UNDERSTANDS IT FOR HER OPINIONS.

16           THE COURT: ALL RIGHT. ANY RESPONSE, MS. CLARK?

17           MS. CLARK: I MIGHT HAVE MISSED SOMETHING. I AM NOT  
18 SURE IF THEY ARE OBJECTING TO THE ABORTION COMPLICATIONS AND  
19 HER VIEWS ON ABORTION COMPLICATIONS. BUT I THINK HER  
20 RESEARCH -- SHE WROTE AN ARTICLE ABOUT -- SPECIFICALLY ABOUT  
21 ABORTION COMPLICATIONS. WHETHER AN EXPERT IS QUALIFIED IS  
22 BASED ON KNOWLEDGE, SKILL, EXPERIENCE AND TRAINING. AND SHE  
23 HAS HAD SUFFICIENT TRAINING IN ABORTION COMPLICATIONS. SHE HAS  
24 TREATED PATIENTS WITH ABORTION COMPLICATIONS.

25           WITH RESPECT TO PREGNANCY TERMINATION, AS SHE

1 TESTIFIED SHE HAS PERFORMED MEDICAL INDUCTION WHEN IT WAS BEEN  
2 NECESSARY FOR MEDICAL HEALTH CONDITIONS FOR THE WOMAN. SHE'S  
3 OBSERVED D&E'S ON LIVE FETUSES. SHE'S PERFORMED D&E'S --

4 THE COURT: I THINK YOU WEREN'T PAYING ATTENTION TO  
5 HER OBJECTION.

6 FIRST OF ALL, DID YOU OBJECT TO THE WITNESS BEING  
7 QUALIFIED ON THE QUESTION OF ABORTION COMPLICATIONS?

8 MS. KRASNOFF: NOT AS THEY RELATE TO ALL METHODS OF  
9 ABORTIONS. IN FACT, I WOULD HAPPY TO VOIR DIRE ON HER RESEARCH  
10 PARTICULARLY RELATED --

11 THE COURT: NO. I THINK THAT IS ACTUALLY  
12 SATISFACTORY.

13 HER OBJECTION WAS THE SAME AS WITH REGARD TO DR.  
14 SPRANG, WITH REGARD TO HER TESTIFYING AS AN EXPERT ON INTACT  
15 D&E. MY RULING WOULD BE THE SAME, UNLESS YOU HAVE SOME  
16 COMPELLING REASON WHY I SHOULD CHANGE MY RULING WITH RESPECT TO  
17 THIS DOCTOR.

18 MS. CLARK: I THINK THE RULING IS CONSISTENT WITH  
19 DR. SPRANG'S RULING.

20 THE COURT: ALL RIGHT. THEN, THE DOCTOR WILL BE --  
21 DR. SHADIGIAN?

22 THE WITNESS: SHADIGIAN, THAT'S RIGHT.

23 THE COURT: -- SHALL BE QUALIFIED TO TESTIFY AS AN  
24 EXPERT IN OBSTETRICS AND GYNECOLOGY AND ON PREGNANCY  
25 TERMINATION WITH THE EXCEPTION OF INTACT D&E AND ABORTION

1 COMPLICATIONS.

2 SHE MAY, HOWEVER, OPINE, OBVIOUSLY, AS TO THE SAFETY  
3 OF THE INTACT METHOD AND MAY TESTIFY AS TO WHAT HER  
4 UNDERSTANDING IS. THAT TESTIMONY OBVIOUSLY WILL NOT BE  
5 CONSIDERED FOR THE TRUTH OF THE MATTER GIVEN THAT SHE HAS NOT  
6 OBSERVED, TAUGHT, OR PERFORMED SUCH PROCEDURE HERSELF.

7 ALL RIGHT. YOU MAY CONTINUE.

8 DIRECT EXAMINATION RESUMED

9 BY MS. CLARK:

10 Q. DR. SHADIGIAN, WHAT DO YOU UNDERSTAND THE PARTIAL-BIRTH  
11 ABORTION PROCEDURE TO BE?

12 A. IN SHORT, THE PARTIAL-BIRTH ABORTION PROCEDURE CAN BE  
13 BROKEN DOWN INTO FOUR SEPARATE PARTS. ONE IS SERIAL DILATION  
14 OF THE CERVIX OVER TWO DAYS TO OPEN THE CERVIX OR DILATE IT.

15 THE SECOND IS THE INSTRUMENTAL CONVERSION OF FETUS  
16 OR BABY IN A NONBREECH PRESENTATION TO A BREECH PRESENTATION.

17 AND THEN, DELIVERY OF THE BABY UP TO THE BASE OF THE  
18 SKULL.

19 AND THEN, FINALLY, PLACING, FOR EXAMPLE, SCISSORS OR  
20 OTHER SUCH INSTRUMENTS IN THE BASE OF THE SKULL AND EXTRACTING  
21 THE CONTENTS OF THE SKULL, AND THEN DELIVERING THE REST OF THE  
22 BABY.

23 Q. WHAT MATERIALS HAVE YOU REVIEWED THAT FORM THE BASIS OF  
24 YOUR OPINION THAT WHAT YOU JUST DESCRIBED IS A PARTIAL-BIRTH  
25 ABORTION PROCEDURE?

1 A. I'VE REVIEWED DR. HASKELL'S INITIAL REPORT IN 1992. I  
2 REVIEWED DR. PAUL'S BOOK, WHICH DESCRIBES BOTH THE HASKELL  
3 CASES AS WELL AS MCMAHON'S CASES. AND THEN, I'VE ALSO LOOKED  
4 CAREFULLY AT THE ACOG DOCUMENT ABOUT D&X PROCEDURE.

5 Q. DO YOU UNDERSTAND THE TERMS "D&X" AND PARTIAL-BIRTH  
6 ABORTION? DO YOU USE THOSE TERMS INTERCHANGEABLY?

7 A. I DO, AND I ALSO INCLUDE INTACT D&E WITH ALL THE OTHER  
8 DEFINITIONS.

9 Q. DR. SHADIGIAN, IS IT YOUR UNDERSTANDING THAT A D&X  
10 PROCEDURE WOULD ALSO BE A SURGICAL ABORTION IN WHICH THE  
11 PHYSICIAN INTENTIONALLY EXTRACTS A LIVE FETUS INTACT IN A  
12 BREECH PRESENTATION UNTIL THE HEAD GETS LODGED AT THE WOMEN'S  
13 INTERNAL CERVICAL OS, AND THEN DECOMPRESSES THE HEAD IN ORDER  
14 TO VAGINALLY DELIVER A DEAD FETUS?

15 A. YES.

16 Q. DOCTOR, CAN YOU BRIEFLY -- WHAT IS YOUR OPINION AS AN  
17 EXPERT IN THE FIELD OF OBSTETRICS AND GYNECOLOGY ABOUT THE  
18 MEDICAL NECESSITY OF A PARTIAL-BIRTH ABORTION PROCEDURE?

19 A. I HAVE NEVER PERSONALLY HAD TO USE A PARTIAL-BIRTH ABORTION  
20 PROCEDURE TO TAKE CARE OF WOMEN, EVEN SICK WOMEN WITH MEDICAL  
21 CONDITIONS.

22 I NEVER SEEN ANY OF MY COLLEAGUES AT THE UNIVERSITY  
23 OF MICHIGAN USE IT, NOR HAVE I IN MEDICAL SCHOOL OR RESIDENCY  
24 EVER SEEN THIS USED TO TAKE CARE OF EVEN THE SICKEST WOMEN.

25 Q. DR. SHADIGIAN, WHAT IS YOUR OPINION AS AN EXPERT IN THE

1 FIELD OF OBSTETRICS AND GYNECOLOGY ABOUT WHETHER THE  
2 PARTIAL-BIRTH ABORTION PROCEDURE OFFERS SAFETY ADVANTAGES OVER  
3 OTHER METHODS OF ABORTION DURING THE SECOND-TRIMESTER OF  
4 PREGNANCY?

5 A. THE PARTIAL-BIRTH ABORTION PROCEDURE HAS NEVER BEEN STUDIED  
6 IN A SYSTEMATIC WAY AND REPORTED IN THE LITERATURE IN A  
7 PEER-REVIEWED PRESENTATION NOR IN A PEER-REVIEWED JOURNAL  
8 ARTICLE. SO, THERE IS NO SOUND BASIS TO SAY THERE IS ANYTHING  
9 SAFE ABOUT THE D&X PROCEDURE, ESPECIALLY WHEN THERE ARE OTHER  
10 PROCEDURES, LIKE THE D&E PROCEDURE AND THE MEDICAL INDUCTION  
11 PROCEDURE THAT ARE SAFE AND WELL-STUDIED IN THE MEDICAL  
12 LITERATURE.

13 Q. IS THERE ANYTHING IN YOUR TRAINING AND EXPERIENCE THAT YOU  
14 FOUND PARTICULARLY USEFUL IN EVALUATING THE MEDICAL NECESSITY  
15 OF THE PARTIAL-BIRTH ABORTION PROCEDURE?

16 A. WELL, I DID PERFORM BOTH A DOMESTIC AND INTERNATIONAL  
17 LITERATURE SEARCH JUST BECAUSE I WASN'T SURE IF THERE WERE  
18 ARTICLES THAT HAD BEEN PUBLISHED OR NOT. AND SO UP THROUGH THE  
19 BEGINNING OF JANUARY 2004, I PERFORMED A FULL LITERATURE  
20 SEARCH, AND I HAD SPECIALIZED LIBRARIANS HELP ME TO MAKE SURE I  
21 DIDN'T MISS ANY KEYWORDS. SO BECAUSE I ACTUALLY HAVE DONE THAT  
22 MYSELF I FEEL CONFIDENT SAYING THERE HADN'T BEEN ANY PUBLISHED  
23 DATA ON THE D&X PROCEDURE.

24 Q. AND IS THERE ANYTHING WITH RESPECT TO YOUR TRAINING OR  
25 CLINICAL EXPERIENCE THAT HELPS YOU FORM YOUR OPINION?

1 A. I'VE TAKEN CARE OF ONE PATIENT WHO HAD A D&X PROCEDURE, AND  
2 THEN I TOOK CARE OF HER IN THE NEXT PREGNANCY, SO I HAD THAT  
3 EXPERIENCE, AS WELL.

4 Q. DOCTOR, YOU TESTIFIED EARLIER THAT YOU HAVE SOMETIMES HAD  
5 TO TERMINATE A PREGNANCY IN ORDER TO IMPROVE A WOMAN'S HEALTH  
6 CONDITION; IS THAT CORRECT?

7 A. YES.

8 Q. HOW WOULD YOU CHARACTERIZE THE FREQUENCY OF THE NEED TO  
9 TERMINATE A PREGNANCY BECAUSE OF THE WOMAN'S HEALTH CONDITION?

10 A. IT'S NOT COMMON, BUT IT IS NOT RARE, EITHER. IF YOU  
11 CONSIDER BOTH LATE SECOND-TRIMESTER AND THIRD-TRIMESTER THERE  
12 ARE MANY MEDICAL CONDITIONS THAT WARRANT HAVING A BABY BORN  
13 EARLY TO IMPROVE THE HEALTH CONDITION OF A WOMAN.

14 Q. IS IT COMMON THAT A WOMAN'S PREGNANCY HAS TO BE TERMINATED  
15 BECAUSE OF HEALTH CONDITIONS THAT MANIFEST IN THE  
16 SECOND-TRIMESTER OF PREGNANCY?

17 A. IT IS MUCH MORE RARE IN THE SECOND-TRIMESTER AND ALMOST  
18 ALWAYS LIMITED TO THE END OF THE SECOND-TRIMESTER WHEN A WOMAN  
19 BECOMES SEVERELY ILL.

20 Q. HOW DO YOU KNOW THAT IT IS UNCOMMON THAT TERMINATION OF  
21 PREGNANCY IS RARELY MEDICALLY INDICATED IN THE  
22 SECOND-TRIMESTER?

23 A. BECAUSE I HAVE PRACTICED AT BIG TERTIARY CARE CENTERS WHERE  
24 THE EXPERIENCE HAS BEEN WE GET TRANSFERRED THE SICKEST  
25 PATIENTS. AND EVEN IN A SITUATION SUCH AS TERTIARY CARE

1 CENTER, WE STILL ONLY TAKE CARE OF A FEW PER YEAR, 10 TO 20 PER  
2 YEAR THAT ARE SO SICK THEY NEED TO BE TERMINATED.

3 IN ADDITION, JUST LOOKING AT THE MEDICAL LITERATURE,  
4 WE CAN LOOK AT INCIDENTS, RATES OF SEVERE PREECLAMPSIA AND  
5 OTHER MEDICAL CONDITIONS.

6 Q. OKAY. AND YOU'VE MENTIONED PREECLAMPSIA A COUPLE OF TIMES  
7 NOW. WHAT IS PREECLAMPSIA?

8 A. PREECLAMPSIA IS A MEDICAL CONDITION THAT IS LIMITED TO  
9 PREGNANCY, AND IT'S A CONSTELLATION OF BASICALLY THREE  
10 DIFFERENT MANIFESTATIONS.

11 ONE IS HIGH BLOOD PRESSURE IN PREGNANT WOMEN. THERE  
12 CAN BE PROTEIN IN THE URINE, WHICH IS WHEN THE KIDNEYS AREN'T  
13 WORKING PROPERLY. AND THEN THE WOMEN CAN GET GENERALLY  
14 SWELLING ALL OVER THEIR BODY. AND THERE ARE DIFFERENT SUBSETS  
15 OF PREECLAMPSIA THAT MAKE IT SEVERE. AND ONE OF THEM IS  
16 SOMETHING CALLED HELP SYNDROME, WHICH IS AN ACRONYM FOR WHEN  
17 THE BLOOD ISN'T WORKING PROPERLY, AS WELL.

18 Q. AND HAVE YOU EVER NEEDED TO TERMINATE A PREGNANCY WHEN A  
19 WOMAN IS SUFFERING FROM PREECLAMPSIA?

20 A. YES.

21 Q. AND HAVE YOU PERFORMED THE PREGNANCY TERMINATION YOURSELF?

22 A. YES.

23 Q. WHAT METHOD HAVE YOU EMPLOYED?

24 A. GENERALLY, WE WOULD DO A MEDICAL INDUCTION. BUT IF THE  
25 BABY IS VIABLE AND THE PATIENT WOULD PREFER, OR THERE WOULD BE

1 ANOTHER INDICATION, SOMETIMES WE DO A CESAREAN SECTION, AS  
2 WELL.

3 Q. YOU PREVIOUSLY TESTIFIED ABOUT CHORIOAMNIONITIS. WHAT IS  
4 CHORIOAMNIONITIS?

5 A. CHORIOAMNIONITIS IS AN INFECTION OF THE MEMBRANES AROUND  
6 THE BABY, BUT IT CAN ALSO INCLUDE THE FLUID AROUND THE BABY,  
7 THE BABY, HIM OR HERSELF, OR THE MOTHER.

8 Q. DOES THAT CONDITION -- WHEN THAT CONDITION IS PRESENTED  
9 DOES THAT EVER REQUIRE TERMINATION OF PREGNANCY?

10 A. YES, IT CAN.

11 Q. AND WHAT METHOD OF PREGNANCY TERMINATION HAVE YOU UTILIZED  
12 WHEN A PATIENT HAS PRESENTED WITH CHORIOAMNIONITIS REQUIRING  
13 THAT THE PREGNANCY BE TERMINATED?

14 A. GENERALLY, WE USE MEDICAL INDUCTIONS, AS WELL.

15 Q. WHEN FACED WITH THE NEED TO TERMINATE A PREGNANCY BECAUSE  
16 OF A MATERNAL HEALTH COMPLICATION, IS THAT SITUATION APPROACHED  
17 DIFFERENTLY DEPENDING ON WHETHER THE BABY IS PREVIABLE OR  
18 POSTVIABLE?

19 A. THE GENERAL APPROACH WOULD BE SIMILAR, BUT IN A PREVIABLE  
20 INFANT, WE MAY USE HIGHER DOSES OF SIMILAR MEDICATIONS BECAUSE  
21 WE ARE NOT CONCERNED THAT THE BABY COULD ACTUALLY SURVIVE THE  
22 INDUCTION.

23 Q. DOCTOR, HOW DO YOU EVALUATE THE MEDICAL HEALTH CONDITIONS  
24 DURING A PREGNANCY IN ORDER TO DETERMINE WHETHER AND WHEN YOU  
25 SHOULD END A PREGNANCY?



1 A. WELL, IT DEPENDS ON WHAT THE CONDITION IS, AND THEN WHAT A  
2 WOMAN'S HISTORY MIGHT BE AND WHAT HER CURRENT SITUATION IS IN  
3 TERMS OF BLOOD PRESSURE, DIFFERENT LABORATORY VALUES THAT WE  
4 MAY NEED TO EVALUATE DURING THE PREGNANCY.

5 SO IT DEPENDS ON THE PARTICULAR SITUATION.

6 Q. WHEN A PREGNANCY HAS TO BE ENDED PREVIABLE BECAUSE OF A  
7 MATERNAL HEALTH REASON, IS IT EVER NECESSARY TO TAKE A  
8 DESTRUCTIVE ACT AGAINST THE FETUS IN ORDER TO PROTECT THE  
9 HEALTH INTERESTS OF THE MOTHER?

10 A. NO, IT IS NOT.

11 Q. WHAT IS NECESSARY TO SERVE THE HEALTH INTEREST OF THE  
12 MOTHER WHEN SHE NEEDS HER PREGNANCY TO BE ENDED PREVIABILITY?

13 A. WHETHER IT IS PREVIABILITY OR POSTVIABILITY WHAT WE HAVE TO  
14 DO IS DELIVER THE BABY IN SOME WAY, AND SO THE ACTUAL ACT OF  
15 DELIVERING THE BABY IS WHAT -- AND PLACENTA -- IS WHAT ACTUALLY  
16 HELPS REVERSE THE MEDICAL CONDITION THAT IS MAKING A WOMAN  
17 SICKER AND SICKER.

18 Q. WHY IN THE SECOND-TRIMESTER OF PREGNANCY, WHEN PREGNANCY  
19 TERMINATION IS DEEMED TO BE NECESSARY TO PROTECT THE MOTHER'S  
20 HEALTH INTEREST, DO YOU USE THE INDUCTION METHOD?

21 A. WELL, THE REASON I AND OTHERS AT THE UNIVERSITY OF MICHIGAN  
22 DO IS BECAUSE OF THE SAFETY DATA. AFTER 20 WEEKS, IT IS  
23 ACTUALLY SAFER TO HAVE A MEDICAL INDUCTION FOR MOST WOMEN,  
24 LOOKING AT BOTH THE MORTALITY RATE, MEANING HOW MANY WOMEN DIE  
25 WITH A MEDICAL INDUCTION VERSUS A D&E PROCEDURE.

1                   AND ALSO, NOW WE HAVE MISOPROSTOL, WHICH IS A MORE  
2   MODERN PROSTAGLANDIN, GIVES US EVEN BETTER SAFETY DATA.

3   Q.   WHEN IT HAS BEEN MEDICALLY INDICATED TO TERMINATE A  
4   PREGNANCY, HAVE YOU EVER THOUGHT IT MIGHT BE HELPFUL IN TERMS  
5   OF THE HEALTH OF THE MOTHER TO PERFORM A D&X PROCEDURE?

6   A.   NO.

7   Q.   HAVE YOU EVER THOUGHT WHEN PERFORMING A VAGINAL SURGICAL  
8   REMOVAL OF A FETUS THAT IT WOULD BE PREFERABLE IN TERMS OF  
9   SAFETY TO THE MOTHER TO REMOVE THE FETUS INTACT UP UNTIL ITS  
10  HEAD GOT STUCK AT THE WOMAN'S INTERNAL CERVICAL OS?

11                   MS. KRASNOFF:  OBJECTION, YOUR HONOR.  SHE'S NEVER  
12  PERFORMED A SURGICAL ABORTION ON A LIVE FETUS.

13                   THE COURT:  SUSTAINED.

14  BY MS. CLARK:

15  Q.   DOCTOR, HAVE YOU PERFORMED INDUCTIONS FOR THE PURPOSE OF  
16  TERMINATION OF PREGNANCY ON A LIVE FETUS?

17  A.   YES.

18  Q.   HAVE YOU DONE THAT PREVIABILITY?

19  A.   YES.

20  Q.   AND IN PERFORMING AN INDUCTION PROCEDURE ON THE LIVE FETUS  
21  FOR THE PURPOSE OF TERMINATING A PREGNANCY, HAVE YOU EVER  
22  THOUGHT IT WOULD BE PREFERABLE IN TERMS OF THE SAFETY TO THE  
23  MOTHER TO REMOVE THE FETUS INTACT UP UNTIL ITS HEAD GOT STUCK  
24  AT THE WOMAN'S INTERNAL CERVICAL OS, AND THEN DECOMPRESS THE  
25  SKULL OF THE FETUS IN ORDER TO COMPLETE THE DELIVERY?

1 A. NO.

2 Q. ARE THERE, IN YOUR OPINION, SAFE AND EFFECTIVE METHODS TO  
3 TERMINATE A PREGNANCY FOR MATERNAL HEALTH REASONS WITHOUT THE  
4 D&X PROCEDURE?

5 A. YES.

6 Q. WOULD A D&X PROCEDURE EVER BE AN APPROPRIATE PROCEDURE TO  
7 TERMINATE A PREGNANCY IF THE CIRCUMSTANCE IN WHICH THE WOMAN'S  
8 HEALTH WAS RAPIDLY DETERIORATING?

9 A. NO, BECAUSE IT NEEDS THE DILATION OF THE CERVIX OVER TWO  
10 DAYS BEFORE IT CAN BE ACCOMPLISHED. SO WITH SICK WOMEN WE  
11 DON'T HAVE TWO OR THREE DAYS, MANY TIMES. THEY WOULD  
12 DECOMPENSATE AND BE NEAR DEATH AT THAT POINT.

13 Q. I NOW WOULD LIKE TO ASK YOU SOME QUESTIONS ABOUT FETAL  
14 ANOMALIES. DO YOU DIAGNOSE YOUR PATIENTS WITH FETAL ANOMALIES?

15 A. YES, I DO.

16 Q. HOW DO YOU GO ABOUT MAKING SUCH A DIAGNOSIS?

17 A. IT IS COMMON TO ORDER A SECOND-TRIMESTER ULTRASOUND, WHICH  
18 WOULD LOOK AT SPECIFIC ORGAN SYSTEMS OF THE BABY AND SEE IF  
19 THEY ARE WITHIN NORMAL LIMITS OR THEY MAY HAVE SOME KIND OF  
20 ORGAN ABNORMALITIES.

21 WE DO THIS BASICALLY WITH ALL OUR PREGNANT PATIENTS.

22 Q. WHAT HAPPENS WHEN ONE OF YOUR PATIENTS IS DIAGNOSED WITH A  
23 FETAL ANOMALY?

24 A. FIRST WHAT HAPPENS IS I WILL SIT DOWN FACE-TO-FACE AND  
25 EXPLAIN WHAT THE ULTRASOUND SHOWED. I MIGHT SHOW HER PICTURES.

1 I WOULD AFFORD THEM THE OPPORTUNITY, AFTER I EXPLAINED WHAT IT  
2 WAS, FOR THEM TO ASK QUESTIONS. AND THEN, MANY TIMES, I WILL  
3 MAKE CONSULTATIVE REFERRAL TO THE MATERNAL FETAL MEDICINE GROUP  
4 SO THAT THE WOMAN CAN HAVE A SECOND OPINION ABOUT THE FETAL  
5 ANOMALY AND WHAT IT MIGHT MEAN FOR HER AND THE BABY AND WHAT  
6 HER OPTIONS ARE.

7 Q. IN CASES INVOLVING A FETAL ANOMALY, CAN THERE BE MATERNAL  
8 HEALTH PROBLEMS ASSOCIATED WITH THE ANOMALY THAT MAY REQUIRE  
9 TERMINATION OF THE PREGNANCY IN ORDER TO PROTECT THE HEALTH  
10 INTERESTS OF THE MOTHER?

11 A. GENERALLY, THEY ARE SEPARATE CONDITIONS. THE FETAL ANOMALY  
12 IS ONE OPTION -- IS ONE SEPARATE SET OF ISSUES AROUND THE BABY.  
13 AND THEN, THE MATERNAL HEALTH CONDITION IS A SEPARATE ISSUE.

14 Q. DO YOU HAVE KNOWLEDGE ABOUT THE PROCEDURES THAT MAY BE USED  
15 TO TERMINATE A PREGNANCY FOR A FETAL ANOMALY?

16 A. YES.

17 Q. WHAT KINDS OF ABORTIONS ARE AVAILABLE FOR SECOND-TRIMESTER  
18 ABORTIONS AT THE UNIVERSITY OF MICHIGAN?

19 A. WOMEN ARE OFFERED BOTH THE D&E, THE DISARTICULATION  
20 PROCEDURE, AS WELL AS MEDICAL INDUCTIONS OF LABOR. AND THAT  
21 STARTS AS EARLY AS 16 WEEKS FOR MEDICAL INDUCTION OF LABOR WITH  
22 ANOMALIES.

23 Q. WHAT METHOD OF TERMINATION WOULD YOU RECOMMEND FOR A  
24 PREGNANCY TERMINATION INVOLVING A FETAL ANOMALY AFTER 20 WEEKS?

25 A. GENERALLY, WE ALMOST ALWAYS OFFER THE MEDICAL INDUCTION AS

1 OUR FIRST CHOICE.

2 Q. AND WHY DO YOU OFFER MEDICAL INDUCTION AS THE FIRST CHOICE  
3 AT 20 WEEKS OR LATER?

4 A. JUST BECAUSE THE SAFETY DATA IS SO MUCH BETTER AT 20 WEEKS  
5 AND GREATER, ESPECIALLY NOW THAT WE USE ALMOST EXCLUSIVELY  
6 MISOPROSTOL FOR INDUCTIONS, ALTHOUGH NOT EXCLUSIVELY.

7 Q. DO YOU CONTINUE TO TREAT YOUR PATIENTS AFTER THEY HAVE HAD  
8 A TERMINATION FOR A FETAL ANOMALY?

9 A. I MAKE IT REALLY CLEAR TO WOMEN THAT I AM THEIR DOCTOR,  
10 WHETHER THEY CHOOSE TO HAVE AN ABORTION FOR EITHER FETAL  
11 ANOMALIES OR ELECTIVELY OR FOR WHATEVER REASON; THAT I WANT TO  
12 CONTINUE TO BE THEIR DOCTOR AFTERWARDS. AND I HAVE DONE THAT  
13 ON MANY OCCASIONS.

14 Q. HAVE YOU DELIVERED BABIES FOR SOME OF YOUR PATIENTS AFTER  
15 THEY HAVE HAD A TERMINATION FOR MATERNAL COMPLICATION OR  
16 BECAUSE OF A FETAL ANOMALY?

17 A. YES, I HAVE.

18 Q. DOCTOR, IN YOUR OPINION, IS THE D&X PROCEDURE EVER  
19 NECESSARY TO TERMINATE A PREGNANCY IN WHICH THERE IS A FETAL  
20 ANOMALY?

21 A. NO.

22 Q. WHY NOT?

23 A. THERE ARE JUST OTHER BETTER METHODS, BOTH THE D&E  
24 DISARTICULATION METHOD AS WELL AS MEDICAL INDUCTION HAVE SAFETY  
25 DATA THAT WE KNOW ABOUT FROM MANY DIFFERENT SOURCES, FROM MANY

1 DIFFERENT INSTITUTIONS, BOTH NATIONALLY, INTERNATIONALLY, SO  
2 THAT WE HAVE SOME BASIS TO TALK ABOUT SAFETY WHEN WE TALK ABOUT  
3 THOSE TWO PROCEDURES.

4 Q. IN YOUR EXPERIENCE IN TREATING PATIENTS WITH FETAL  
5 ANOMALIES, IS THERE ANYTHING UNIQUE ABOUT THE FETAL ANOMALIES  
6 THAT YOU HAVE SEEN THAT WOULD REQUIRE AN INTACT EXTRACTION AS  
7 PERFORMED IN THE D&X PROCEDURE AS YOU UNDERSTAND THAT  
8 PROCEDURE?

9 A. NO, I HAVE NOT.

10 Q. HAVE YOU EVER HAD A PATIENT WITH THE FETAL ANOMALY OF  
11 CONJOINED TWINS?

12 A. YES, I HAVE.

13 Q. WHAT HAPPENED WITH THAT PATIENT?

14 A. THIS WAS A PATIENT OF MINE WHO I HAD HELPED WITH HER FIRST  
15 PREGNANCY, AND THIS WAS A SECOND PREGNANCY. AND SHE WAS  
16 DIAGNOSED ON HER ROUTINE ULTRASOUND OF HAVING TWO BABIES, AND  
17 TWO BABIES CONNECTED AT BOTH THE THORAX OR UPPER CHEST AND  
18 LOWER ABDOMEN. SO THERE WERE TWO BABIES, TWO HEADS, TWO SETS  
19 OF SHOULDERS, ET CETERA.

20 AND SO, WE TALKED IN THE OFFICE RIGHT AFTERWARDS,  
21 THAT THIS, BECAUSE OF THE KIND OF ANOMALY IT WAS, WASN'T  
22 SOMETHING THAT COULD BE FIXED BECAUSE OF HOW COMPLICATED THE  
23 HEART DEFECT WAS. AND IT WASN'T SOMETHING THAT YOU COULD JUST  
24 SEPARATE THE BABIES AND THEY WOULD BE FINE LATER; YOU KNOW,  
25 THAT IT PROBABLY WAS A LETHAL ANOMALY FOR THE BABIES.

1 SO WE WENT OVER THAT INFORMATION. WE TALKED ABOUT  
2 IT. I ANSWERED ALL HER QUESTIONS. AND THEN, I HAD HER GO SEE  
3 THE MATERNAL FETAL MEDICINE SPECIALIST, AS WELL.

4 AND THEN, IN THE END, WE TALKED AGAIN BEFORE SHE  
5 MADE HER DECISION AND SHE CHOSE TO HAVE A TERMINATION OF THE  
6 PREGNANCY. AND THE TECHNIQUE WAS USED WAS MEDICAL INDUCTION.

7 Q. DID YOU LATER TREAT THAT PATIENT?

8 A. YES. SHE LATER -- NOT ONLY DID I DO HER POSTPARTUM EXAM  
9 AFTER THE TERMINATION OF PREGNANCY, BUT ALSO IN ANOTHER  
10 PREGNANCY I TOOK CARE OF HER AND SHE DELIVERED AT TERM A  
11 HEALTHY BABY.

12 Q. DR. SHADIGIAN, AT THE UNIVERSITY OF MICHIGAN ARE YOU AWARE  
13 OF THE D&X PROCEDURE BEING TAUGHT TO MEDICAL STUDENTS?

14 A. NO, I AM NOT.

15 Q. TO RESIDENTS?

16 A. NO, I AM NOT.

17 Q. WOULD YOU KNOW IF THE D&X PROCEDURE WERE BEING TAUGHT?

18 A. YES, I PROBABLY WOULD, BECAUSE I ATTEND AS MUCH AS I CAN A  
19 WEEKLY CONFERENCE CALLED "MORBIDITY AND MORTALITY" WHERE WE GO  
20 OVER ALL THE DIFFERENT SURGICAL CASES AND ALL THE DIFFERENT  
21 LABOR COMPLICATIONS. SO THAT WOULD BE CONSIDERED A SURGICAL  
22 CASE, AND WE WOULD TALK ABOUT IT AT OUR WEEKLY MEETING.

23 Q. ARE YOU AWARE OF RESIDENTS BEING TAUGHT THEY SHOULD TRY TO  
24 REMOVE THE FETUS AS INTACT AS POSSIBLE WHEN PERFORMING A D&E  
25 PROCEDURE WITH A GOAL TOWARD AN INTACT REMOVAL?

1 A. NO, I AM NOT.

2 Q. HAVE YOU EVER PERFORMED A D&E PROCEDURE WHEN THE FETUS CAME  
3 OUT INTACT UP TO THE HEAD?

4 A. NO, I HAVE NOT.

5 Q. HAVE YOU EVER WITNESSED ANOTHER PHYSICIAN PERFORM A  
6 PROCEDURE IN WHICH THE FETUS WAS REMOVED INTACT UP TO THE HEAD?

7 A. NO, I HAVE NOT.

8 Q. DO YOU THINK THERE ARE BENEFITS TO PERFORMING THE D&X  
9 PROCEDURE ON WOMEN AT THIS TIME?

10 A. I DON'T KNOW.

11 Q. AND WHY DON'T YOU KNOW?

12 A. WELL, IN THE ABSENCE OF ANY SAFETY DATA, I CAN'T REALLY SAY  
13 THERE IS OR THERE ISN'T.

14 Q. IN YOUR MEDICAL OPINION, IF A PHYSICIAN WERE GOING TO  
15 SURGICALLY REMOVE A FETUS AS INTACT AS POSSIBLE, WHAT DO YOU  
16 THINK PATIENTS SHOULD BE TOLD ABOUT THE INTACT SURGICAL  
17 REMOVAL?

18 A. I THINK THAT THEY SHOULD BE TOLD THAT IT IS A DIFFERENT  
19 PROCEDURE THAN A DISARTICULATION D&E PROCEDURE; THAT THEY  
20 SHOULD BE SEPARATELY CONSENTED FOR THIS PROCEDURE. JUST LIKE  
21 D&C IS A FIRST-TRIMESTER PROCEDURE THAT REMOVES THE BABY AND  
22 THE PLACENTA FROM THE UTERUS, WE CALL IT A SEPARATE PROCEDURE  
23 TO CALL IT D&E PROCEDURE, EVEN THOUGH, IN ESSENCE, THEY  
24 ACCOMPLISH A SIMILAR TASK.

25 SO IN THE SAME VEIN, I WOULD TELL A PATIENT THAT A



1 D&X PROCEDURE IS A DIFFERENT PROCEDURE THAN THE D&E PROCEDURE,  
2 AND THAT IT DILATES THE CERVIX MORE. THAT IT IS USUALLY  
3 PERFORMED LATER IN A PREGNANCY, AND THAT IT INVOLVES A  
4 NONPHYSIOLOGIC PULLING THE BABY THROUGH THE CERVICAL OS AND  
5 THEN EXPLAINING THE WHOLE PROCEDURE IN TERMS OF WHAT HAPPENS  
6 WITH THE BABY'S HEAD, ET CETERA, SO THAT THEY COULD BE TRULY  
7 INFORMED OF WHAT IT IS.

8 Q. IN YOUR MEDICAL OPINION, IS IT SOUND FOR PHYSICIANS TO RELY  
9 ON THEIR OWN EXPERIENCE IN PERFORMING THE D&X IN DECIDING TO  
10 PERFORM A D&X ON A PATIENT?

11 A. NO.

12 Q. DOCTOR, THE COURT HAS HEARD PHYSICIANS TESTIFY WHO HAVE  
13 PERFORMED D&X PROCEDURES AND WHO PERFORMED SOME VARIATION OF  
14 THE D&X PROCEDURE. THEY HAVE TESTIFIED THAT THE PROCEDURE IS  
15 SAFE, BASED ON EXPERIENCE.

16 WHAT IS YOUR OPINION WITH RESPECT TO THE ASSERTIONS  
17 THAT THE D&X PROCEDURE IS INTUITIVELY SAFE BASED ON CLINICAL  
18 EXPERIENCES WITH THAT PROCEDURE?

19 A. WELL, I BELIEVE THAT THOSE ABORTION PROVIDERS ARE TELLING  
20 THE TRUTH; THAT THEY BELIEVE THAT THE D&X IS JUST AS SAFE AS A  
21 D&E DISARTICULATION PROCEDURE. BUT IT IS REALLY BASED ON  
22 ANECDOTE. IT'S JUST BASED ON DOING THIS PROCEDURE AT THE SAME  
23 TIME ON DIFFERENT PATIENTS.

24 SO THAT IT CAN BE CONSIDERED SORT OF LIKE A CASE,  
25 BUT IT CAN'T BE CONSIDERED LONG-TERM SAFETY DATA. IT CAN'T BE

1 CONSIDERED SHORT-TERM SAFETY DATA, ESPECIALLY BECAUSE MOST  
2 ABORTION PROVIDERS NEVER SEE THEIR PATIENTS BACK AFTER THE  
3 ABORTION PROCEDURE.

4 MS. KRASNOFF: OBJECTION, YOUR HONOR, FOUNDATION.

5 THE COURT: SUSTAINED.

6 MS. CLARK: IS IT SUSTAINED ON A PATIENT -- I MEAN,  
7 THEY NEVER SEE THEM BACK, THOUGH, THAT PART OF THE FOUNDATION?

8 THE COURT: THE FIRST PART OF THE QUESTION.

9 BY MS. CLARK:

10 Q. DOCTOR, YOU TESTIFIED THAT MANY PATIENTS DON'T GO BACK TO  
11 THE DOCTOR FOR WHOM THEY RECEIVE ABORTION FOLLOW-UP CARE; IS  
12 THAT CORRECT? OR SOMETHING TO THAT --

13 MS. KRASNOFF: I BELIEVE THAT WAS STRICKEN BASED ON  
14 THE OBJECTION.

15 THE COURT: THE OBJECTION WAS SUSTAINED. YOU NEED  
16 TO ESTABLISH A FOUNDATION THAT SHE HAS THAT KNOWLEDGE.

17 BY MS. CLARK:

18 Q. DOCTOR, DO YOU HAVE AN OPINION AS TO WHETHER OR NOT  
19 PATIENTS FREQUENTLY RETURN TO THEIR PHYSICIAN WHO PERFORMED THE  
20 ABORTION FOR FOLLOW-UP CARE? JUST DO YOU HAVE AN OPINION?

21 A. YES, I DO HAVE AN OPINION.

22 Q. WHAT IS THAT OPINION BASED ON?

23 A. THE OPINION IS BASED ON TWO THINGS: ONE, MY OWN PATIENTS  
24 WHO HAVE RECEIVED ABORTIONS FROM DIFFERENT PROVIDERS, AND  
25 SECOND FROM MEDICAL RESEARCH.

1 Q. AND WHEN YOU ARE REFERRING TO MEDICAL RESEARCH, WHAT  
2 MEDICAL RESEARCH ARE YOU REFERRING TO?

3 A. SPECIFICALLY THERE HAVE BEEN STUDIES LOOKING AT THE QUALITY  
4 OF ABORTION CARE AND HOW WOMEN PERCEIVE THEIR ABORTION CARE.  
5 AND ONE OF THE STUDIES I REVIEWED SPECIFICALLY FOR THIS, BUT I  
6 REVIEWED IT IN THE PAST, WAS SOMETHING CALLED A PICKER REPORT  
7 FROM 1999.

8 AND SPECIFICALLY THEY ASKED WOMEN -- WHICH WAS OVER  
9 A THOUSAND WOMEN -- IF THEY ACTUALLY GO BACK FOR THEIR  
10 FOLLOW-UP EXAM TO THE SAME PROVIDER THAT PROVIDED THE ABORTION.  
11 AND THEY SAID -- 29 PERCENT OF WOMEN SAID THAT THEY DID GO BACK  
12 TO THE SAME ABORTION PROVIDER. AND 71 PERCENT SAID THEY DID  
13 NOT.

14 MS. CLARK: MAY I APPROACH?

15 BY MS. CLARK:

16 Q. I AM SHOWING YOU WHAT HAS BEEN IDENTIFIED AS DEFENDANT'S  
17 EXHIBIT NUMBER LT A-42. IS THIS THE PICKER STUDY THAT YOU WERE  
18 MENTIONING?

19 A. YES, IT IS.

20 Q. IF YOU WOULD TURN TO PAGE 43.

21 A. I AM THERE.

22 Q. WHERE ON PAGE 43 DOES THIS SUPPORT YOUR OPINION THAT WOMEN  
23 DON'T RETURN FOR FOLLOW-UP AFTER AN ABORTION HAS BEEN  
24 PERFORMED?

25 A. ON QUESTION NUMBER 60, THE QUESTION ASKED:

1 "DID YOU GO BACK TO THIS CLINIC FOR A FOLLOW-UP  
2 VISIT?"

3 "YES," 30 PERCENT. "NO," 69 PERCENT. "DON'T KNOW"  
4 OR REFUSED TO ANSWER, ONE PERCENT.

5 Q. THANK YOU.

6 DOCTOR, HAVE YOU REVIEWED DR. HASKELL'S 1992 PAPER  
7 REGARDING THE D&X PROCEDURE?

8 A. YES, I HAVE.

9 Q. WOULD YOU AGREE IN THE PAPER DR. HASKELL REPORTED ON THE  
10 RESULT OF THE CASES HE HAD UNDERTAKEN USING THE D&X PROCEDURE,  
11 AND THAT HE FOUND NO COMPLICATIONS WITH THE PROCEDURE?

12 MS. KRASNOFF: OBJECTION, HEARSAY.

13 THE COURT: I AM SORRY. I CAN'T QUITE -- OKAY. THE  
14 QUESTION WAS -- COULD YOU REPEAT IT?

15 BY MS. CLARK:

16 Q. WOULD YOU AGREE THAT IN THAT DR. HASKELL PAPER THAT HE  
17 REPORTED ON THE RESULTS OF CASES HE HAD UNDERTAKEN USING THE  
18 D&X PROCEDURE AND THAT HE FOUND NO COMPLICATIONS WITH THE  
19 PROCEDURE?

20 THE COURT: OKAY. I WILL ALLOW THE QUESTION.

21 THE WITNESS: THAT'S WHAT DR. HASKELL DID SAY IN HIS  
22 PAPER.

23 BY MS. CLARK:

24 Q. ISN'T THAT A CASE REVIEW THAT PROVIDES SOME BASIS OF  
25 EVIDENCE FOR THE PROCEDURE'S SAFETY?

1 A. DR. HASKELL'S PAPER CAN BE CONSIDERED LIKE A SERIES OF  
2 CASES, YES.

3 Q. AND ASSUMING HIS REPORT ABOUT NO COMPLICATIONS IS CORRECT,  
4 IT'S TRUE, ISN'T IT, THAT IN UNDERSTANDING THE SAFETY OF A  
5 PROCEDURE THAT BEGINS WITH CASE REVIEWS SUCH AS DR. HASKELL'S;  
6 IS THAT RIGHT?

7 A. YES, MANY TIMES WHEN WE START EVALUATING A NEW PROCEDURE WE  
8 LOOK TO CASE REPORTS AS A FIRST LINE OF A NEW PROCEDURE.

9 Q. IN YOUR OPINION, IS IT SUFFICIENT TO RELY ON SUCH  
10 SELF-REPORTED CASE REVIEWS OF PHYSICIANS WHO ARE REPORTING A  
11 PROCEDURE AND EVALUATING THE SAFETY OF THE PROCEDURE?

12 A. NO, IT IS NOT.

13 Q. WHY NOT?

14 A. THERE ARE SEVERAL REASONS WHY THAT IS NOT ADEQUATE MEDICAL  
15 EVIDENCE-BASED MEDICINE. AND FIRST OF ALL, FOR EXAMPLE,  
16 DR. HASKELL NEVER EXPLAINS TO US HOW HE KNOWS THERE WERE NO  
17 COMPLICATIONS. HE DOESN'T EXPLAIN HOW WOMEN WERE FOLLOWED OR  
18 IF THEY EVEN GAVE A FOLLOW-UP PHONE CALL TO THE PATIENTS.

19 IN ADDITION --

20 MS. KRASNOFF: OBJECTION, HEARSAY.

21 THE COURT: I AM GOING TO PERMIT IT. WE ALL READ  
22 THE REPORT. YOU KNOWS WHAT IT SAYS. YOU KNOW IT DOESN'T  
23 EXPLAIN IT.

24 THE WITNESS: THE OTHER ISSUES ARE THAT THERE WERE  
25 NO CONTROL GROUPS FOR WHICH TO COMPARE THE NEW PROCEDURE, THE

1 D&X PROCEDURE, TO WELL-STUDIED AND WELL-EXPLAINED PROCEDURES  
2 SUCH AS A DISARTICULATION D&E OR MEDICAL INDUCTION, FOR  
3 EXAMPLE.

4 AND SO IT IS JUST A SERIES OF "I DID THIS PROCEDURE,  
5 AND THIS IS THE OUTCOME I REPORT."

6 FINALLY, BECAUSE THERE WAS NO ONE ELSE COMPARING IT,  
7 MANY TIMES WE LIKE TO HAVE SURGEONS OR OTHER PEOPLE WHO DO A  
8 CERTAIN KIND OF PROCEDURE HAVE OTHER PEOPLE EVALUATE THE DATA  
9 SO IT LOOKS MORE BALANCED. AND THAT WASN'T DONE IN THE HASKELL  
10 REPORT, AS WELL.

11 BY MS. CLARK:

12 Q. NOW, WHAT IF A PHYSICIAN WHO IS PERFORMING THE PROCEDURE  
13 CONSULTS WITH OTHER PHYSICIANS WHO HAVE PERFORMED THE PROCEDURE  
14 AND COLLECTIVELY THOSE PHYSICIANS BELIEVE THAT THE PROCEDURE IS  
15 SAFE. IS THAT A WAY IN THE MEDICAL FIELD TO ASSESS THE SAFETY  
16 OF A PROCEDURE?

17 A. NO, IT IS NOT.

18 Q. AND WHY NOT?

19 A. IF I TALKED TO MY -- IF I AM DOING A NEW PROCEDURE THAT I  
20 THOUGHT UP OR DESIGNED, AND THEN I ASKED A COLLEAGUE TO DO IT  
21 AND TO ALSO TELL ME THEIR FEEDBACK ON IT, THAT IS CONSIDERED  
22 ANECDOTAL EVIDENCE OR NO DIFFERENT THAN CASE REPORT EVIDENCE.  
23 IT DOESN'T MEET AS A COMPARISON GROUP, AND IT HASN'T BEEN PEER  
24 REVIEWED, FOR EXAMPLE.

25 Q. WHAT IS YOUR RESPONSE TO THE ASSERTION THAT IN TRYING TO

1 COMPARE D&X TO DISMEMBERMENT D&E IN PROSPECTIVE STUDY, THAT IT  
2 WOULD BE DIFFICULT TO DO BECAUSE SOME WOMEN WOULD CHOOSE TO  
3 UNDERGO DISMEMBERMENT -- THAT SOME WOMEN WOULD NOT CHOOSE TO  
4 UNDERGO DISMEMBERMENT WHEN THE INTACT PROCEDURE IS AVAILABLE?

5 A. I WOULD SAY YOU WOULD BE ABLE TO DO A PROSPECTIVE TRIAL.  
6 AND WE HAVE EXAMPLES IN THE MEDICAL LITERATURE WHERE WE HAVE  
7 DONE SUCH THINGS, AND WE DIDN'T KNOW THE BEST OUTCOME FOR  
8 WOMEN.

9 FOR EXAMPLE, THERE IS SOMETHING CALLED A "TERM  
10 BREECH TRIAL" WHERE WOMEN WHO HAD -- WELL, WHERE THE MEDICAL  
11 COMMUNITY HAD SAID WITH RETROSPECT IN LOOKING BACK AT THE DATA  
12 THAT WE WEREN'T SURE IF IT WAS BETTER FOR WOMEN WITH A BREECH  
13 PRESENTATION AT TERM TO UNDERGO A C-SECTION TO DELIVER THE BABY  
14 OR HAVE A VAGINAL BREECH DELIVERY.

15 SO WE THOUGHT WE KNEW THE RIGHT ANSWER FROM THE  
16 MEDICAL LITERATURE, LOOKING BACKWARDS, BUT EVERYONE UNDERSTOOD,  
17 EPIDEMIOLOGICALLY, WE COULDN'T REALLY KNOW THE RIGHT ANSWER  
18 UNTIL WE DID A PROSPECTIVE TRIAL.

19 SO WHAT HAPPENED IS MANY MEDICAL CENTERS ALL OVER  
20 THE WORLD CAME TOGETHER AND SAID:

21 "WE WANT TO DESIGN A STUDY WHERE WOMEN ARE  
22 RANDOMIZED OR ARBITRARILY PLACED IN ONE GROUP OR  
23 THE OTHER TO DELIVER BY BASICALLY PICKING OUT OF THE  
24 HAT A NUMBER."

25 AND SO WOMEN WOULD ACTUALLY SIGN ON TO THIS STUDY

1 AND SAY:

2 "YES, YOU MAY RANDOMIZE ME TO EITHER CESAREAN  
3 SECTION OR TO VAGINAL BREECH DELIVERY."

4 Q. DID YOU HAVE ANY PARTICIPATION AT ALL IN THAT RANDOMIZED  
5 TRIAL?

6 A. I WAS NOT A PRINCIPAL INVESTIGATOR, BUT I ACTUALLY HAD THE  
7 MOST NUMBER OF PATIENTS ENROLLED AT UNIVERSITY OF MICHIGAN IN  
8 THE TERM BREECH TRIAL.

9 Q. AND WITH YOUR PATIENTS, HOW DID YOU GO ABOUT EXPLAINING THE  
10 RISK OF THE TWO PROCEDURES IN THAT PROCEDURE TO YOUR PATIENTS?

11 A. SORT OF WHAT I JUST SAID. BASICALLY, THAT WE DON'T KNOW  
12 WHAT THE RIGHT ANSWER IS. AND THAT THAT IS WHY WE ARE DOING  
13 THIS TRIAL IS TO FIGURE OUT IS IT SAFER FOR WOMEN AND BABIES TO  
14 HAVE A C-SECTION WHEN THERE IS A BREECH PRESENTATION OR IS IT  
15 SAFER FOR WOMEN AND BABIES TO HAVE A VAGINAL BREECH DELIVERY?

16 SO JUST THAT I COULD EXPLAIN TO THEM THAT I DIDN'T  
17 KNOW WHAT THE RIGHT ANSWER WAS NOR DID OTHER PEOPLE IN THE  
18 FIELD KNOW WHAT THE TRUE, RIGHT ANSWER WAS UNTIL WE DO THIS  
19 PROSPECTIVE, RANDOMIZED TRIAL.

20 Q. AND WHY DID YOU PICK THIS BREECH VERSUS C-SECTION AS A  
21 COMPARISON TO A D&X RANDOMIZED TRIAL?

22 A. WELL, BECAUSE IT'S A SIMILAR KIND OF ISSUE. YOU ARE ASKING  
23 WOMEN:

24 "DO YOU WANT TO UNDERGO A PROCEDURE LOOKING AT  
25 A SURGICAL PROCEDURE VERSUS" -- YOU CAN GIVE AN



1                   EXAMPLE A MEDICAL INDUCTION PROCEDURE. THAT WOMEN  
2 WOULD CONSENT TO BE RANDOMIZED TO SURGERY VERSUS MEDICAL  
3 INDUCTION OR POSSIBLY EVEN TWO DIFFERENT KINDS OF SURGERY.

4 Q. IN YOUR OPINION, DOCTOR, COULD THE D&X PROCEDURE BE  
5 COMPARED TO THE INDUCTION PROCEDURE IN RANDOMIZED PROSPECTIVE  
6 TRIAL?

7 A. YES.

8 Q. DR. SHADIGIAN, I NOW WOULD LIKE TO ASK YOU SOME QUESTIONS  
9 ABOUT LONG-TERM COMPLICATIONS OF ABORTION. HAVE YOU EVER  
10 WRITTEN ABOUT THIS ISSUE?

11 A. YES, I HAVE.

12                   MS. KRASNOFF: YOUR HONOR, I WANT TO CLARIFY. I AM  
13 A LITTLE CONFUSED ABOUT THIS TESTIMONY. MY UNDERSTANDING THAT  
14 THE RESEARCH THAT DR. SHADIGIAN IS ABOUT TO DISCUSS LOOKS AT  
15 ALL METHODS OF ABORTION AND DOESN'T RELATE IN ANY WAY TO A  
16 SPECIFIC METHOD OF ABORTION OR A SPECIFIC GESTATIONAL AGE. AND  
17 I AM CONFUSED IF DEFENDANTS ARE SEEKING TO USE THIS BECAUSE  
18 THEY BELIEVE THAT THIS ARTICLE AND THESE COMPLICATIONS APPLY TO  
19 CERTAIN SPECIFIC SECOND-TRIMESTER ABORTION METHODS.

20                   THE COURT: DO YOU HAVE AN ANSWER?

21                   MS. CLARK: I AM GOING TO ASK DR. SHADIGIAN TO GO  
22 THROUGH HER ARTICLE THAT IS ABOUT LONG-TERM COMPLICATIONS OF  
23 ABORTION. AND THE MAIN PURPOSE OF IT IS TO ESTABLISH THAT  
24 THERE ARE LONG-TERM COMPLICATIONS OF ABORTION.

25                   THE COURT: WHICH KIND OF ABORTION?

1 MS. CLARK: INDUCED ABORTION. AND IT IS NOT  
2 SPECIFIC TO D&X OR A PARTICULAR KIND OF ABORTION, BUT INDUCED  
3 ABORTION IN THE FIRST-TRIMESTER AND ALSO IN THE  
4 SECOND-TRIMESTER, I BELIEVE. AND TO THE EXTENT THAT SHE HAS  
5 WRITTEN AN ARTICLE ABOUT IT, THAT THAT ESTABLISHES THERE ARE  
6 LONG-TERM COMPLICATIONS TO ABORTION WHICH, IF STUDIED, MAY, IN  
7 FACT, APPLY TO THE D&X PROCEDURE.

8 THE COURT: BUT WE DON'T KNOW NOW WHETHER OR NOT IT  
9 DOES APPLY? I AM NOT PARTICULARLY INTERESTED IN THE LONG-TERM  
10 HEALTH EFFECTS OF FIRST-TRIMESTER ABORTIONS, FOR INSTANCE.  
11 THAT IS NOT AT ISSUE HERE.

12 MS. CLARK: WELL, I THINK IT IS TO ESTABLISH THAT  
13 THERE ARE LONG-TERM EFFECTS RATHER THAN JUST THE SHORT-TERM  
14 COMPLICATIONS, THAT THERE ARE LONG-TERM COMPLICATIONS FROM  
15 ABORTION PROCEDURES.

16 D&X HASN'T BEEN STUDIED WHETHER OR NOT THERE ARE  
17 LONG-TERM COMPLICATIONS. AND TO THE EXTENT THERE IS LONG-TERM  
18 COMPLICATIONS FROM OTHER ABORTIONS THAT SUGGESTS THAT THERE MAY  
19 WELL BE LONG-TERM COMPLICATIONS FROM THE D&X PROCEDURE.

20 THE COURT: ALL RIGHT. WHAT IS YOUR OBJECTION?

21 MS. KRASNOFF: THIS ARTICLE DOESN'T SEPARATE OUT ANY  
22 METHOD OF ABORTION FROM THE OTHER, SO IT WOULD APPLY EQUALLY TO  
23 ALL METHODS OF ABORTION. IN FACT, THE MAJORITY OF THE  
24 ABORTIONS INCLUDED IN THE STUDY ARE FIRST-TRIMESTER ABORTIONS.

25 UNLESS DEFENDANT IS SUGGESTING THAT THIS LAW APPLIES

1 TO ALL OF THOSE METHODS OF ABORTION, I DON'T SEE HOW IT IS  
2 RELEVANT.

3 THE COURT: I AM GOING TO ALLOW YOU TO DO IT,  
4 MS. CLARK. AND IT SEEMS TO ME THAT MOST OF YOUR ARGUMENT GOES  
5 TO THE WEIGHT ACCORDED THIS EVIDENCE. GIVEN THAT IT IS NOT  
6 CLEAR THAT IT APPLIES TO THE PROCEDURES WE ARE INTERESTED IN, I  
7 WOULD LIKE YOU TO TRY TO AVOID QUESTIONS THAT ARE GOING TO  
8 RESULT IN ANSWERS BASED UPON FIRST-TRIMESTER ABORTIONS.

9 I AM SIMPLY NOT INTERESTED IN HEARING THAT, AND I  
10 CAN'T IMAGINE HOW THAT WOULD AFFECT THE DECISION THAT NEEDS TO  
11 BE MADE HERE. TO THE EXTENT THAT YOU ARE TALKING GENERALLY  
12 ABOUT THE LONG-TERM EFFECTS OF SECOND-TRIMESTER ABORTIONS, THAT  
13 IS FINE, AND I WILL ACCORD WHATEVER WEIGHT I THINK IS  
14 APPROPRIATE, DEPENDING ON THE METHODS USED.

15 MS. CLARK: I GUESS I WOULD JUST OFFER THAT THERE  
16 MAY BE -- THE FACT THAT THERE IS COMPLICATIONS IN THE  
17 FIRST-TRIMESTER, THAT MAY PROVIDE A BASIS FOR ANALYSIS ABOUT  
18 WHETHER OR NOT THERE WOULD BE COMPLICATIONS RELATED TO AN  
19 ABORTION PERFORMED IN THE SECOND-TRIMESTER.

20 THE COURT: I WILL TELL THE DOCTOR: I AM INTERESTED  
21 MORE IN SECOND-TRIMESTERS THAN FIRST-TRIMESTERS, SO TO THE  
22 EXTENT THAT YOU CAN DIFFERENTIATE YOUR ANSWERS, THE DIFFERENCES  
23 BETWEEN THOSE TWO TRIMESTERS, I WOULD APPRECIATE IT.

24 THE WITNESS: NOTED.

25 MS. CLARK: MAY I APPROACH?

1 THE COURT: YES.

2 BY MS. CLARK:

3 Q. DR. SHADIGIAN, I HAVE JUST SHOWN YOU AND HANDED YOU WHAT  
4 HAS BEEN IDENTIFIED AS DEFENDANT'S EXHIBIT A-56. IS THAT THE  
5 ARTICLE THAT YOU HAVE CO-AUTHORED REGARDING ABORTION  
6 COMPLICATIONS?

7 A. YES, IT IS.

8 Q. WHAT JOURNAL WAS THIS ARTICLE PUBLISHED IN?

9 A. IT WAS PUBLISHED IN A JOURNAL CALLED THE OBSTETRICAL AND  
10 GYNECOLOGICAL SURVEY.

11 Q. WHEN WAS IT PUBLISHED?

12 A. IT WAS PUBLISHED IN JANUARY OF 2003.

13 Q. WHAT WAS THE FULL NAME OF THE ARTICLE?

14 A. "LONG-TERM PHYSICAL AND PSYCHOLOGICAL HEALTH CONSEQUENCES  
15 OF INDUCED ABORTION: REVIEW OF THE EVIDENCE."

16 Q. ARE YOU RELYING ON THIS ARTICLE IN PROVIDING YOUR OPINIONS  
17 TODAY?

18 A. YES, I AM.

19 Q. IN WHAT WAY ARE YOU RELYING ON THIS ARTICLE IN YOUR  
20 OPINIONS YOU ARE OFFERING TODAY?

21 A. THIS IS AN EXAMPLE OF WHAT WE CALL "A SYSTEMATIC REVIEW OF  
22 THE LITERATURE."

23 SO RATHER THAN JUST LOOKING AT ONE STUDY THAT MAY  
24 HAVE LOOKED AT JUST, FOR EXAMPLE, FIRST-TRIMESTER ABORTIONS, WE  
25 TRIED TO COMPILE ALL OF THE STUDIES LOOKING AT SEVEN SEPARATE

DIANE E. SKILLMAN, OFFICIAL COURT REPORTER, USDC (415) 552-5393

1 POSSIBLE LONG-TERM EFFECTS OF INDUCED ABORTION.

2 SO IT IS TO ACTUALLY GIVE PEOPLE A FEEL, A FLAVOR  
3 AND A COMPILATION OF WHAT LONG-TERM EFFECTS MAY OR MAY NOT BE  
4 ASSOCIATED WITH INDUCED ABORTION.

5 THE COURT: LET ME MAKE SURE I UNDERSTAND. THIS  
6 ARTICLE HAS NOTHING TO DO WITH D&E'S. IT IS ALL INDUCED  
7 ABORTION?

8 THE WITNESS: NO. I AM SORRY. WE ARE USING THE  
9 TERM DIFFERENTLY. THIS ARTICLE -- EACH INDIVIDUAL ARTICLE THAT  
10 IS IN THIS ARTICLE THAT WE LOOKED AT, SOME MAY LOOK AT  
11 SECOND-TRIMESTER D&E'S. SOME MAY LOOK AT D&C'S IN THE  
12 FIRST-TRIMESTER. BECAUSE OF WHEN THESE STUDIES WERE PERFORMED,  
13 IT IS A COMBINATION. AND THE WAY I USE THAT WORD "INDUCED  
14 ABORTION" IS DIFFERENT.

15 WE MEAN IT JUST REGULAR ELECTIVE TERMINATION OF  
16 PREGNANCY WHEN WE USE IT IN THIS ARTICLE.

17 SO IF YOU WOULD LIKE ME TO USE A DIFFERENT TERM JUST  
18 SO WE ARE CONSISTENT IN THE RECORD, I WOULD BE GLAD TO.

19 THE COURT: I MIGHT CONFUSE THAT WITH INDUCTION  
20 ABORTIONS.

21 THE WITNESS: RIGHT. I GOT YOU. SO WOULD YOU  
22 PREFER "ELECTIVE TERMINATION OF PREGNANCY"? WOULD THAT BE A  
23 BETTER TERM?

24 THE COURT: YES.

25 THE WITNESS: OKAY. I WILL BE GLAD TO DO THAT.

1 MS. CLARK: SO --

2 MS. KRASNOFF: YOUR HONOR, I DON'T WANT TO BE PICKY  
3 ABOUT THE TERMINOLOGY, BUT I DON'T BELIEVE THERE IS ANY  
4 EVIDENCE THAT THE ABORTIONS IN THE UNDERLYING STUDIES WERE ALL  
5 ELECTIVE.

6 THE COURT: IS THAT CORRECT? DO YOU KNOW?

7 THE WITNESS: WHICH QUESTION DO YOU WANT ME TO  
8 ANSWER?

9 THE COURT: DO YOU KNOW WHETHER OR NOT THE ARTICLES  
10 UPON WHICH THIS ARTICLE RELIES ONLY STUDIED ELECTIVE ABORTIONS  
11 OR NOT?

12 THE WITNESS: IN FACT, IT DEPENDS ON THE ARTICLE  
13 ITSELF. SO THERE IS QUITE A FEW ARTICLES FROM DIFFERENT --  
14 EVEN INTERNATIONAL DATABASES. SO SOME WILL BE ELECTIVE  
15 TERMINATIONS AND SOME WILL NOT BE ELECTIVE TERMINATIONS. IT IS  
16 A MIX, BASICALLY, IS WHAT I AM TRYING TO SAY.

17 THE COURT: LET'S STAY AWAY FROM THAT TERM.

18 INSTEAD OF USING "INDUCED ABORTION," CAN YOU JUST  
19 USE "ABORTION"?

20 THE WITNESS: OKAY. THAT WOULD BE FINE. THANK YOU.

21 THE COURT: ALL RIGHT. START YOUR QUESTION OVER  
22 AGAIN.

23 BY MS. CLARK:

24 Q. WHAT KINDS OF THINGS DOES THIS ARTICLE ADDRESS?

25 A. BASICALLY, IT LOOKS AT THE ACTUAL TERMINATION OF A

1 PREGNANCY OR ABORTION AND TRIES TO SEE IF THERE IS A GREATER  
2 EFFECT LATER ON, MEANING GREATER THAN 60 DAYS AFTER THE  
3 PROCEDURE WITH SEVEN DIFFERENT POSSIBLE OUTCOMES.

4 Q. JUST AS A LITTLE BIT MORE BACKGROUND, HOW DID YOU GO ABOUT  
5 PREPARING AND WRITING THIS ARTICLE?

6 A. BASICALLY, WE STARTED WITH THE IDEA THAT WE WANTED TO SEE  
7 IF THERE WERE ANY LONG-TERM EFFECTS OF ABORTION. SO WE DECIDED  
8 TO DO A SYSTEMATIC REVIEW OF THE LITERATURE LOOKING AT MEDLINE,  
9 WHICH IS A DATABASE THAT COVERS MOST OF THE MAJOR, MAJOR  
10 JOURNALS IN THE INTERNATIONAL AND DOMESTIC OB/GYN AND  
11 EPIDEMIOLOGY LITERATURE.

12 AND THEN, WE DECIDED TO LOOK AT PAPERS THAT HAD AT  
13 LEAST A HUNDRED SUBJECTS IN IT SO IT WOULDN'T BE JUST THESE  
14 ANECDOTAL CASE REPORTS. IT WOULD BE ACTUALLY GOOD, FULL-FLEDGED  
15 STUDIES. AND TO LOOK AT THE GREATER THAN 60 DAYS, BECAUSE MOST  
16 OF THE STUDIES PRIOR TO THIS COMPILATION STUDY LOOKED AT JUST  
17 SHORT-TERM COMPLICATIONS. I MEAN, INFECTION RATES RIGHT AFTER  
18 THE PROCEDURE; HOW MANY RETAINED PRODUCTS WE WOULD HAVE; HOW  
19 MANY HEMORRHAGES.

20 SO IT IS TO DISTINGUISH BETWEEN THESE SHORT-TERM  
21 EFFECTS, WHICH WERE WELL STUDIED AND LONGER TERM EFFECTS THAT  
22 PRIOR TO THIS PUBLICATION HADN'T BEEN PUT TOGETHER IN THE SAME  
23 KIND OF WAY.

24 Q. SO WHEN YOU SAY "60 DAYS," YOU ARE LOOKING AT EFFECTS OF  
25 ABORTION THAT OCCURRED 60 DAYS AFTER THE ABORTION AND LATER; IS

1 THAT CORRECT?

2 A. YES, THAT IS CORRECT.

3 Q. AND DID YOU PARTICIPATE IN THE SYSTEMATIC REVIEW OF THE  
4 LITERATURE?

5 A. YES.

6 THE COURT: MS. CLARK, WE ARE LITTLE BIT PAST THE  
7 TIME FOR THE FIRST BREAK. WE WILL TAKE OUR 15-MINUTE BREAK.

8 (RECESS TAKEN AT 10:05 A.M.)

9 (PROCEEDINGS RESUMED AT 10:25 A.M.)

10 THE COURT: ALL RIGHT. PLEASE CONTINUE.

11 BY MS. CLARK:

12 Q. DR. SHADIGIAN, JUST TO BE CLEAR HERE, SOME OF THE  
13 UNDERLYING STUDIES RELIED UPON IN YOUR ARTICLE INVOLVE ABORTION  
14 COMPLICATIONS RESULTING FROM BOTH THE FIRST AND  
15 SECOND-TRIMESTER?

16 A. YES, THEY DO.

17 Q. IN THIS ARTICLE, YOU LOOKED AT SEVEN DIFFERENT  
18 COMPLICATIONS, DIFFERENT KINDS OF COMPLICATIONS. WHAT WERE  
19 THOSE COMPLICATIONS THAT YOU REVIEWED IN THIS ARTICLE?

20 A. THE SEVEN DIFFERENT COMPLICATIONS THAT WE LOOKED AT  
21 AGGREGATE STUDIES TO DETERMINE IF THERE WAS AN EFFECT OR NO  
22 LONG-TERM EFFECT WERE THE FOLLOWING: FIRST, SUBSEQUENT  
23 INFERTILITY OR NOT BEING ABLE TO GET PREGNANT AFTERWARDS;  
24 SUBSEQUENT SPONTANEOUS MISCARRIAGE. OTHER ONES WERE BREAST  
25 CANCER, PLACENTA PREVIA, PRE-TERM BIRTH, AND RISKS SUCH AS



1 DEPRESSION OR SELF-HARM.

2 AND, FINALLY, WE LOOKED AT ECTOPIC PREGNANCY, AS  
3 WELL.

4 Q. FOR ANY OF THE CONDITIONS THAT YOU EVALUATED IN THE  
5 SYSTEMATIC REVIEW, DID YOU FIND THAT THERE WAS INSUFFICIENT  
6 EVIDENCE TO SHOW THAT ABORTION LED TO ADVERSE HEALTH  
7 CONSEQUENCES?

8 A. YES. THREE OF THE HEALTH OUTCOMES WE EVALUATED THAT WERE  
9 GREATER THAN A HUNDRED DAYS -- SORRY -- GREATER THAN 60 DAYS  
10 AFTER THE TIME PERIOD WE LOOKED AT, THREE OF THEM DIDN'T SHOW  
11 ANY EFFECT OR A MINIMAL EFFECT. AND THOSE WERE ECTOPIC OR  
12 TUBAL PREGNANCIES, AND THEN, SUBSEQUENT MISCARRIAGES AND  
13 SUBSEQUENT INFERTILITY WERE NOT ASSOCIATED WITH ABORTION.

14 Q. AND, AGAIN, JUST TO MAKE THE RECORD CLEAR, IN THIS ARTICLE  
15 WHEN IT REFERS TO "ABORTION," WHAT DOES THAT REFER TO?

16 A. WE ARE TALKING ABOUT THE MIXTURE OF ABORTION FOR DIFFERENT  
17 ELECTIVE AND NONELECTIVE REASONS, AND IN THE FIRST AND  
18 SECOND-TRIMESTER.

19 Q. DOCTOR, WHAT ARE SOME OF THE LIMITATIONS IN TRYING TO  
20 DETERMINE THE HEALTH EFFECTS OF AN ABORTION?

21 A. THE IMPORTANT THINGS PEOPLE NEED TO REALIZE ARE THAT THESE  
22 ARE NOT ABSOLUTE CAUSATION EFFECTS. INSTEAD, WE SEE THAT THERE  
23 MAY HAVE BEEN A TIME AT A POINT IN TIME WHEN A CERTAIN  
24 PROCEDURE WAS DONE, FOR EXAMPLE, AN ABORTION. AND THEN, WE  
25 LOOK LATER TO SEE IF A WHOLE BUNCH OF WOMEN WHO HAD UNDERGONE

1 THE SAME KIND OF PROCEDURE HAD HEALTH EFFECTS THAT ARE  
2 DIFFERENT FROM WOMEN WHO DIDN'T UNDERGO THE SAME KIND OF  
3 PROCEDURE. SO THAT THE LIMITATIONS ARE THINGS LIKE: CAN WE  
4 FOLLOW THE WOMEN OVER A LONG PERIOD OF TIME? CAN WE ACTUALLY  
5 FIND THE WOMEN WHO HAD THOSE PROCEDURES MANY YEARS BEFORE, AND  
6 THEN, CAN WE LOOK AT THEIR HEALTH OUTCOMES?

7 Q. IS THE LACK OF FOLLOW-UP YOU TESTIFIED ABOUT EARLIER, IS  
8 THAT -- IN WHAT WAY IS THAT A LIMITATION IN STUDYING THE  
9 LONG-TERM COMPLICATIONS OF ABORTIONS?

10 MS. KRASNOFF: OBJECTION, YOUR HONOR. SHE HASN'T  
11 DONE ANY STUDIES. SHE HAS REVIEWED OTHER PEOPLE'S STUDIES.

12 THE COURT: SUSTAINED. REPHRASE.

13 BY MS. CLARK:

14 Q. DOCTOR, IN YOUR OPINION, IS THE LACK OF FOLLOW-UP YOU  
15 TESTIFIED ABOUT, IS THAT A LIMITATION IN TRYING TO DETERMINE  
16 THE LONG-TERM HEALTH EFFECTS OF ABORTION COMPLICATIONS ON  
17 WOMEN?

18 MS. KRASNOFF: SAME OBJECTION.

19 THE COURT: OVERRULED.

20 THE WITNESS: THAT IS ONE OF THE ISSUES WE NEED TO  
21 ALWAYS ADDRESS IN THESE KINDS OF STUDIES ARE: WHAT IS THE  
22 FOLLOW-UP CAN WE SEE FOR WOMEN?

23 FOR EXAMPLE, THERE IS NO DATABASE IN AMERICA THAT  
24 LOOKS AT ALL WOMEN WHO HAVE HAD INDUCED ABORTIONS AND WHAT  
25 THEIR HEALTH EFFECTS ARE. SO WE ARE LIMITED IN THIS COUNTRY

1 WITH NATIONAL DATABASES BECAUSE IT JUST DOESN'T EXIST HERE.

2           HOWEVER, IN MANY EUROPEAN COUNTRIES, THEY ACTUALLY  
3 DO HAVE ABORTION REGISTRIES AND ALSO HAVE NATIONAL HEALTH CARE.  
4 SO THEY ARE ABLE TO DO DIFFERENT KINDS OF STUDIES THAN WE ARE  
5 IN AMERICA.

6 BY MS. CLARK:

7 Q. DESPITE THESE LIMITATIONS, DOES THAT MEAN THAT LONG-TERM  
8 HEALTH CONSEQUENCES OF ABORTION CANNOT BE EVALUATED OR STUDIED?

9 A. NO, WE JUST NEED TO UNDERSTAND WHAT THE LIMITATIONS OF OUR  
10 STUDIES ARE AND WHAT THE POWER OF OUR STUDIES ARE SO THAT WE  
11 CAN DRAW CONCLUSIONS THAT MAKE MEDICAL SENSE, RATHER THAN JUST  
12 CONJECTURE.

13 Q. IN GENERAL TERMS, CAN YOU PLEASE DESCRIBE THIS ARTICLE AND  
14 WHAT IT CONCLUDES?

15 A. THE FINAL CONCLUSION OF THE ARTICLE IS THAT THERE ARE FOUR  
16 EFFECTS THAT WE NEED TO BE CONCERNED ABOUT IN THE LONG-TERM FOR  
17 WOMEN. AND THE ONE SPECIFIC ONE THAT IS ONE OF THE MOST  
18 CONCERNING ONES IS THE PRE-TERM BIRTH RATE THAT IS HIGHER FOR  
19 WOMEN WHO HAVE HAD AN ABORTION AS COMPARED TO WOMEN WHO HADN'T.

20           OTHER ONES WERE PLACENTA PREVIA WHERE THE PLACENTA  
21 CAN GROW OVER THE CERVIX. IT NECESSITATES A CESAREAN SECTION  
22 AND WILL GET INCREASED BLEEDING TO WOMEN. AND THEN, LONG-TERM  
23 PSYCHOLOGICAL EFFECTS, SUCH AS SELF-HARM AND SUICIDE OR SUICIDE  
24 ATTEMPTS. AND, FINALLY, BREAST CANCER THAT MAY BE INCREASED  
25 AFTER A WOMAN HAS HAD AN ABORTION AS COMPARED TO A WOMAN WHO

1 HAD NOT HAD AN ABORTION.

2 Q. DOCTOR, TURNING TO PAGE --

3 THE COURT: EXCUSE ME. IT DOESN'T MATTER WHAT KIND  
4 OF ABORTION; IS THAT CORRECT? WITH REGARD TO, FOR INSTANCE,  
5 THE PRE-TERM BIRTH RATE?

6 THE WITNESS: THE ANSWER IS THAT EACH STUDY DIVIDED  
7 IT UP DIFFERENTLY. SO YOU CAN LOOK AT INDIVIDUAL STUDIES TO IT  
8 HOW IT IS DIVIDED UP INTO FIRST-TRIMESTER ABORTION AND  
9 SECOND-TRIMESTER ABORTION.

10 THE COURT: WELL, WITHIN THE SECOND-TRIMESTER IS  
11 THERE A DISTINCTION BETWEEN INDUCTION ABORTION AND D&E'S?

12 THE WITNESS: IT WOULD DEPEND ON THE STUDY. I WOULD  
13 HAVE TO REVIEW THE ORIGINAL AGAIN TO BE ABLE TO ANSWER THAT  
14 ACCURATELY.

15 THE COURT: ALL RIGHT. AT SOME POINT DURING YOUR  
16 TESTIMONY I AM HOPING TO HEAR THAT. ALL RIGHT. YOU DON'T NEED  
17 TO DO IT RIGHT NOW.

18 BUT, COUNSEL, KEEP THAT IN MIND.

19 BY MS. CLARK:

20 Q. DOCTOR, IN THIS ARTICLE, DID YOU SEPARATE OUT WHETHER THE  
21 CONCLUSIONS WERE BASED ON FIRST-TRIMESTER OR SECOND-TRIMESTER  
22 ABORTIONS?

23 A. THAT WAS NOT DONE IN THIS PARTICULAR ARTICLE.

24 Q. DID YOU SEPARATE OUT WHETHER THE ABORTION WAS DONE BY AN  
25 INDUCTION METHOD OR A D&E METHOD?

1 A. THAT WAS NOT SEPARATED OUT IN THIS ARTICLE.

2 Q. AND IN WRITING THIS ARTICLE, DID YOU THINK IT WAS IMPORTANT  
3 TO SEPARATE OUT?

4 A. THE POINT OF THIS ARTICLE WAS TO LOOK AT ABORTION IN THE  
5 AGGREGATE. SO EVEN THOUGH INDIVIDUAL STUDIES MAY HAVE  
6 SEPARATED OUT, THERE WEREN'T ENOUGH OF THEM TO BE ABLE TO DO A  
7 SUBANALYSIS, SO THAT IS WHY THOSE WERE NOT DONE, SPECIFICALLY.

8 Q. DOCTOR, TURNING TO PAGE 74 OF THE ARTICLE, IF YOU TURN TO  
9 THE SECOND COLUMN ALMOST ALL THE WAY DOWN TO THE BOTTOM IT'S  
10 BEFORE THE LAST PARAGRAPH, AND THE SENTENCE BEGINNING:

11 "WOMEN DESERVE TO BE" -- DO YOU SEE THAT  
12 SENTENCE?

13 A. YES, I DO.

14 Q. CAN YOU READ THAT SENTENCE OUT LOUD, PLEASE?

15 A. YES.

16 "WOMEN DESERVE TO BE FULLY AND ACCURATELY  
17 INFORMED ABOUT POTENTIAL HEALTH EFFECTS OF ELECTIVE  
18 ABORTION, PREFERABLY IN A HEALTH EDUCATION CONTEXT  
19 SEPARATE AND DISTINCT FROM THE TIMEFRAME OF  
20 ACTUALLY BEING FACED WITH MAKING DIFFICULT DECISIONS  
21 ABOUT WHETHER TO CONTINUE OR END A PREGNANCY."

22 Q. DOES THAT SENTENCE REFLECT YOUR VIEWS AND OPINIONS ABOUT  
23 THE NEED TO INFORM WOMEN ABOUT THE HEALTH RISKS OF ABORTION?

24 A. YES.

25 Q. WHY DO YOU THINK IT IS IMPORTANT THAT WOMEN ARE FULLY

1 INFORMED?

2 A. WHEN A WOMAN CHOOSES TO HAVE AN ABORTION, IT'S IMPORTANT  
3 NOT TO JUST UNDERSTAND THE SHORT-TERM EFFECTS, BUT WHAT THAT  
4 WILL DO FOR THE REST OF HER LIFE IN TERMS OF IF SOME WOMEN WANT  
5 TO HAVE ANOTHER BABY LATER ON, THEY NEED TO KNOW THAT THEY  
6 MIGHT BE AT HIGH RISK OF A PRE-TERM BIRTH, OR THEY MIGHT HAVE A  
7 HIGH RISK OF A PLACENTA PREVIA WHERE THE PLACENTA GROWS OVER  
8 THE CERVIX. THAT THEY MIGHT HAVE A RISK OF WANTING TO HURT  
9 THEMSELVES, OR THEY MIGHT HAVE A RISK FOR MORE BREAST CANCER IN  
10 THEIR LIVES.

11 Q. DOES ANYTHING ABOUT THIS ARTICLE INFLUENCE THE WAY IN WHICH  
12 YOU COUNSEL YOUR PATIENTS ABOUT ABORTION?

13 A. IT DOES. IT MAKES ME ABSOLUTELY FEEL THAT I NEED TO TALK  
14 ABOUT LONG-TERM RISKS, NOT JUST SHORT-TERM RISKS, TO BE FULLY  
15 ACCOUNTABLE TO MY PATIENTS.

16 Q. AND WHICH FINDINGS IN THIS REVIEW DO YOU THINK IS MOST  
17 SIGNIFICANT WITH RESPECT TO THE PARTIAL-BIRTH ABORTION DEBATE?

18 A. I THINK THE TWO THINGS THAT WE NEED TO CAREFULLY LOOK AT  
19 ARE THE PRE-TERM BIRTH BEING HIGHER AFTER ABORTION AND THE  
20 PLACENTA PREVIA.

21 Q. WHAT IS "PRE-TERM BIRTH"?

22 A. "PRE-TERM BIRTH" IS WHEN A BABY IS BORN BEFORE THE 37TH  
23 WEEK OF GESTATION. AND THEN, WE ALSO CONSIDER VERY PRE-TERM  
24 BIRTH BEFORE 28 WEEKS OF GESTATION.

25 Q. AND IS PRE-TERM BIRTH THE SAME THING AS CERVICAL

1 INCOMPETENCE?

2 A. IT IS NOT THE SAME THING.

3 Q. AND DO THEY RELATE TO EACH OTHER IN ANY WAY?

4 A. CERVICAL INCOMPETENCE IS ONE OF THE THEORIES SET FORTH AS  
5 TO WHY PRE-TERM BIRTH MIGHT BE HIGHER AFTER ABORTION. THERE  
6 ARE OTHER THEORIES SUCH AS INFECTIONS BEING HIGHER AND SCAR  
7 TISSUE BEING HIGHER.

8 Q. DOCTOR, TURNING TO PAGE 75 OF THE ARTICLE, IF YOU WOULD  
9 READ OUT LOUD, BEGINNING ON THE LEFT-HAND COLUMN BEGINNING WITH  
10 THE PARAGRAPH THAT SAYS "ABORTION," AND READ OUT LOUD? I WILL  
11 JUST STOP YOU, BUT CONTINUE.

12 A. STARTING WITH "ABORTION IS A PROCEDURE" --

13 Q. THAT'S CORRECT.

14 A. OKAY.

15 "ABORTION IS A PROCEDURE MOST USED BY WOMEN AT  
16 THE OUTSET OF THEIR REPRODUCTIVE LIFE. MOST WOMEN  
17 HAVING AN INDUCED ABORTION ARE UNDER 30 YEARS OLD.  
18 PRETERM BIRTH IS COMMON, AFFECTING AROUND 10 PERCENT  
19 OF DELIVERIES IN THE WESTERN WORLD, AND IS THE  
20 LEADING CAUSE OF INFANT MORBIDITY AND MORTALITY.  
21 DESPITE SUBSTANTIAL INVESTIGATIVE EFFORT, PRIMARY  
22 PREVENTIVE MEASURES TO LOWER THE RATE OF PRETERM  
23 BIRTHS HAVE PROVEN FUTILE AND RATES HAVE BEEN STEADY  
24 OR INCREASED OVER THE PAST TWO DECADES. THE  
25 POPULATION-BASED STUDIES WE REVIEWED SUGGEST THAT

1 INDUCED ABORTION INCREASES THE RISK OF PRETERM BIRTH  
2 IN SUBSEQUENT PREGNANCIES."

3 Q. KEEP GOING.

4 A. "MOREOVER, THESE REPORTS SUGGEST THAT A DOSE-RESPONSE  
5 EFFECT IS PRESENT WITH INCREASING NUMBERS OF  
6 ABORTIONS ASSOCIATED WITH INCREASING RISK, AND THAT  
7 THE LINKAGE IS MOST STRONG WITH EXTREMELY PREMATURE  
8 DELIVERIES (LESS THAN 32 WEEKS), WHICH IS THE  
9 POPULATION OF NEWBORNS THAT EXPERIENCES THE BULK OF  
10 THE MORBIDITY AND MORTALITY THAT OCCUR FROM BEING  
11 BORN PREMATURELY."

12 Q. DOES THE STATEMENT YOU JUST READ REFLECT THE RESULTS OF THE  
13 RESEARCH YOU UNDERTOOK IN PREPARING THIS ARTICLE?

14 A. YES, IT DOES.

15 Q. AND WHAT DOES "DOSE-RESPONSE EFFECT" MEAN?

16 A. THAT MEANS THE MORE ABORTIONS A WOMAN HAS, THE HIGHER THE  
17 CHANCE THAT SHE'LL HAVE A PRE-TERM BIRTH. FOR EXAMPLE, IF ONE  
18 ABORTION WOULD DOUBLE RISK, TWO ABORTIONS MAY TRIPLE OR  
19 QUADRUPLE HER RISK.

20 Q. WOULD YOU SUMMARIZE FOR THE COURT WHAT YOUR ARTICLE  
21 CONCLUDES WITH RESPECT TO THE CONNECTION BETWEEN ABORTION AND  
22 PRE-TERM BIRTH IN SUBSEQUENT PREGNANCIES?

23 MS. KRASNOFF: OBJECTION. WE WOULD LIKE TO RENEW  
24 OUR OBJECTION NOW THAT SHE'S READ FROM THE ARTICLE; THAT IT  
25 CLEARLY IS NOT RELATED TO ANY METHODS OF ABORTION.



1 THE COURT: YES, IT DOESN'T -- IT CERTAINLY DOESN'T  
2 APPEAR TO ME TO BE. FRANKLY, I DON'T UNDERSTAND WHY YOU ARE  
3 PURSUING THIS PARTICULAR LINE OF QUESTIONING. I DON'T SEE THE  
4 BEARING THIS ARTICLE HAS ON THE ISSUE CURRENTLY BEFORE ME.

5 MS. CLARK: I MEAN, I CAN ASK DR. SHADIGIAN.

6 BY MS. CLARK:

7 Q. DR. SHADIGIAN, THIS ARTICLE, DOES THIS INFLUENCE YOUR  
8 OPINION AT ALL ABOUT THE SAFETY OF THE D&X PROCEDURE?

9 A. THE REASON I THINK THIS IS LINKED AND WHY IT CAN BE LINKED  
10 TO D&X IS UNTIL WE STUDY THE D&X PROCEDURE AND FOLLOW WOMEN WE  
11 ARE NOT SURE IF WOMEN ARE GOING TO BE ABLE TO CARRY EVEN INTO  
12 VIABILITY AFTER THE D&X PROCEDURE BECAUSE IT JUST HASN'T BEEN  
13 STUDIED.

14 IT COULD BE THAT IT IS JUST AS SAFE AS A D&E  
15 PROCEDURE OR MEDICAL INDUCTION, BUT IT COULD BE AND IT IS VERY  
16 POSSIBLE TO HAVE IT INCUR A VERY HIGH RISK FOR PREMATURE  
17 DELIVERY BECAUSE OF HOW MUCH MORE DILATED A WOMAN'S CERVIX IS  
18 WITH THE D&X PROCEDURE, AND HOW MUCH FARTHER IN GESTATION D&X  
19 PROCEDURES ARE PERFORMED.

20 SO THAT IS THE RELEVANCE IS THE CONCERN FOR SAFETY  
21 FOR WOMEN BECAUSE IT HASN'T BEEN STUDIED YET. AND THAT WE KNOW  
22 PRE-TERM BIRTH AND INDUCED ABORTION HAS BEEN STUDIED, AND IT IS  
23 WORRISOME.

24 Q. AND, DOCTOR, EVEN THOUGH THE STUDY DOESN'T FOCUS  
25 EXCLUSIVELY ON SECOND-TRIMESTER ABORTIONS, WHY, IF YOU DO, WHY

1 DO YOU THINK THIS ARTICLE IS IMPORTANT WITH RESPECT TO  
2 EVALUATING THE SAFETY OF THE D&X PROCEDURE?

3 A. WELL, THIS ARTICLE IS THE FIRST ONE IN AGGREGATE TO EVER  
4 PUT FORTH WHAT THE RISKS MAY BE OF ANY ABORTION. AND SO, IN  
5 FACT, D&X IS A FORM OF ABORTION. AND THIS IS SOMETHING THAT WE  
6 WILL NEED TO STUDY WITH THE D&X PROCEDURE, AS WELL AS THE OTHER  
7 PROCEDURES.

8 SO IT IS IMPORTANT BECAUSE OF WHAT I SAID PREVIOUSLY  
9 WITH THE TWO ISSUES AROUND D&X AND ALSO BECAUSE OF JUST  
10 ACKNOWLEDGING THAT THERE CAN BE LONG-TERM EFFECTS. AND, IN  
11 FACT, THEY ARE THINGS THAT WOMEN CARE ABOUT WHEN THEY ARE  
12 MAKING CHOICES.

13 THE COURT: EXCUSE ME. WITH REGARD TO THE PRE-TERM  
14 BIRTH RATE BEING HIGHER IN WOMEN WHO HAD ABORTIONS, IS THAT IN  
15 WOMEN WHO HAVE HAD ABORTIONS AS COMPARED TO WOMEN WHO HAVE NOT  
16 HAD ABORTIONS? OR WOMEN WHO HAVE HAD ABORTIONS IN COMPARISON  
17 TO WOMEN WHO HAD PREVIOUS BIRTHS? OR WHAT IS THE COMPARISON  
18 HERE?

19 THE WITNESS: IT DEPENDS ON THE STUDY, BUT IT DOES  
20 COMPARE WOMEN WHO HAD CHILDBIRTH AND ABORTIONS, AND IT DOES  
21 COMPARE WOMEN WHO HAVE HAD ABORTION AND NO PREGNANCY  
22 WHATSOEVER.

23 SO IT DEPENDS ON THE PARTICULAR STUDY. SO I CAN'T,  
24 IN AGGREGATE, GIVE YOU AN ANSWER, BUT IT DEPENDS ON THE STUDY.  
25 AND MANY OF THEM SEPARATE THEM OUT SO WE CAN LOOK AT THEM

1 INDIVIDUALLY.

2 THE COURT: OKAY. GO AHEAD.

3 BY MS. CLARK:

4 Q. DOCTOR, BASED ON YOUR REVIEW OF DR. HASKELL'S REPORT AND  
5 BASED ON YOUR REVIEW OF ACOG AND ALSO READING DR. PAUL'S BOOK,  
6 WHAT IS YOUR UNDERSTANDING OF THE DILATION PROCESS IN A D&X  
7 PROCEDURE?

8 A. MY UNDERSTANDING OF THE DILATION PROCESS IS THAT IT USUALLY  
9 INVOLVES DILATION OF THE CERVIX WITH OSMOTIC DILATORS OR  
10 LAMINARIA OVER TWO DAYS WHERE A SET IS PLACED INSIDE THE  
11 CERVIX. A WOMAN RETURNS TO THE DOCTOR'S OFFICE OR THE  
12 HOSPITAL. THE NEXT DAY, HAVE THOSE REMOVED AND PLACED AGAIN.  
13 AND THEN, ON THE THIRD DAY, HAVE THE ACTUAL PROCEDURE  
14 PERFORMED.

15 Q. NOW, ISN'T IT THE CASE THAT D&X REQUIRES LESS DILATION THAN  
16 AN INDUCTION PROCEDURE IF THE PROCEDURES ARE PERFORMED AT THE  
17 SAME GESTATIONAL AGE?

18 A. THAT IS CORRECT.

19 Q. SO WHY WOULDN'T D&X, IN YOUR OPINION, BE LESS HARMFUL THAN  
20 INDUCTION WHEN PERFORMED AT THE SAME GESTATIONAL AGE?

21 A. THERE ARE TWO REASONS. ONE IS THE ACTUAL PHYSICAL PUTTING  
22 THE DILATORS IN ACTUALLY FORCING THEM IN IS NOT PHYSIOLOGICAL.  
23 IT IS NOT LIKE THE MEDICAL INDUCTION WHERE A WOMAN'S NATURAL  
24 BODY WITH THE MEDICINES, IT JUST MAKES THE MYOMETRIUM, MUSCLE  
25 FIBERS OF THE UTERUS CONTRACT, AND THAT GENTLY, SLOWLY DILATES

1 THE CERVIX IN A PHYSIOLOGICAL MANNER.

2 AND WITH ANY KIND OF LAMINARIA, WHETHER IT'S IN THE  
3 FIRST-TRIMESTER OR, YOU KNOW, D&X, STILL IS A DILATION THAT  
4 INVOLVES PUSHING IN A FOREIGN OBJECT INTO THE CERVIX.

5 Q. SO, TO SUMMARIZE FOR THE COURT, WHAT ARE YOUR SPECIFIC  
6 CONCERNS ABOUT THE D&X WITH RESPECT TO THE DILATION PROCEDURE?

7 A. ONE IS THAT THE PROVIDERS OF ABORTION SERVICES USING THE  
8 D&X PROCEDURE HAVE SAID, AND I HAVE READ IN THEIR DIFFERENT  
9 EITHER EXPERT REPORTS OR ARTICLES, THAT THEY DILATE THE CERVIX  
10 MANY TIMES TO ABOUT 5 CENTIMETERS, AND THAT THEY NEED TO PULL  
11 THE BABY THROUGH THE CERVIX. SO EVEN AFTER THE HEAD IS CRUSHED  
12 OR THE CONTENTS OF THE INTRACRANIUM ARE REMOVED, THEY STILL  
13 NEED TO PULL IT THROUGH IN A NONPHYSIOLOGICAL WAY.

14 Q. IS THE DILATION PROCESS OF THE D&X PROCEDURE, IS THAT  
15 SOMETHING THAT REQUIRES FURTHER STUDY IN YOUR OPINION?

16 A. YES.

17 Q. WHY IS THAT THE CASE?

18 A. WELL, IT MAY BE THAT THE D&X DILATION IS SAFER THAN JUST  
19 DOING IT OVER ONE DAY OR IT MAY BE THAT IT IS LESS SAFE.  
20 WITHOUT REAL STUDIES, WE CAN'T REALLY SAY IF IT IS SAFE OR NOT  
21 SAFE.

22 SO, AGAIN, IT NEEDS TO BE BASED NOT ON ANECDOTE, ON  
23 WHAT I SAY OR WHAT DR. HASKELL SAYS, BUT, IN FACT, ON LOOKING  
24 AT GROUPS OF WOMEN STUDIED WITH CONTROLLED GROUP SO THAT WE CAN  
25 MAKE SOME KIND OF MEANINGFUL MEDICAL JUDGMENT ABOUT USE OF

1 LAMINARIA AND USE OF MISOPROSTOL AND WHAT THE SHORT AND  
2 LONG-TERM EFFECTS MAY BE.

3 Q. IN YOUR OPINION, HOW SHOULD ONE GO ABOUT DETERMINING  
4 WHETHER ABORTION RESULTS IN LONG-TERM RISKS, SUCH AS PRE-TERM  
5 BIRTH?

6 A. THE BEST WAY TO GO ABOUT THOSE KINDS OF DETERMINATIONS ARE  
7 LOOKING AT CASE CONTROL OR RETROSPECTIVE STUDIES AND THEN DOING  
8 THE PROSPECTIVE STUDIES LOOKING INTO THE FUTURE AND HAVING A  
9 CONTROL GROUP OF WOMEN WHO HAVE HAD A PROCEDURE AND WHO  
10 HAVEN'T, OR MAYBE HAD A DIFFERENT KIND OF PROCEDURE, AND THEN,  
11 FOLLOWING THEM OVER TIME.

12 Q. AND IN YOUR OPINION IS IT FEASIBLE TO CONDUCT SUCH A STUDY  
13 OF EVALUATING THE LONG-TERM RISKS OF WOMEN UNDERGOING A D&X  
14 ABORTION PROCEDURE?

15 A. YES, IT IS.

16 Q. DOCTOR, IN EVALUATING THE NECESSITY OF THE D&X PROCEDURE,  
17 WHAT METHOD OF PREGNANCY TERMINATION DO YOU THINK D&X SHOULD BE  
18 COMPARED AGAINST?

19 A. WELL, THE BEST PROCEDURE TO COMPARE D&X AGAINST IS PROBABLY  
20 THE MEDICAL INDUCTION, BECAUSE IT IS DONE AT GREATER  
21 GESTATIONAL AGES AND BECAUSE IT MAY BE DONE FOR SIMILAR  
22 INDICATIONS.

23 Q. DOCTOR, IN YOUR OPINION, CAN YOU USE THE SAFETY DATA OF THE  
24 D&E PROCEDURE TO ACCURATELY PORTRAY THE SAFETY OF A D&X  
25 PROCEDURE?

1 A. NO, YOU CANNOT.

2 Q. AND WHY NOT, IN YOUR OPINION?

3 A. WELL, THEY ARE JUST SEPARATE PROCEDURES AND THEY USE MORE  
4 DILATION OR LESS DILATION, AND THEY INVOLVE BRINGING, FOR  
5 EXAMPLE, THE D&X PROCEDURE, A LARGER BODY PART THROUGH THE  
6 CERVIX.

7 IN OTHER WORDS, NOT PIECEMEAL OR SMALLER PARTS, BUT  
8 WITH A QUITE A BIT LARGER PIECE: THE HEAD.

9 Q. AND IS THERE SOMETHING ALSO ABOUT THE GESTATIONAL AGE WITH  
10 RESPECT TO THE COMPARISON OF D&E TO D&X THAT MAKES D&E AN  
11 INSUFFICIENT BASIS TO MAKE AN EVALUATION OF D&X?

12 A. IF, IN GENERAL, AS I UNDERSTAND IT, D&X IS USED WITH  
13 GREATER GESTATIONAL AGES.

14 MS. KRASNOFF: OBJECTION, LACK OF FOUNDATION.

15 THE COURT: SUSTAINED.

16 THE WITNESS: WHEREAS DNA --

17 THE COURT: I SAID I SUSTAINED THE OBJECTION.

18 THE WITNESS: OH, I AM SORRY.

19 BY MS. CLARK:

20 Q. DOCTOR, BASED ON REVIEWING DR. HASKELL'S REPORT, DOCTOR  
21 PAUL'S WRITINGS IN HER BOOK, AND ALSO THE ACOG, WHAT IS YOUR  
22 UNDERSTANDING OF WHEN THE D&X PROCEDURE IS PERFORMED? AT WHAT  
23 GESTATIONAL AGE?

24 A. GENERALLY, AS I UNDERSTAND IT, IT HAS BEEN AFTER 20 WEEKS  
25 THAT THE D&X PROCEDURE IS MOST PERFORMED.

1 Q. SO IS THERE SOMETHING ABOUT THE GESTATIONAL AGE IN  
2 COMPARING D&E TO D&X THAT LIMITS THE ABILITY OF DRAWING  
3 CONCLUSIONS OF D&X BASED ON THE D&E PROCEDURE?

4 A. YES, BECAUSE THE D&E'S GENERALLY USED FROM 13 UP TO 24  
5 WEEKS, AND THE D&X IS USUALLY USED ONLY 20 AND UP WEEKS. SO IT  
6 IS HARD TO USE EARLIER DATA FROM SMALLER BABIES IN COMPARING  
7 THEM TO OLDER BABIES.

8 Q. BUT EVEN IF YOU WERE TO USE D&E, WHAT WOULD YOU CONCLUDE  
9 ABOUT THE SAFETY OF D&X AS COMPARED TO THE SAFETY OF INDUCTION?

10 A. SO IF I WAS TO USE THE DATA WE NOW HAVE ON D&E AS A BASIS  
11 FOR THE D&X PROCEDURE, WE STILL HAVE GOOD DATA SHOWING THAT  
12 MEDICAL INDUCTION IS SAFER AFTER 20 WEEKS, AS COMPARED TO A D&X  
13 PROCEDURE THAT IS BOTH BASED ON MORTALITY, MOM'S DYING, AND  
14 MORBIDITY OR COMPLICATIONS OF THE PROCEDURE.

15 THE COURT: WAIT. I AM SORRY. I THOUGHT HER ANSWER  
16 WAS THAT THERE IS GOOD DATA SHOWING THAT INDUCTION IS SAFER AS  
17 COMPARED TO D&X?

18 THE WITNESS: NO, I SAID IF YOU USE D&E AS A  
19 COMPARISON. WE DON'T HAVE ANY DATA ON THE D&X, BUT IF WE ARE  
20 GOING TO USE THAT AS A COMPARISON, THEN I CAN SAY THAT.

21 OTHERWISE, WE DON'T HAVE ANY DATA. THANK YOU.

22 BY MS. CLARK:

23 Q. NOW, WOULD THE FACT THAT THERE WOULD BE LESS DILATION  
24 NECESSARY IN A D&X AS COMPARED TO INDUCTION, WOULD THAT WEIGH  
25 AS AN ADVANTAGE OF D&X OVER INDUCTION?

1 A. WE JUST DON'T KNOW.

2 Q. NOW, DR. SHADIGIAN, I WOULD LIKE TO ASK YOU SOME MORE  
3 POINTED QUESTIONS ABOUT THE INDUCTION PROCEDURE AS IT'S USED IN  
4 THE SECOND-TRIMESTER OF PREGNANCY TO TERMINATE A PREGNANCY.

5 WHAT IS THE LATEST GESTATIONAL AGE THAT YOU HAVE  
6 PERFORMED AN INDUCTION?

7 A. I GUESS 42 WEEKS OF GESTATION.

8 Q. WHAT IS THE LATEST AGE, GESTATIONAL AGE, THAT YOU PERFORMED  
9 AN INDUCTION ON A PREVIABLE FETUS?

10 A. WELL, UP TO 23 WEEKS IS PREVIABLE, SO RIGHT BEFORE 23  
11 WEEKS.

12 Q. NOW, YOU TALKED TODAY BEFORE ABOUT INDUCTION BEING THE  
13 PRIMARY METHOD OF PREGNANCY TERMINATION THAT YOU USE; IS THAT  
14 CORRECT?

15 A. THAT IS CORRECT.

16 Q. AND, AGAIN, WHY IS THAT THE METHOD THAT YOU GENERALLY  
17 CHOOSE?

18 A. BECAUSE OF MY PRACTICE WE SEE SICKER WOMEN AT THE  
19 UNIVERSITY OF MICHIGAN, AND THEY ARE GENERALLY OVER 20 WEEKS.  
20 SO NOT JUST MINE, BUT THE ENTIRE FACULTY'S GENERAL WAY OF  
21 PRACTICE IS TO USE MEDICAL INDUCTION BECAUSE OF THE BETTER  
22 SAFETY DATA WITH AN INDUCTION AS COMPARED WITH D&E AFTER 20  
23 WEEKS.

24 Q. DOCTOR, YOU TESTIFIED EARLIER ABOUT PREECLAMPSIA. HAVE YOU  
25 EVER HAD ANY PATIENTS WITH PREECLAMPSIA?



1 A. YES.

2 Q. AND DO ALL OF YOUR PATIENTS WHO DEVELOP PREECLAMPSIA NEED  
3 TO HAVE THEIR PREGNANCY TERMINATED TO PROTECT THE MOTHER'S  
4 HEALTH INTEREST?

5 A. ONLY IF THEY HAVEN'T GONE INTO SPONTANEOUS LABOR. MANY  
6 WOMEN ACTUALLY GO INTO SPONTANEOUS LABOR AND NATURE TAKES ITS  
7 COURSE.

8 Q. BUT DOES THE FACT THAT A WOMAN HAS PREECLAMPSIA, DOES THAT  
9 NECESSARILY REQUIRE PREGNANCY TERMINATION?

10 A. NO, IT DOES NOT, IN MILD CASES.

11 Q. AND YOU HAVE HAD SOME PATIENTS WHO HAVE HAD PREECLAMPSIA  
12 AND HAVE REQUIRED TERMINATION OF PREGNANCY?

13 A. YES, I HAVE.

14 Q. AND HOW HAVE YOU TERMINATED THOSE PREGNANCIES?

15 A. GENERALLY THEY HAVE BEEN MOSTLY WITH MEDICAL INDUCTION OF  
16 LABOR, BUT SOME PEOPLE REQUIRE CESAREAN SECTION, AS WELL.

17 Q. FOR THOSE PATIENTS WHY HAVE YOU CHOSEN INDUCTION WHEN THEY  
18 HAVE HAD PREECLAMPSIA AND REQUIRED TERMINATION OF PREGNANCY?

19 A. ARE YOU LIMITING IT TO THE SECOND-TRIMESTER OR NOT?

20 Q. YES, IN THE SECOND-TRIMESTER.

21 A. BECAUSE OF THE SAFETY DATA OF MEDICAL INDUCTION OF THE LATE  
22 SECOND-TRIMESTER IT WAS DEEMED HEALTHIER FOR THE MOM TO GO  
23 AHEAD WITH A MEDICAL INDUCTION, AND IT WOULDN'T TAKE TWO OR  
24 THREE DAYS AS IT MIGHT WITH A SERIAL LAMINARIA AND GREATER  
25 DILATION WITH A D&E PROCEDURE.

1 Q. HAVE YOU EVER PERFORMED A PREGNANCY TERMINATION ON A WOMAN  
2 WHO HAS HAD PREECLAMPSIA USING THE D&E METHOD?

3 A. I HAVE NOT, PERSONALLY.

4 Q. AND WHY HAVE YOU NOT PERFORMED A D&E OR OTHER SURGICAL  
5 PROCEDURE ON A WOMEN PRESENTING WITH PREECLAMPSIA NEEDING HER  
6 PREGNANCY TO BE TERMINATED?

7 A. BECAUSE USUALLY THEY ARE 21, 22, ALMOST 23 WEEKS PREGNANT,  
8 SO THEY ARE IN THE LATER HALF OF THE SECOND-TRIMESTER.

9 Q. WHEN PREECLAMPSIA DEVELOPS PREVIABILITY, IS A MOTHER'S  
10 HEALTH THE ONLY ISSUE THAT YOU CONSIDER?

11 A. THE MOTHER'S HEALTH IS THE MAIN ISSUE ALWAYS IN THAT  
12 SITUATION.

13 Q. AND IN DECIDING TO TERMINATE HER PREGNANCY PREVIABILITY, IS  
14 A MOTHER'S HEALTH INTEREST THE ONLY ISSUE THAT YOU HAVE -- THAT  
15 YOU CONSIDER?

16 A. IF I CAN BE COMPLETELY SURE THAT THAT BABY CAN'T LIVE  
17 OUTSIDE MOM, EVEN WITH INTENSIVE NEONATAL CONSIDERATIONS, THEN,  
18 YES, THAT IS WHAT I AM GOING TO BE FOCUSED ON.

19 Q. DOCTOR, NOW, EARLIER YOU TESTIFIED THAT IT MAY BE NECESSARY  
20 TO TERMINATE A PREGNANCY OF A WOMAN WHO A UTERINE INFECTION OR  
21 CHORIOAMNIONITIS; IS THAT RIGHT?

22 A. THAT IS CORRECT.

23 Q. HAVE YOU EVER HAD TO TERMINATE A PREGNANCY BECAUSE A WOMAN  
24 HAD AN UTERINE INFECTION?

25 A. YES.

1 Q. IS IT COMMON THAT A PREGNANCY HAS TO BE TERMINATED BECAUSE  
2 OF AN UTERINE INFECTION?

3 A. IT'S FAIRLY UNCOMMON, BUT AT THE TERTIARY CARE CENTER WE  
4 SEE IT MORE OFTEN.

5 Q. WHY IS IT YOU SEE IT MORE OFTEN AT THE TERTIARY CARE  
6 CENTER?

7 A. BECAUSE WOMEN ARE REFERRED IN TO HAVE INVASIVE TESTS MORE  
8 LIKE AMNIOCENTESIS AND CVS SO WE ACTUALLY DO MORE PROCEDURES  
9 WHERE WE INSERT INSTRUMENTS INTO THE UTERUS, LIKE A NEEDLE, AND  
10 THAT MAY ACTUALLY INTRODUCE THE INFECTION TO THE WOMEN.

11 Q. HOW WOULD YOU TERMINATE A PREGNANCY WHEN IT IS REQUIRED  
12 BECAUSE OF UTERINE INFECTION?

13 A. FIRST, WE NEED TO MAKE AN ACCURATE DIAGNOSIS AS TO REAL  
14 INFECTION AND NOT JUST, FOR EXAMPLE, PREMATURE RUPTURE OF  
15 MEMBRANES. PREMATURE RUPTURE OF MEMBRANES IS ONE OF THE FIRST  
16 THINGS WE SEE SOMETIMES WHEN THERE IS AN UTERINE INFECTION.

17 SO FIRST WE MAKE THE ACCURATE DIAGNOSIS. AND THEN,  
18 BECAUSE THERE IS ALREADY INFECTION GOING ON, WE TRY TO AVOID  
19 SURGERY WHEN THERE IS AN INFECTION GOING ON, RATHER THAN GO IN  
20 AND POSSIBLY SPREAD THE INFECTION TO MOTHER MORE.

21 Q. AND SO IF YOU TERMINATE THE PREGNANCY, THEN WHAT METHOD  
22 WOULD YOU USE?

23 A. WE GENERALLY USE A MEDICAL INDUCTION METHOD.

24 Q. AND IF THERE IS PREMATURE RUPTURE OF MEMBRANES, DOES THAT  
25 REQUIRE TERMINATION OF PREGNANCY?

1 A. NO, IT DOES NOT, IN AND OF ITSELF.

2 Q. AND IF YOU CAN EXPLAIN A LITTLE BIT MORE -- YOU TOUCHED ON  
3 THIS -- WHY WOULD YOU USE INDUCTION METHOD OF TERMINATION  
4 PREGNANCY IN A SITUATION IN WHICH A WOMAN PRESENTED WITH AN  
5 UTERINE INFECTION?

6 A. BECAUSE IT WOULD MOST LIKELY LIMIT THE INFECTION AND NOT  
7 SPREAD IT TO THE REST OF THE MOTHER'S BODY IF WE DID A MEDICAL  
8 INDUCTION. ALSO, IT MAY BE QUICKER TO GO AHEAD AND INDUCE THE  
9 LABOR AND GET HER DELIVERED SO THAT THE INFECTION DOESN'T  
10 CONTINUE FOR LONGER PERIODS OF TIME.

11 Q. ARE YOU FAMILIAR WITH THE METHOD OTHER OB/GYN'S USE AT  
12 UNIVERSITY OF MICHIGAN WHEN THEY ENCOUNTER A WOMAN WITH AN  
13 UTERINE INFECTION THAT REQUIRES TERMINATION OF PREGNANCY?

14 A. YES.

15 Q. WHAT METHOD DO THEY USE?

16 A. AS I UNDERSTAND IT MOST PHYSICIANS IN MY INSTITUTION WHERE  
17 I PRACTICE ALSO USE MEDICAL INDUCTIONS OF LABOR.

18 Q. DR. SHADIGIAN, HOW LONG DOES IT TAKE YOU TO PERFORM AN  
19 INDUCTION PROCEDURE, APPROXIMATELY, IN THE PREVIABILITY STAGE?

20 A. USING MISOPROSTOL, ON AVERAGE, TAKING BETWEEN FOUR AND 24  
21 HOURS.

22 Q. DR. SHADIGIAN, YOU'VE TESTIFIED TODAY ABOUT THE GESTATIONAL  
23 AGE OF THE FETUS WHEN YOU ARE TERMINATING THE PREGNANCY. AND  
24 IN WHAT WAY DOES THE GESTATIONAL AGE OF THE FETUS HAVE A  
25 BEARING ON THE METHOD OF PREGNANCY TERMINATION USED TO, IN

1 FACT, TERMINATE THE PREGNANCY?

2 A. WELL, WHAT WE TRY TO DO IS LOOK AT THE EVIDENCE AND  
3 STUDIES. SO WHAT WE TRY TO DO IS LOOK AT, YOU KNOW, D&E  
4 PROCEDURE AT DIFFERENT GESTATIONAL AGES AND MEDICAL INDUCTION  
5 PROCEDURE AT DIFFERENT GESTATIONAL AGES, AND SEE IF WE CAN DRAW  
6 SOME KIND OF CONCLUSIONS FROM ACTUAL STUDIES. NOT JUST AT U OF  
7 M, BUT PEOPLE'S STUDIES ACROSS THE COUNTRY AND ACROSS THE  
8 WORLD, SO THAT WE CAN LOOK AT DATA AND KNOW THAT WE ARE  
9 OFFERING OUR PATIENTS THE BEST MEDICAL CARE POSSIBLE AND TRY TO  
10 REDUCE THE AMOUNT OF MORBIDITY AND MORTALITY THAT A WOMAN MAKES  
11 DURING THIS FROM THE CHOICES AROUND INDUCTION OR D&E PROCEDURE.

12 MS. CLARK: YOUR HONOR, MAY I APPROACH?

13 THE COURT: YES.

14 BY MS. CLARK:

15 Q. DOCTOR, I HAVE JUST SHOWN YOU WHAT HAS BEEN IDENTIFIED AS  
16 DEFENDANT'S EXHIBIT LT A-15. HAVE YOU SEEN THIS ARTICLE  
17 BEFORE?

18 A. YES, I HAVE.

19 Q. AND DOES THIS ARTICLE SUPPORT YOUR OPINION IN ANY WAY ABOUT  
20 THE SAFETY OF INDUCTION AT THE LATER STAGES IN THE -- OF THE  
21 SECOND-TRIMESTER OF PREGNANCY?

22 A. YES, IT DOES.

23 Q. I DIRECT YOU TO TABLE NUMBER 4, WHICH IS ON PAGE 727.

24 DOES THIS TABLE SUPPORT YOUR OPINIONS IN ANY WAY?

25 A. YES. THIS TABLE LOOKS AT D&E, OR DILATION AND EVACUATION,

1 PROCEDURE VERSUS LABOR INDUCTION. AND IT SHOWS THAT LABOR  
2 INDUCTION IS SAFER AT 21 WEEKS AND GREATER. AND THIS IS USING  
3 EVEN THE OLD INSTILLATION METHODS, NOT THE MORE MODERN  
4 MISOPROSTOL.

5 Q. WHAT IS THE SIGNIFICANCE OF USING THE EARLY METHODS AS  
6 OPPOSED TO THE MISOPROSTOL DRUG USED WITH LABOR INDUCTION?

7 A. WELL, THE NEWER STUDIES HAVE SHOWN MISOPROSTOL IS, IN FACT,  
8 EVEN SAFER THAN OLD INSTILLATION METHODS. SO THAT WE CAN  
9 SAFELY ASSUME THAT IF THIS IS DONE WITH MISOPROSTOL MODERNLY,  
10 WE WOULD HAVE EVEN LOWER RATES OF MORTALITY FOR WOMEN AT 21  
11 WEEKS AND GREATER.

12 Q. AND THIS DATA, WHAT YEAR WAS THIS DATA BASED UPON?

13 A. THIS WAS BASED ON EARLY DATA FROM 1972 TO 1987.

14 Q. IF YOU LOOK AT TABLE 4, I THINK IT -- I WILL JUST LEAVE  
15 THAT.

16 NOW, DOCTOR, ARE THERE OTHER STUDIES OR ARTICLES  
17 THAT YOU HAVE RELIED UPON IN FORMING YOUR OPINION THAT  
18 INDUCTION IS AS SAFE OR SAFER THAN THE D&E PROCEDURE AT CERTAIN  
19 STAGES IN THE SECOND-TRIMESTER OF PREGNANCY?

20 A. YES.

21 Q. AND ARE THOSE THE GRIMES STUDIES?

22 A. YES.

23 MS. CLARK: YOUR HONOR, MAY I APPROACH?

24 THE COURT: YES.

25 BY MS. CLARK:

1 Q. DR. SHADIGIAN, I HAVE HANDED YOU WHAT HAS BEEN MARKED AS  
2 DEFENDANTS EXHIBIT LT A-25. IS THIS ONE OF THE GRIMES STUDIES  
3 YOU WERE REFERRING TO?

4 A. YES, IT IS.

5 Q. WHAT YEAR WAS THIS STUDY PUBLISHED?

6 A. THIS STUDY WAS PUBLISHED IN 1985.

7 Q. IF I COULD HAVE YOU RETURN TO PAGE 93. AND IN THE SECOND  
8 FULL PARAGRAPH, THE PARAGRAPH BEGINS:

9 "THE GREATER COMPARATIVES."

10 A. YES.

11 Q. IF YOU READ THAT SECOND SENTENCE IN THAT PARAGRAPH, WOULD  
12 YOU READ THAT SECOND SENTENCE OUT LOUD?

13 A. CERTAINLY.

14 "AT GREATER THAN OR EQUAL TO 16 WEEKS GESTATION  
15 THE RISKS OF DEATH FROM D&E AND FROM INSTILLATION  
16 ABORTION ARE SIMILAR AND STATISTICALLY  
17 INDISTINGUISHABLE."

18 Q. AND DOES THIS SENTENCE SUPPORT YOUR OPINION ABOUT THE  
19 RELATIVE SAFETY OF D&E AND INDUCTION?

20 A. YES, IT DOES.

21 Q. AND DOES THE CHANGE IN THE USE OF MISOPROSTOL EFFECT THE  
22 STUDY IN ANY WAY, DO YOU THINK, WITH RESPECT TO INDUCTION  
23 PROCEDURE?

24 A. WELL, JUST WITH THE NEWER MISOPROSTOL, IN FACT, IT HAS BEEN  
25 SHOWN IT IS EVEN SAFER THAN INSTILLATION METHODS, SO WE SHOULD

1 FIND THAT MORTALITY IS LOWER WITH MODERN USE OF PROSTAGLANDINS,  
2 AS COMPARED TO D&E.

3 Q. NOW, WHAT IS YOUR BASIS FOR YOUR OPINION THAT MISOPROSTOL  
4 HAS IMPROVED THE METHOD OF INDUCTION?

5 A. THERE ARE SEVERAL ARTICLES AND SEVERAL STUDIES THAT HAVE  
6 BEEN PERFORMED AROUND THE WORLD THAT ARE HOW I BASE MY OPINION  
7 ABOUT MISOPROSTOL.

8 MS. CLARK: MAY I APPROACH THE WITNESS?

9 THE COURT: YES.

10 BY MS. CLARK:

11 Q. THIS IS DEFENDANT'S LT A-27.

12 DR. SHADIGIAN, I HAVE HANDED YOU WHAT HAS BEEN  
13 IDENTIFIED AS DEFENDANT'S EXHIBIT LT A-27.

14 A. YES, I HAVE IT.

15 Q. IF YOU WOULD LOOK AT THE FIRST COLUMN, TURNING TO THE  
16 SECOND PARAGRAPH WHERE IT BEGINS:

17 "THE DETAILS OF THE BENEFICIAL EFFECTS."

18 DO YOU SEE THAT?

19 A. YES.

20 Q. WOULD YOU READ OUT LOUD THE SECOND SENTENCE IN THAT  
21 PARAGRAPH, BEGINNING WITH "HOWEVER"?

22 A. "HOWEVER, FOR ONE SPECIFICATION INDICATION, CERVICAL  
23 RIPENING AS A PRELUDE TO INDUCTION OF LABOR,  
24 MISOPROSTOL HAS BEEN USED SO FREQUENTLY AND  
25 EFFECTIVELY THAT IT HAS BECOME THE TREATMENT OF



1 CHOICE."

2 Q. WOULD YOU AGREE WITH THAT STATEMENT?

3 A. YES, I DO.

4 Q. IF YOU TURN TO THE NEXT PAGE, THE LEFT-HAND COLUMN, AT THE  
5 VERY BOTTOM THE SENTENCE BEGINNING:

6 "YET WE REAFFIRM." WOULD YOU BEGIN WITH "WE  
7 REAFFIRM," AND READ THAT SENTENCE?

8 A. "WE REAFFIRM THAT MISOPROSTOL IS A SAFE AND EFFECTIVE DRUG  
9 FOR CERVICAL RIPENING AND INDUCTION OF LABOR WHEN  
10 USED APPROPRIATELY."

11 Q. AND DO YOU AGREE WITH THAT STATEMENT?

12 A. YES, I DO.

13 MS. CLARK: MAY I APPROACH?

14 THE COURT: YES.

15 BY MS. CLARK:

16 Q. I AM HANDING YOU WHAT HAS BEEN IDENTIFIED AS PLAINTIFFS'  
17 31. I WOULD LIKE YOU TO TURN TO PAGE 142, PLEASE. AND THE  
18 "ABORTION BY LABOR INDUCTION" CHAPTER.

19 IF YOU LOOK UNDER THE SECTION "MORBIDITY AND  
20 MORTALITY," IN THAT FIRST PARAGRAPH, WOULD YOU READ OUT LOUD  
21 THE VERY LAST SENTENCE?

22 A. STARTING WITH "ALTHOUGH"?

23 Q. OH, I AM SORRY. NO. STARTING WITH -- WE'RE ON PAGE 142,  
24 UNDER "MORBIDITY AND MORTALITY," THE FIRST FULL PARAGRAPH. THE  
25 SENTENCE THAT BEGINS:

1 "AN INCREASE USE, INCREASED USE OF VAGINAL  
2 PROSTAGLANDINS."

3 A. OKAY. "INCREASED USE OF VAGINAL PROSTAGLANDINS.  
4 IMPROVEMENTS IN TECHNIQUE AND BETTER CERVICAL  
5 PREPARATION HAVE PROBABLY REDUCED MORTALITY FROM  
6 INDUCTION ABORTIONS."

7 Q. AND DO YOU AGREE WITH THAT SENTENCE?

8 A. YES, I DO.

9 Q. DO YOU UNDERSTAND THAT SENTENCE TO REFER TO IMPROVING IT  
10 FROM THE INSTILLATION METHOD OF INDUCTION?

11 A. YES. THEY HAVE TABLES ABOUT INSTILLATION METHODS ON THE  
12 SAME PAGE, EVEN.

13 Q. AND IS MISOPROSTOL A PROSTAGLANDIN?

14 A. YES, IT IS.

15 Q. DO YOU KNOW IF OTHER PHYSICIANS BESIDES YOURSELF ARE USING  
16 MISOPROSTOL IN CONNECTION WITH THE INDUCTION METHOD OF  
17 PREGNANCY TERMINATION?

18 A. YES, I DO.

19 Q. HOW DO YOU KNOW THAT?

20 A. BECAUSE I PRACTICE AT U OF M, AND I HAVE TO TAKE OVER AFTER  
21 THEY HAVE STARTED AN INDUCTION, AND I KNOW WHAT TECHNIQUES THEY  
22 ARE USING.

23 IN ADDITION, WE HAVE A WEB SITE WHERE WE HAVE  
24 DIFFERENT PROTOCOLS. AND ONE OF THE PROTOCOLS IS ABOUT  
25 MISOPROSTOL.

1 Q. DO YOU HAVE AN UNDERSTANDING ABOUT THE METHODS USED TO  
2 TERMINATE PREGNANCY AT THE UNIVERSITY OF MICHIGAN?

3 A. YES, I DO.

4 Q. WHAT IS YOUR UNDERSTANDING ABOUT THE METHODS USED TO  
5 TERMINATE PREGNANCY AT THE UNIVERSITY OF MICHIGAN IN THE  
6 SECOND-TRIMESTER OF PREGNANCY?

7 A. THAT BOTH D&E IS USED AND INDUCTION OF LABOR TECHNIQUES.

8 Q. DO YOU HAVE AN IDEA AS GESTATIONAL AGE INCREASES WHAT THE  
9 OTHER PHYSICIANS AT UNIVERSITY OF MICHIGAN ARE USING IN THE  
10 SECOND-TRIMESTER?

11 A. AS I UNDERSTAND IT, BASICALLY AFTER 20 WEEKS D&E'S AREN'T  
12 BEING OFFERED IN MOST SITUATIONS.

13 MS. CLARK: YOUR HONOR, MAY I APPROACH?

14 THE COURT: YES.

15 BY MS. CLARK:

16 Q. I AM SHOWING YOU PLAINTIFFS LT-15. DOCTOR, HAVE YOU SEEN  
17 THIS ARTICLE BEFORE?

18 A. I BELIEVE SO.

19 Q. IF YOU PLEASE TURN TO TABLE 3.

20 MS. KRASNOFF: WHAT EXHIBIT?

21 MS. CLARK: LT-15.

22 BY MS. CLARK:

23 Q. DOCTOR, IF YOU WOULD TURN TO TABLE 3, PLEASE.

24 A. YES.

25 Q. AND WHAT IS SET FORTH IN TABLE 3?

1 A. THE TITLE OF TABLE 3 IS:

2 "ABORTION MORTALITY RATES BY GESTATIONAL AGE  
3 AND PROCEDURE IN THE UNITED STATES."

4 MS. KRASNOFF: OBJECTION, YOUR HONOR. THIS ARTICLE  
5 WAS NOT DISCUSSED BY DR. SHADIGIAN IN HER EXPERT REPORT OR  
6 TALKED ABOUT AT DEPOSITION.

7 MS. CLARK: YOUR HONOR, IT WASN'T IN HER EXPERT  
8 REPORT OR DEPOSITION, BUT TO THE EXTENT DR. PAUL TESTIFIED  
9 ABOUT IT, THIS IS IN RESPONSE TO DR. PAUL'S TESTIMONY.

10 THE COURT: SO YOU ARE USING IT AS REBUTTAL?

11 MS. CLARK: YES.

12 THE COURT: I WILL PERMIT IT.

13 BY MS. CLARK:

14 Q. DR. SHADIGIAN, IF YOU -- I THINK YOU WERE REFERRING TO  
15 TABLE 3. AND WHAT DOES TABLE 3 SET FORTH?

16 A. IT SETS FORTH ABORTION MORTALITY RATES BY GESTATIONAL AGE  
17 AND PROCEDURE IN THE UNITED STATES IN TWO TIME FRAMES: FROM  
18 1972 TO '76, AND THEN FROM 1977 TO '81.

19 Q. AND ARE THESE TABLES, IN YOUR OPINION, VALID TODAY?

20 A. THEY ARE IN THAT THESE ARE TECHNIQUES THAT WERE USED DURING  
21 THAT PERIOD OF TIME. HOWEVER, WE DON'T USE INSTILLATION  
22 TECHNIQUES ALMOST AT ALL ANY MORE.

23 SO, IN EFFECT, IT DOESN'T REALLY REFLECT MODERN  
24 PRACTICES MUCH.

25 Q. ARE THE INSTILLATION METHODS OF INDUCTION -- OF TERMINATION

1 OF PREGNANCY BY INDUCTION METHOD IN THE SECOND-TRIMESTER  
2 INSTILLATION METHOD USED AT THE UNIVERSITY OF MICHIGAN?

3 A. IT IS NOT ANYMORE.

4 Q. ARE YOU AWARE OF ANY OB/GYN'S USING THE INSTILLATION METHOD  
5 OF INDUCTION?

6 A. NOT PERSONALLY, NO.

7 Q. WOULD YOU KNOW IF OTHER PHYSICIANS WERE USING INSTILLATION?

8 A. I WOULD BECAUSE I GO TO OUR WEEKLY CONFERENCES AND HEAR  
9 ABOUT WHAT OTHER PHYSICIANS DO IN MY OWN INSTITUTION.

10 Q. YOU'RE AWARE THAT THE CENTER FOR DISEASE CONTROL REPORTS ON  
11 THE NUMBER OF ABORTIONS THAT ARE PERFORMED IN THE UNITED  
12 STATES?

13 A. YES, I DO.

14 Q. IN YOUR OPINION IS A CDC INFORMATION RELIABLE?

15 A. IT IS NOT RELIABLE.

16 Q. WHY DON'T YOU THINK IT IS RELIABLE?

17 A. BECAUSE THE CENTER FOR DISEASE CONTROL DOES NOT EVEN GET  
18 MORTALITY DATA FROM ALL 50 STATES. IT IS LIMITED TO ABOUT 39  
19 STATES, IT RECEIVES ANY INFORMATION FROM. AND IT IS NOT  
20 REQUIRED OR MANDATED BY LAW TO ACTUALLY GIVE THE INFORMATION TO  
21 THE CDC, SO THAT THERE ARE MANY HOLES IN THE SYSTEM.

22 Q. DO YOU HAVE AN OPINION ABOUT WHETHER THE INDUCED  
23 CONTRACTIONS SEEN IN AN INDUCTION METHOD FOR TERMINATION OF  
24 PREGNANCY, WHETHER THEY ARE TRAUMATIC PHYSICALLY AND  
25 EMOTIONALLY TO THE PATIENT?

1 A. I WOULD THINK CONTRACTIONS ARE CONTRACTIONS. THEY ARE  
2 SOMETHING TO BE AWARE OF AND TAKE NOTE OF, BUT I WOULDN'T CALL  
3 THEM "TRAUMATIC."

4 Q. DOCTOR, ARE YOU FAMILIAR WITH AN ARTICLE WRITTEN RECENTLY  
5 COMPARING D&E TO INDUCTION BY AUTRY, ENTITLED:

6 "A COMPARISON OF MEDICAL INDUCTION AND  
7 DILATION AND EVACUATION FOR SECOND-TRIMESTER OF  
8 PREGNANCY"?

9 A. YES, I AM AWARE OF THAT ARTICLE.

10 MS. CLARK: MAY I APPROACH?

11 THE COURT: YES.

12 BY MS. CLARK:

13 Q. THIS IS PLAINTIFFS' EXHIBIT LT 5. DO YOU RECOGNIZE WHAT I  
14 HAVE JUST HANDED YOU?

15 A. YES, I DO.

16 Q. IS THAT THE AUTRY ARTICLE?

17 A. YES.

18 Q. HAVE YOU REVIEWED IT PRIOR TO TODAY?

19 A. YES, I HAVE.

20 Q. HAVE YOU RELIED UPON IT IN PROVIDING YOUR EXPERT TESTIMONY  
21 HERE TODAY?

22 A. YES, I HAVE.

23 Q. COULD YOU SUMMARIZE THE CONCLUSIONS IN THIS ARTICLE?

24 A. THE ARTICLE CONCLUDED THAT DILATION EVACUATION IS THE  
25 SAFEST METHOD OF SECOND-TRIMESTER ABORTION. MISOPROSTOL IS

1 SAFER THAN OTHER METHODS FOR MEDICAL ABORTION.

2 Q. DO YOU AGREE WITH THE CONCLUSIONS IN THIS ARTICLE?

3 A. I DO NOT AGREE WITH THE CONCLUSION THAT DILATION AND  
4 EVACUATION IS THE SAFEST METHOD FOR SECOND-TRIMESTER ABORTION.

5 Q. AND WHY DO YOU NOT AGREE WITH THE CONCLUSIONS REACHED IN  
6 THIS ARTICLE, SPECIFICALLY?

7 A. THERE WERE SEVERAL SERIOUSLY FLAWED METHODOLOGIES USED TO  
8 COME TO THIS CONCLUSION. SOME OF THEM INCLUDE THE FOLLOWING:  
9 FIRST, THEY COUNTED AS A COMPLICATION RETAINED PLACENTA, WHICH  
10 IS WHERE THE PLACENTA DOESN'T COME OUT RIGHT AFTER THE BABY  
11 DOES. HOWEVER, IT NEVER DEFINED WAS A WHAT A RETAINED PLACENTA  
12 WAS.

13 IN GENERAL PRACTICE, WE SAY RETAINED PLACENTA AT  
14 TERM IS ABOUT 30 MINUTES, AND IN THE SECOND-TRIMESTER ABORTION  
15 WE CONSIDER IT UP TO TWO HOURS AS A RETAINED PLACENTA, AFTER  
16 TWO HOURS IT HAS BEEN INSIDE. BUT THEY DON'T DEFINE WHAT EACH  
17 INDIVIDUAL PHYSICIAN DID WITH THE PATIENTS IN THIS.

18 AND THE OTHER MAJOR CONCERN WITH THIS ARTICLE IS  
19 THAT THE TWO GROUPS THAT THEY LOOKED, AT THE MEDICAL INDUCTION  
20 GROUP AND THE SURGICAL INDUCTION GROUP HAD A VERY STATISTICALLY  
21 SIGNIFICANT DIFFERENCE IN THE GESTATIONAL AGE OF THE WOMEN IN  
22 EACH SUBGROUP. SPECIFICALLY, THAT WITH MEDICAL INDUCTION IT  
23 WAS ALMOST 20-AND-A-HALF-WEEKS OF GESTATION AND IN THE SURGICAL  
24 GROUP IT WAS ABOUT 18-AND-A-HALF.

25 SO, JUST THE CONCLUSION COULD BE FOUND IF -- I AM

1 SORRY. STARTING AGAIN. THE CONCLUSION FOUND BY THE ARTICLE  
2 COULD BE EXPLAINED BY JUST THE FACT THAT THE GESTATIONAL AGES  
3 ARE DIFFERENT IN THE TWO GROUPS.

4 Q. DOCTOR, YOU MENTIONED THAT YOU WILL WAIT UP UNTIL ABOUT TWO  
5 HOURS TO REMOVE THE PLACENTA IN AN INDUCTION TERMINATION. AND  
6 IS THIS THE PRACTICE AT THE UNIVERSITY OF MICHIGAN?

7 A. YES, IT IS.

8 Q. AND IF THERE IS RETAINED PLACENTA AFTER TWO HOURS, WHAT IS  
9 DONE TO REMOVE THE RETAINED PLACENTA?

10 A. SEVERAL DIFFERENT METHODS ARE USED TO REMOVE THE RETAINED  
11 PLACENTA. USUALLY, WE TAKE A WOMAN BACK TO THE OPERATING ROOM  
12 WHEN WE ARE GOING TO REMOVE A PLACENTA AND IT HASN'T COME OUT  
13 IN TWO HOURS OR MORE, WHERE WE MAY REACH UP WITH A GLOVED HAND  
14 AND REMOVE THE PLACENTA BY SHEERING IT OFF THE SIDE OF THE  
15 UTERUS.

16 SOMETIMES WE ACTUALLY HAVE TO USE INSTRUMENTS AND  
17 ULTRASOUND GUIDANCE TO REMOVE THE PLACENTA IN PIECES OR IN  
18 WHOLE.

19 Q. AND IN THE INSTANCES IN WHICH YOU HAVE TO USE INSTRUMENTS  
20 TO REMOVE THE RETAINED PLACENTA, IS THIS ANY DIFFERENT THAN THE  
21 WAY IN WHICH PLACENTA IS REMOVED IN A D&E PROCEDURE?

22 A. IT IS THE SAME PROCEDURE.

23 Q. SO SURGERY IS DONE TO REMOVE THE PLACENTA AFTER AN  
24 INDUCTION, WHAT IS BEING DONE IS THE SAME THING AS THE  
25 PROCEDURE THAT IS DONE IN ALL D&E'S; IS THAT CORRECT?



1 A. THAT IS CORRECT.

2 Q. IN YOUR OPINION IS RETAINED PLACENTA A RISK FACTOR FOR  
3 INDUCTION?

4 A. IT IS SOMETHING THAT DOES HAPPEN, BUT I WOULDN'T CONSIDER  
5 IT A RISK.

6 Q. AT SOME POINT WOULD YOU EVER CONSIDER RETAINED PLACENTA TO  
7 BE A RISK OR COMPLICATION IN A MEDICAL INDUCTION?

8 A. I WOULD CONSIDER IT A COMPLICATION ONLY IF WE DID SOMETHING  
9 LIKE PERFORATE THE UTERUS DURING AN ATTEMPT TO REMOVE THE  
10 PLACENTA OR HAD SOME KIND OF INCREASED INFECTION RATES BECAUSE  
11 OF A RETAINED PLACENTA.

12 Q. IN YOUR OPINION HAS THE INCLUSION OF RETAINED PLACENTA IN  
13 THIS STUDY SKEWED THE COMPARISON OF THE SAFETY OF D&E VERSUS  
14 INDUCTION?

15 A. YES, IT HAS.

16 MS. CLARK: YOUR HONOR, NO FURTHER QUESTIONS.

17 THE COURT: ALL RIGHT. CROSS-EXAMINATION.

18 CROSS-EXAMINATION

19 BY MS. KRASNOFF:

20 Q. DR. SHADIGIAN, I WOULD LIKE TO TALK WITH YOU ABOUT D&E  
21 ABORTIONS. IN A D&E THE CERVIX IS DILATED OVER A PERIOD OF  
22 TIME; IS THAT CORRECT?

23 A. YES.

24 Q. AND SOMETIMES THE PHYSICIAN USES ONE SET OF LAMINARIA, BUT  
25 SOMETIMES THEY MAY DO MORE THAN ONE INSERTION OF LAMINARIA; IS

- 1 THAT CORRECT?
- 2 A. SOMETIMES.
- 3 Q. AND THAT'S REFERRED TO AS "SERIAL DILATION"; IS THAT RIGHT?
- 4 A. THAT IS CORRECT.
- 5 Q. AND YOU YOURSELF HAVE USED SERIAL LAMINARIA BEFORE A D&E,
- 6 HAVEN'T YOU?
- 7 A. RARELY, YES.
- 8 Q. AND YOU WOULDN'T USE TECHNIQUES OR PROCEDURES THAT YOU
- 9 BELIEVE WERE UNSAFE FOR YOUR PATIENTS, WOULD YOU?
- 10 A. I DON'T UNDERSTAND THE QUESTION.
- 11 Q. DO YOU USE ANY TECHNIQUES OR PROCEDURES ON YOUR PATIENTS
- 12 THAT YOU BELIEVE WERE NOT SAFE?
- 13 A. ARE YOU SPEAKING OF LAMINARIA OR SOMETHING ELSE?
- 14 Q. IN GENERAL.
- 15 A. I GUESS IT WOULD DEPEND ON THE PARTICULAR SITUATION.
- 16 Q. DO YOU BELIEVE THAT THE SERIAL USE OF LAMINARIA IS UNSAFE?
- 17 A. NO.
- 18 Q. YOU ARE ALSO CONSIDERING USING MISOPROSTOL ALONG WITH
- 19 LAMINARIA IN THE FUTURE; IS THAT RIGHT?
- 20 A. YES, AND MANY PHYSICIANS USE THAT ALREADY AT THE UNIVERSITY
- 21 OF MICHIGAN.
- 22 Q. AND YOU AGREE THAT THAT MIGHT HOLD SAFETY ADVANTAGES FOR
- 23 THE DILATION PROCESS; IS THAT CORRECT?
- 24 A. YES, IT MAY.
- 25 Q. WHEN USING LAMINARIA, IT IS POSSIBLE, IS IT NOT, TO SPEED

1 THE DILATION PROCESS BY CHANGING THE LAMINARIA MORE FREQUENTLY?

2 A. YES.

3 Q. AND YOU WOULD AGREE, WOULD YOU NOT, IF THERE WERE TWO WOMEN

4 AT 20 WEEKS GESTATIONAL AGE, BOTH ARE GOING TO HAVE D&E

5 ABORTIONS, AND BOTH GET THE SAME DOSES OF MISOPROSTOL AND THE

6 SAME NUMBER OF LAMINARIA, YOU WILL NOT NECESSARILY GET THE SAME

7 AMOUNT OF DILATION IN EACH OF THOSE TWO WOMEN; IS THAT CORRECT?

8 A. YES.

9 Q. NOW, YOU AGREE, WOULD YOU NOT, THAT IN PERFORMING A D&E THE

10 PHYSICIAN MAY APPLY TRACTION TO THE FETAL PART THAT HE OR SHE

11 IS GRASPING AND BE ABLE TO PULL IT THROUGH THE CERVICAL OS?

12 A. YES, THAT CAN BE DONE.

13 Q. AND IF THAT HAPPENS, THE PART THAT HAS BEEN BROUGHT THROUGH

14 THE CERVIX MAY DISARTICULATE AT THE INTERNAL CERVICAL OS DUE TO

15 THE TRACTION; IS THAT CORRECT?

16 A. YES, IT MAY.

17 Q. BUT YOU AGREE IT IS POSSIBLE IN THAT SITUATION IF THERE IS

18 ADEQUATE DILATION THAT THE PHYSICIAN WOULD BE ABLE TO EXTRACT

19 THE FETUS UP TO THE TORSO; IS THAT CORRECT?

20 A. POSSIBLY.

21 Q. AND IF THAT HAPPENED AND YOU WERE SUPERVISING A RESIDENT IN

22 A D&E, YOU WOULD TELL THEM TO DISARTICULATE, WOULD YOU NOT?

23 A. YES.

24 Q. AND IF THE FETUS WERE ALIVE AT THE POINT IT EMERGED UP TO

25 THE TORSO THAT DISARTICULATION WOULD BE A LEGAL ACT, WOULD IT

1 NOT?

2 A. I WOULDN'T BE PERFORMING THAT PROCEDURE IF IT WAS A LIVE  
3 BABY.

4 Q. WELL, CAN YOU OFFER AN OPINION IF ANOTHER PHYSICIAN WERE  
5 PERFORMING THAT AND THAT SITUATION PRESENTED ITSELF WHERE THE  
6 FETUS HAD EMERGED IN A D&E UP TO THE TORSO, AND THEN THE  
7 PHYSICIAN DISARTICULATED, WOULD THAT BE A LETHAL ACT?

8 A. IT COULD BE, BUT IT WOULDN'T NECESSARILY BE.

9 Q. AND WHEN WOULD IT NOT BE?

10 A. WELL, DISARTICULATION TAKES SEVERAL PASSES, SO IT IS NOT  
11 WHEN YOU JUST TWIST A FOOT OFF THAT THE BABY IS GOING TO DIE  
12 IMMEDIATELY. IN FACT, IT IS GOING TO HEMORRHAGE OVER A PERIOD  
13 OF TIME. SO IT WILL DEPEND ON HOW MANY OTHER PASSES YOU TAKE  
14 AND DISARTICULATION MOVES YOU DO.

15 Q. WELL, IN THIS EXAMPLE, IT HAD BEEN REMOVED ALL THE WAY TO  
16 THE TORSO. COULD YOU DISARTICULATE AT THE TORSO AND HAVE THE  
17 FETUS SURVIVE?

18 A. NOT FOR MANY MINUTES.

19 Q. YOU TESTIFIED EARLIER YOU'VE ONLY PERFORMED D&E'S ON  
20 DEMISED FETUSES; THAT'S CORRECT?

21 A. YES, THAT IS CORRECT.

22 Q. AND SOMETIMES THOSE FETUSES HAVE BEEN DEMISED FOR A DAY OR  
23 TWO; IS THAT RIGHT?

24 A. YES.

25 Q. I THINK YOU MENTIONED THIS, BUT THE FRIABILITY OF THE FETUS

1 IS EFFECTED BY FETAL DEMISE SUCH THAT IT BREAKS APART MORE  
2 READILY WHEN THERE HAS BEEN FETAL DEMISE; IS THAT CORRECT?

3 A. YES, COMPARED TO LIVE BABIES.

4 Q. AND YOU WOULD AGREE, WOULD YOU NOT, THAT THERE IS ALWAYS A  
5 RISK OF DAMAGE TO THE CERVIX OR TO THE UTERUS WHENEVER  
6 INSTRUMENTS ARE PASSED INTO THE UTERUS?

7 A. YES.

8 Q. IT IS TRUE THAT ONE RISK OF D&E IS THAT FETAL BONES MAY BE  
9 EXPOSED WHICH PRESENTS A RISK OF PUNCTURING OR LACERATING THE  
10 UTERUS; IS THAT CORRECT?

11 A. YES.

12 Q. AND YOU WOULD AGREE THAT REMOVAL OF THE FETUS INTACT DURING  
13 A SURGICAL ABORTION WOULD REDUCE THAT RISK, WOULDN'T IT?

14 A. YES.

15 Q. AND NOW I AM GOING TO SWITCH GEARS A BIT AND TALK IN  
16 GENERAL ABOUT INDUCTIONS.

17 I BELIEVE YOU HAVE TALKED ABOUT TWO DIFFERENT KINDS  
18 OF INDUCING AGENTS TODAY, OXYTOCIN OR PITOCIN AND  
19 PROSTAGLANDINS, SUCH AS MISOPROSTOL; IS THAT CORRECT?

20 A. YES.

21 Q. IT'S POSSIBLE WITH OXYTOCIN THAT THE WOMAN CAN HAVE TOO  
22 MANY UTERINE CONTRACTIONS OR TETANY; IS THAT RIGHT?

23 A. YES.

24 Q. AND TETANY CAN RESULT IN UTERINE RUPTURE; IS THAT CORRECT?

25 A. YES.

1 Q. AND YOU WOULD AGREE THAT OXYTOCIN MAY BE CONTRAINDICATED OR  
2 AT LEAST RELATIVELY CONTRAINDICATED IF A WOMEN HAS A PREVIOUSLY  
3 SCARRED UTERUS, WOULD YOU NOT?

4 A. I WOULD SAY RELATIVELY, BUT NOT ABSOLUTELY.

5 Q. AND THAT WOULD ESPECIALLY BE THE CASE IF THE SCAR IS WHAT  
6 IS KNOWN AS A VERTICAL OR CLASSICAL CESAREAN SECTION SCAR; IS  
7 THAT RIGHT?

8 A. YES, IT COULD BE.

9 Q. AND PROSTAGLANDINS, LIKE MISOPROSTOL, ARE ALSO  
10 CONTRAINDICATED FOR A WOMAN WHO HAS A PRIOR CESAREAN SECTION;  
11 ARE THEY NOT?

12 A. NOT ABSOLUTELY, BUT THAT IS OUR GENERAL PRACTICE NOT TO USE  
13 THEM.

14 Q. AND YOU WOULD AGREE THAT AN INDUCTION MAY NOT BE ADVISABLE  
15 FOR SOME WOMEN WITH SERIOUS MEDICAL CONDITIONS SUCH AS A  
16 SERIOUS HEART CONDITION, BECAUSE THE CONTRACTIONS COULD  
17 COMPROMISE HER CARDIOPULMONARY SITUATION; IS THAT RIGHT?

18 A. THAT IS POSSIBLE.

19 Q. AND SOME WOMEN MAY HAVE AN ALLERGY TO THE MEDICINES THAT  
20 ARE USED IN INDUCTION MAKING THAT METHOD NOT APPROPRIATE FOR  
21 THEM; IS THAT CORRECT?

22 A. YES.

23 Q. SO, YOU WOULD AGREE WITH ME, THEN, THAT THERE MAY BE  
24 SITUATIONS WHERE AN INDUCTION WOULD NOT BE THE OPTIMAL FORM OF  
25 ABORTION FOR A WOMAN?

- 1 A. THERE COULD BE.
- 2 Q. AND YOU WOULD AGREE THERE ARE CERTAIN RISKS ASSOCIATED WITH
- 3 INDUCTION; IS THAT RIGHT?
- 4 A. YES.
- 5 Q. AND THOSE INCLUDE, I BELIEVE, CHORIOAMNIONITIS OR
- 6 INFECTION?
- 7 A. YES.
- 8 Q. EXCESSIVE BLOOD LOSS FROM HEMORRHAGING?
- 9 A. YES.
- 10 Q. AND POTENTIAL RUPTURE OF THE UTERUS?
- 11 A. YES.
- 12 Q. INDUCTIONS ARE INPATIENT PROCEDURES, AREN'T THEY?
- 13 A. YES.
- 14 Q. THAT MEANS THEY ARE PERFORMED IN HOSPITALS, RIGHT?
- 15 A. YES.
- 16 Q. AND THE WOMAN IS IN THE HOSPITAL THE ENTIRE TIME OF THE
- 17 PROCEDURE; IS THAT RIGHT?
- 18 A. YES.
- 19 Q. AND I THINK YOU TESTIFIED EARLIER THAT THE AVERAGE LENGTH
- 20 OF TIME USING THE MEDICATIONS THAT YOU USE IS -- FOR AN
- 21 INDUCTION IS BETWEEN FOUR AND 24 HOURS; IS THAT CORRECT?
- 22 A. YES.
- 23 Q. BUT IN YOUR EXPERIENCE AN INDUCTION HAS TAKEN AS LONG AS
- 24 TWO-AND-A-HALF DAYS; IS THAT CORRECT?
- 25 A. YES.

1 Q. WOULD YOU AGREE WITH ME THAT INDUCTION, THEREFORE, IS  
2 UNPREDICTABLE IN LENGTH?

3 A. NOT NECESSARILY.

4 Q. BETWEEN -- WOULD YOU AGREE IT IS NOT PREDICTABLE BETWEEN  
5 FOUR HOURS AND TWO-AND-A-HALF DAYS?

6 A. ONE MIGHT BE ABLE TO PREDICT DEPENDING ON WHAT MEDICATIONS  
7 ARE USED AND WHAT RISK FACTORS A WOMAN HAS.

8 Q. AND ARE THOSE -- DO YOU BELIEVE YOU CAN PREDICT ACCURATELY  
9 HOW LONG THE INDUCTION WILL LAST?

10 A. I THINK IT IS EASIER TO PREDICT IF YOU DIVIDE UP THE SAMPLE  
11 SIZE. FOR EXAMPLE, IF YOU JUST LOOKED AT WOMEN WHO USED  
12 MISOPROSTOL YOU MIGHT BE ABLE TO MAKE A FAIRLY ACCURATE  
13 PREDICTION. AND IF YOU TOOK OXYTOCIN AS A SEPARATE ONE, AND  
14 MAKE A DIFFERENT ONE.

15 Q. WELL, COULD YOU TRY AND DO THOSE? THAT DOES CHANGE YOUR  
16 FOUR TO 24 HOURS FIGURES? WOULD IT BE DIFFERENT FOR EACH OF  
17 THOSE?

18 A. IT MIGHT BE.

19 Q. DO YOU HAVE AN OPINION ON WHAT IT MIGHT BE?

20 A. I THINK WHEN I SAID "FOUR TO 24 HOURS," I WAS THINKING MORE  
21 ABOUT MISOPROSTOL. AND THE ONES I HAVE SEEN THAT HAVE TAKEN  
22 LONGER HAVE BEEN WOMEN WITH SCARRED UTERUSES THAT WE COULDN'T  
23 USE PROSTAGLANDINS, AND THEY MAY TAKE LONGER.

24 Q. AND WHAT ABOUT OXYTOCIN? WHAT IS THE AVERAGE THAT WOULD  
25 TAKE?



1 A. AGAIN, IT DEPENDS ON IF IT IS A WOMAN'S FIRST BIRTH OR IF  
2 IT MIGHT BE THE SECOND OR THIRD BIRTH.

3 Q. CAN YOU GIVE ME A RANGE?

4 A. OXYTOCIN MAY RANGE BETWEEN SIX AND ONE TO TWO DAYS, SIX  
5 HOURS AND ONE TO TWO DAYS.

6 Q. WE TALKED JUST A FEW MINUTES AGO ABOUT HOW IN THE ABORTIONS  
7 YOU HAVE PERFORMED THERE HAS BEEN FETAL DEMISE BEFORE YOU  
8 REMOVE A FETUS IN D&E WOULD YOU AGREE THAT LABOR IS INDUCED  
9 MORE QUICKLY IN AN INDUCTION ABORTION WHEN THE FETUS IS  
10 DEMISED?

11 A. IT CAN BE.

12 Q. YOU ALSO TESTIFIED THAT THERE ARE PROTOCOLS FOR THE  
13 PERFORMANCE OF INDUCTION ABORTIONS AT THE UNIVERSITY OF  
14 MICHIGAN; IS THAT CORRECT?

15 A. THERE HAVE BEEN.

16 Q. BUT THESE PROTOCOLS ALLOW FOR INDIVIDUAL PHYSICIANS TO  
17 TAILOR THE PROCEDURE TO THE INDIVIDUAL PATIENT; IS THAT RIGHT?

18 A. YES.

19 Q. FOR EXAMPLE, A PHYSICIAN COULD OPT TO PRETREAT THE CERVIX  
20 OR NOT?

21 A. YES.

22 Q. OR THEY CAN ADD LAMINARIA IF THEY FOUND THEY WEREN'T  
23 GETTING ENOUGH DILATION; IS THAT CORRECT?

24 A. YES.

25 Q. OR THEY COULD ADD A DOSE OF A DIFFERENT KIND OF AGENT?

1 A. YES.

2 Q. AND YOU WOULD NOT SUPPORT HAVING PROTOCOLS THAT ARE SO  
3 STRICT THAT THE PHYSICIAN IS NOT ABLE TO MAKE THESE SORT OF  
4 ADJUSTMENTS, WOULD YOU?

5 A. NO.

6 Q. THAT IS BECAUSE YOU BELIEVE IT IS BEST TO LEAVE THOSE SORTS  
7 OF DECISIONS TO THE PHYSICIAN'S JUDGMENT; IS THAT RIGHT?

8 A. YES, I DO.

9 Q. AND WOULD YOU AGREE EVEN IN THE ABSENCE OF A  
10 CONTRAINDICATION THE EXPERIENCE OF UNDERGOING AN INDUCTION  
11 ABORTION VERSUS UNDERGOING A D&E PROCEDURE WOULD BE QUITE  
12 DIFFERENT FOR SOME WOMEN?

13 A. YES.

14 Q. AND SOME WOMEN WOULD FIND SURGERY MORE PREFERABLE TO LABOR  
15 INDUCTION; WOULD THEY NOT?

16 A. SOME MAY.

17 Q. AND WOULD YOU AGREE THAT SOME OF THE CONSIDERATIONS A WOMAN  
18 MIGHT GIVE TO HER CHOICE OF ABORTION PROCEDURE ARE COST,  
19 CONVENIENCE AND COMPASSION?

20 A. THEY MAY BE.

21 Q. AND YOU BELIEVE WITH FULLY INFORMED CONSENT WOMEN SHOULD  
22 RETAIN DISCRETION ABOUT WHETHER OR NOT TO HAVE A D&E OR AN  
23 INDUCTION; IS THAT CORRECT?

24 A. THEY SHOULD BE NOTIFIED OF THE POTENTIAL RISKS AND  
25 BENEFITS, YES.

1 Q. BUT THEN THEY SHOULD BE ABLE TO RETAIN DISCRETION ABOUT  
2 WHICH THEY CHOOSE; IS THAT CORRECT?

3 A. IF THEY ARE ABLE TO DO SO, YES.

4 Q. AND WHY WOULD THEY NOT BE ABLE TO DO SO?

5 A. WELL, IF A WOMAN IS, FOR EXAMPLE, VERY SICK AND MAY BE  
6 ALMOST COMATOSE, IT IS GOING TO BE THE DOCTOR'S JUDGMENT WHAT  
7 THE BEST THING TO DO FOR THE PATIENT AT THE TIME IS.

8 Q. UNDERSTOOD. IF A WOMAN IS CONSCIOUS AND CAN UNDERSTAND AND  
9 MAKE HER OWN DECISION --

10 A. YES.

11 Q. -- IT IS LEFT TO HER JUDGMENT, RIGHT?

12 A. YES.

13 Q. AND YOU WOULDN'T SUPPORT A LAW THAT REQUIRED EVERY WOMAN  
14 WHO HAD AN ABORTION AFTER 20 WEEKS TO HAVE AN INDUCTION INSTEAD  
15 OF A D&E, WOULD YOU?

16 A. NO.

17 Q. AND THAT'S BECAUSE YOU BELIEVE AN INDIVIDUAL PATIENT, ANY  
18 INDIVIDUAL PATIENT MAY NOT BE AN APPROPRIATE CANDIDATE FOR ONE  
19 KIND OF PROCEDURE VERSUS THE OTHER, AND SUCH A LAW WOULD MAKE  
20 IT DIFFICULT TO FIGURE OUT WHAT WOULD BE BEST FOR THOSE WOMEN;  
21 IS THAT RIGHT?

22 A. COULD YOU RESTATE THE QUESTION, PLEASE?

23 Q. SURE. THE REASON YOU WOULDN'T SUPPORT SUCH A LAW IS  
24 BECAUSE YOU BELIEVE THAT FOR ANY INDIVIDUAL PATIENT ONE  
25 PROCEDURE MIGHT BE BETTER THAN THE OTHER; IS THAT CORRECT?

1 A. YES.

2 Q. YOU'VE OFFERED SEVERAL OPINIONS TODAY ABOUT INTACT D&E OR I  
3 THINK YOU CALLED IT "D&X." IS IT OKAY IF I USE THE TERM  
4 "INTACT D&E"? DO YOU UNDERSTAND THAT TO BE THE SAME THING?

5 A. YOUR HONOR, I DON'T KNOW IF I AM ALLOWED TO DO THAT.

6 Q. DO YOU UNDERSTAND IT?

7 THE COURT: YOU CAN USE WHATEVER TERM YOU WISH. WE  
8 NEED TO MAKE SURE THAT YOU UNDERSTAND THAT SHE'S TALKING ABOUT  
9 WHAT YOU WOULD REFER TO AS D&X.

10 THE WITNESS: I UNDERSTAND, YES.

11 BY MS. KRASNOFF:

12 Q. SO IF I USE "INTACT D&E," YOU WILL UNDERSTAND WHAT I AM  
13 SAYING?

14 A. YES.

15 Q. OKAY. YOU WOULD AGREE THERE IS NO PARTICULAR GESTATIONAL  
16 AGE IN WHICH INTACT D&E IS EXCLUSIVELY PERFORMED, WOULD YOU  
17 NOT?

18 A. AS I UNDERSTAND IT, NO, IT IS NOT BASED ON GESTATIONAL AGE.

19 Q. AND YOU HAVE OFFERED THREE SPECIFIC OPINIONS TODAY ABOUT  
20 INTACT D&E. AND I WOULD LIKE TO TAKE THEM ONE AT A TIME.

21 FIRST, YOU TESTIFIED THAT YOU KNOW OF NO  
22 CIRCUMSTANCE IN WHICH AN INTACT D&E IS MEDICALLY NECESSARY TO  
23 TREAT A WOMAN WITH MEDICAL PROBLEMS; IS THAT CORRECT?

24 A. YES.

25 Q. BUT YOU WOULD AGREE, WOULD YOU NOT, THAT THE PROCEDURE

1 BEING NECESSARY IS NOT THE SAME THING AS SAYING THAT IT IS NOT  
2 A SAFE PROCEDURE; IS THAT CORRECT?

3 A. CORRECT.

4 Q. AND YOU TESTIFIED IN THE CASE OF A MATERNAL HEALTH PROBLEM,  
5 IT IS NEVER NECESSARY TO TAKE A DESTRUCTIVE ACT AGAINST THE  
6 FETUS; IS THAT CORRECT?

7 A. COULD YOU RESTATE THAT, PLEASE?

8 Q. I BELIEVE YOUR TESTIMONY WAS THAT IN PERFORMING A  
9 TERMINATION OF PREGNANCY WHEN THE WOMAN HAS A MATERNAL HEALTH  
10 PROBLEM, IT IS NEVER NECESSARY TO TAKE A DESTRUCTIVE ACT  
11 AGAINST THE FETUS?

12 A. THAT IS CORRECT.

13 Q. BUT YOU WOULD AGREE WITH ME THAT REGARDLESS OF HOW THE  
14 ABORTION IS PERFORMED, IF THE ABORTION IS DONE PRIOR TO FETAL  
15 VIABILITY THE FETUS WILL DIE AS A RESULT OF THE ABORTION?

16 A. YES, THAT IS CALLED A SECONDARY EFFECT.

17 Q. AND WOULD YOU AGREE THAT PRIOR TO FETAL VIABILITY A WOMAN  
18 SHOULD NOT BE REQUIRED TO CHOOSE A NONDESTRUCTIVE ABORTION  
19 METHOD THAT CARRIES GREATER HEALTH RISKS OVER A DESTRUCTIVE  
20 ABORTION METHOD THAT IS SAFER?

21 A. WHAT DO YOU MEAN BY "REQUIRED"? I AM NOT UNDERSTANDING.

22 Q. FORCED.

23 A. LEGALLY REQUIRED?

24 Q. YES.

25 A. COULD YOU RESTATE IT WITH A "LEGALLY REQUIRED" IN THERE? I

- 1 AM SORRY.
- 2 Q. SURE. IT IS A HYPOTHETICAL.
- 3 A. OH.
- 4 Q. IF THERE ARE TWO ABORTION METHODS, ONE WAS A NONDESTRUCTIVE  
5 METHOD THAT HAD GREATER HEALTH RISKS, AND ONE WAS A DESTRUCTIVE  
6 METHOD THAT IS SAFER --
- 7 A. OKAY.
- 8 Q. -- WOULD YOU SUPPORT REQUIRING A WOMAN TO HAVE THE LESS  
9 SAFE METHOD PRIOR TO FETAL VIABILITY?
- 10 A. NO.
- 11 Q. AND YOU YOURSELF DO NOT TAKE CARE OF SOME OF THE MOST SICK  
12 PREGNANT WOMEN AT THE UNIVERSITY OF MICHIGAN; IS THAT RIGHT?
- 13 A. I TAKE CARE OF SOME OF THEM, BUT NOT ALL OF THEM.
- 14 Q. SOME OF THEM ARE TAKEN CARE OF BY THE MATERNAL FETAL  
15 MEDICINE SPECIALIST; IS THAT RIGHT?
- 16 A. YES.
- 17 Q. AND YOU ARE NOT TRAINED IN MATERNAL FETAL MEDICINE; IS THAT  
18 RIGHT?
- 19 A. YES.
- 20 Q. AND, DR. SHADIGIAN, WHO IS THE CHAIR OF YOUR DEPARTMENT AT  
21 THE UNIVERSITY OF MICHIGAN?
- 22 A. HIS NAME IS DR. TIMOTHY R.B. JOHNSON.
- 23 Q. AND HE IS A SPECIALIST IN MATERNAL FETAL MEDICINE; IS HE  
24 NOT?
- 25 A. YES, HE IS.

1 Q. AND YOU RESPECT DR. JOHNSON AS A PHYSICIAN, DON'T YOU?

2 A. YES, I DO.

3 Q. AND YOU ARE ALSO AWARE THAT DR. JOHNSON IS A PLAINTIFF IN  
4 THE CASE PENDING IN NEW YORK WHICH CHALLENGES THE PARTIAL-BIRTH  
5 ABORTION BAN ACT OF 2003, ARE YOU NOT?

6 A. I AM AWARE OF THAT.

7 Q. IN FACT, YOU HAVE REVIEWED HIS EXPERT REPORT, HAVE YOU NOT?

8 A. I BELIEVE I HAVE REVIEWED PORTIONS OF IT.

9 Q. WELL, I AM GOING TO SHOW YOU YOUR DEPOSITION, IF THAT IS  
10 OKAY WITH YOU. COULD I ASK YOU TO TURN TO PAGE 68?

11 MS. CLARK: I AM SORRY. WHAT PAGE?

12 MS. KRASNOFF: SIXTY-EIGHT. AND I BELIEVE IT IS  
13 LINES -- I AM ON THE WRONG PAGE -- 16 TO 17.

14 BY MS. KRASNOFF:

15 Q. DOES THAT REFRESH YOUR RECOLLECTION WHETHER OR NOT YOU HAVE  
16 REVIEWED DR. JOHNSON'S EXPERT REPORT IN THE NEW YORK CASE?

17 A. I DIDN'T KNOW I NEEDED REFRESHING. I DON'T UNDERSTAND THE  
18 QUESTION.

19 Q. THE QUESTION THAT WAS ASKED YOU AT THE DEPOSITION:

20 "HAVE YOU REVIEWED DR. JOHNSON'S EXPERT  
21 REPORT?"

22 AND YOUR RESPONSE WAS:

23 "YES."

24 TODAY YOU SAID YOU ONLY REVIEWED PARTS OF IT. HAVE  
25 YOU REVIEWED IT ALL?

1 A. I CAN'T RECALL HOW MUCH OF WHICH REPORT I'VE REVIEWED HOW  
2 MUCH OF. I HAVE LOOKED AT SO MANY REPORTS. I AM SURE I  
3 REVIEWED HIS REPORT. I DON'T KNOW IF I READ EVERY "A" AND  
4 "THE," BUT I REVIEWED IT.

5 Q. OKAY. AND ARE YOU AWARE, BASED ON THAT REVIEW, THAT IT'S  
6 DR. JOHNSON'S REMOVED?

7 BY MS. KRASNOFF:

8 Q. ARE YOU AWARE BASED ON YOUR REVIEW OF THAT REPORT THAT IT  
9 IS DR. JOHNSON'S OPINION THAT INTACT REMOVAL OF A FETUS DURING  
10 A D&E MAY BE SAFEST AND MOST APPROPRIATE FOR TERMINATING A  
11 PREGNANCY FOR SOME WOMEN?

12 A. I GUESS BEFORE I WOULD AGREE TO THAT I WOULD LIKE TO SEE  
13 IT, BECAUSE I ASSUME YOU ARE READING IT FROM HIS REPORT, BUT I  
14 DON'T KNOW THAT.

15 Q. WELL --

16 A. I CAN'T REMEMBER WHAT HE SAID, EXACTLY.

17 Q. -- IF YOU LOOK AT PAGE 172 OF YOUR DEPOSITION, LINES FOUR  
18 THROUGH EIGHT.

19 A. OKAY.

20 Q. YOU WERE ASKED:

21 "DO YOU UNDERSTAND THAT IT IS HIS OPINION THAT  
22 IN SOME CIRCUMSTANCES D&X MAY BE THE SAFEST AND  
23 MOST APPROPRIATE METHOD FOR TERMINATING A  
24 PREGNANCY?"

25 AND YOU ANSWERED:



1 "IF THAT IS IN HIS REPORT, I DID READ THAT."

2 A. YES. I STILL STAND BEHIND THAT.

3 I THINK I WAS GETTING CONFUSED BETWEEN "DEPOSITION"  
4 AND "REPORT," BECAUSE HIS DEPOSITION IS VERY LONG.

5 Q. YES. AND I ONLY ASKED ABOUT HIS REPORT --

6 A. YES.

7 Q. -- WHICH WAS PRIOR, I BELIEVE, TO YOUR --

8 A. RIGHT. THAT IS WHY I WAS CONFUSED. THANK YOU.

9 Q. SO YOU HAVE REVIEWED THE REPORT --

10 A. YES. YES. I CERTAINLY HAVE.

11 Q. -- WHICH, UNFORTUNATELY, I DON'T HAVE TO SHOW YOU TODAY.

12 SO GIVEN DR. JOHNSON'S PARTICIPATION IN NEW YORK,  
13 YOU WOULD AGREE THAT RESPONSIBLE PHYSICIANS COULD REACH  
14 DIFFERENT CONCLUSIONS AS TO THE MEDICAL APPROPRIATENESS OF  
15 BANNING THE PROCEDURES COVERED BY THE PARTIAL-BIRTH ABORTION  
16 BAN ACT OF 2003; IS THAT TRUE?

17 A. YES.

18 Q. YOU WOULD ALSO AGREE THERE IS NO CONSENSUS IN THE MEDICAL  
19 COMMUNITY THAT THE PROCEDURES BANNED BY THE PARTIAL-BIRTH  
20 ABORTION BAN ACT OF 2003 ARE NOT SAFER FOR SOME WOMEN IN SOME  
21 CIRCUMSTANCES THAN OTHER AVAILABLE PROCEDURES?

22 A. THE OPINION IS DIVERSE.

23 Q. SO THERE IS NO CONSENSUS?

24 A. YES.

25 Q. THE SECOND OPINION YOU'VE OFFERED TODAY IS THERE IS NO

1 BASIS IN THE MEDICAL LITERATURE TO CONCLUDE INTACT D&E IS SAFER  
2 THAN ANY OTHER PROCEDURE; IS THAT CORRECT?

3 A. YES.

4 Q. BUT THERE IS NO BASIS IN THE LITERATURE TO PROVE IT IS ANY  
5 LESS SAFE, EITHER, IS THERE?

6 A. THAT IS CORRECT. THERE IS NO LITERATURE ON WHICH D&X HAS  
7 BEEN STUDIED WHATSOEVER TO BASE ANY OF THOSE THINGS.

8 Q. SO IT IS JUST UNSTUDIED; IS THAT CORRECT?

9 A. YES, IT IS UNSTUDIED.

10 Q. YOU THINK INTACT D&E SHOULD BE STUDIED; IS THAT CORRECT?

11 A. IF WE ARE GOING TO PERFORM D&X PROCEDURES ON WOMEN AND  
12 OFFER IT AS ANOTHER PROCEDURE, THEN, YES, IT SHOULD BE STUDIED.

13 Q. AND IN THE ABSENCE OF STUDIES, DO YOU AGREE THAT THE  
14 CLINICAL EXPERIENCE OF BOARD CERTIFIED OB/GYN'S WHO ROUTINELY  
15 PERFORM SURGICAL SECOND-TRIMESTER ABORTIONS IS OF SOME VALUE IN  
16 ASSESSING THE SAFETY OF A SECOND-TRIMESTER SURGICAL ABORTION  
17 METHOD?

18 A. NO.

19 Q. SO IT IS OF NO VALUE?

20 A. IT'S NOT OF VALUE IN ASSESSING SAFETY IN THE SHORT OR  
21 LONG-TERM.

22 Q. SO THEIR OPINIONS, YOU WOULD SAY, CARRY NO VALUE AS TO THE  
23 SAFETY AT ALL OF THOSE PROCEDURES?

24 A. NO, I WOULD SAY THAT THERE IS -- MAY BE SOME INITIAL  
25 ANECDOTAL EVIDENCE OF THE SAFETY AT THE TIME OF THE PROCEDURE,

1 BUT NOT IN THE SHORT-TERM LEADING UP TO SIX WEEKS. JUST UP TO  
2 SIX WEEKS AFTER THE PROCEDURE, NOR IN THE LONG-TERM, WHICH  
3 WOULD BE GREATER THAN SIX WEEKS.

4 Q. WE DISCUSSED AN ARTICLE BY DAN EPNER, ENTITLED "LATE TERM  
5 ABORTION," WHICH WAS PUBLISHED IN A JOURNAL OF THE AMERICAN  
6 MEDICAL ASSOCIATION IN AUGUST OF 1998.

7 DO YOU HAVE THAT HANDY UP THERE?

8 A. YES.

9 Q. THAT ARTICLE STATES, IN PART, QUOTE:

10 "INTACT D&X MAY MINIMIZE TRAUMA TO THE WOMAN'S  
11 UTERUS, CERVIX AND OTHER VITAL ORGANS."

12 YOU AGREE WITH THAT STATEMENT, DON'T YOU?

13 A. YES, IT MAY.

14 Q. AND, DR. SHADIGIAN, YOU TESTIFIED YOU THINK IT IS FEASIBLE  
15 TO PERFORM A PROSPECTIVE, RANDOMIZED TRIAL COMPARING INTACT D&E  
16 WITH OTHER ABORTION METHODS; IS THAT CORRECT?

17 A. YES.

18 Q. AND THE EXAMPLE YOU OFFERED FOR WHY THAT IS FEASIBLE IS A  
19 RECENT STUDY ON BREECH DELIVERY THAT WAS PUBLISHED IN THE  
20 LANCET IN 2000; IS THAT CORRECT?

21 A. YES, THAT IS ONE REASON TO CONCLUDE THAT IT COULD BE  
22 STUDIED.

23 Q. IS THAT THE STUDY FROM THE LANCET THAT YOU WERE REFERRING  
24 TO?

25 A. YES, I BELIEVE IT IS.

1 Q. WOULD IT HELP IF I SHOWED IT TO YOU?

2 A. YES.

3 MS. KRASNOFF: MAY I APPROACH?

4 THE COURT: YES.

5 IS THIS AN EXHIBIT?

6 MS. KRASNOFF: NO, IT IS NOT. AND HERE IS A COPY.

7 THE COURT: I ACTUALLY ALREADY HAVE A COPY. THAT IS  
8 WHAT I THOUGHT.

9 MS. KRASNOFF: IT IS NOT IN THE BINDER.

10 BY MS. KRASNOFF:

11 Q. IS THAT THE STUDY YOU WERE REFERRING TO?

12 A. YES.

13 Q. AND THAT STUDY INVOLVED 121 DIFFERENT CENTERS IN 26

14 DIFFERENT COUNTRIES, DID IT NOT?

15 A. YES.

16 Q. YOU WOULD AGREE, WOULD YOU NOT, THAT IT WOULD BE DIFFICULT  
17 TO FIND 121 DIFFERENT CENTERS IN 26 DIFFERENT COUNTRIES WHERE  
18 SECOND-TRIMESTER CERVICAL ABORTION IS WIDELY AVAILABLE?

19 A. NO.

20 Q. YOU BELIEVE THAT SECOND-TRIMESTER ABORTION IS WIDELY  
21 AVAILABLE IN 121 DIFFERENT CENTERS IN 26 DIFFERENT COUNTRIES?

22 A. YES.

23 Q. WELL, DO YOU THINK THAT CESAREAN SECTION AND VAGINAL  
24 DELIVERIES, WHICH WERE COMPARED IN THE LANCET STUDY ARE MUCH  
25 MORE COMMON EVENTS AROUND THE WORLD THAN SECOND-TRIMESTER

1 SURGICAL ABORTIONS?

2 A. YOU CAN LOOK AT THE DATA TO DETERMINE THAT.

3 Q. DO YOU HAVE AN OPINION SITTING HERE TODAY ABOUT THAT?

4 A. I COULDN'T SAY ONE WAY OR ANOTHER WHAT THE ACTUAL INCIDENCE  
5 RATE IS IN DIFFERENT COUNTRIES AROUND D&E WITHOUT LOOKING AT  
6 THAT PARTICULAR COUNTRY. BUT, IN FACT, IT IS NOT BANNED IN  
7 MANY, MANY COUNTRIES AROUND THE WORLD.

8 Q. WELL, LET'S JUST TAKE THIS COUNTRY WHERE IT IS NOT BANNED.

9 DO YOU BELIEVE THAT THERE ARE MORE ABORTIONS IN THIS  
10 COUNTRY THAN DELIVERIES?

11 A. NO.

12 Q. AND YOU WOULD AGREE THAT BOTH CESAREAN SECTION AND VAGINAL  
13 DELIVERY, WHICH ARE THE STUDY OF THIS ARTICLE, ARE BOTH STILL  
14 BEING DONE TODAY IN THE INDICATIONS OF BREECH PRESENTATION; IS  
15 THAT CORRECT?

16 A. I WOULD SAY THAT BASED ON THIS STUDY THE VAGINAL BREECH IS  
17 VERY, VERY RESTRICTED IN THIS COUNTRY NOW, BASED ON THIS STUDY.

18 Q. BUT IT IS SOMETIMES USED, IS IT NOT?

19 A. YES.

20 Q. AND YOU WOULDN'T SUPPORT BANNING ITS USE, WOULD YOU?

21 A. NO.

22 Q. DR. SHADIGIAN, YOU YOURSELF HAVE NEVER DESIGNED OR BEEN THE  
23 PRINCIPAL INVESTIGATOR OF A PROSPECTIVE RANDOMIZED TRIAL, HAVE  
24 YOU?

25 A. I HAVE NOT HAD ONE FUNDED AND EXECUTED, BUT I HAVE PLANNED

1 THEM.

2 Q. SO THERE IS NO PUBLISHED STUDIES OF WHICH YOU HAVE BEEN THE  
3 PRINCIPAL INVESTIGATOR IN A PROSPECTIVE RANDOMIZED TRIAL; IS  
4 THAT CORRECT?

5 A. CORRECT.

6 Q. AND YOU HAVE NEVER DONE ANY CLINICAL RESEARCH YOURSELF  
7 RELATED TO ABORTION PROCEDURES, HAVE YOU?

8 A. I DON'T UNDERSTAND THE QUESTION.

9 Q. ANY RESEARCH BASED ON PATIENTS WHICH YOU SAW RELATED TO  
10 SPECIFICALLY ABORTION PROCEDURES?

11 A. ACTUALLY, SOME OF MY PATIENTS HAVE BEEN ENROLLED IN STUDIES  
12 LOOKING AT ABORTION PROCEDURES.

13 Q. AND WERE YOU YOURSELF INVOLVED IN COMPLETING THAT STUDY?

14 A. I WAS NOT THE PRINCIPAL INVESTIGATOR, NO.

15 Q. THE THIRD OPINION YOU OFFERED TODAY IS THAT THERE IS NO  
16 SOUND BASIS ON WHICH TO SAY INTACT D&E IS A SAFER ABORTION  
17 PROCEDURE THAN INDUCTION; IS THAT CORRECT?

18 A. YES.

19 Q. IN FACT, YOU TESTIFIED YOU BELIEVE THAT INDUCTION IS SAFER  
20 THAN INTACT D&E; IS THAT RIGHT?

21 A. YES, IF YOU USED D&E AS A COMPARISON, SINCE WE DON'T HAVE  
22 ANY DATA ON D&X.

23 Q. WELL, THAT IS EXACTLY MY NEXT QUESTION. YOU HOLD THAT  
24 OPINION EVEN THOUGH THERE ARE NO PUBLISHED PEER REVIEWED  
25 MEDICAL STUDIES THAT COMPARE INTACT D&E TO INDUCTION; IS THAT

1 RIGHT?

2 A. THAT IS CORRECT.

3 Q. AND, THEREFORE, YOU WOULD AGREE YOUR OPINION ABOUT THAT IS  
4 OF THE SAME ILK AS THE EXPERTS WHO DISAGREE WITH YOU; WOULD YOU  
5 NOT?

6 A. YES, IT IS BASED ON THE SAME DATA.

7 Q. AND YOUR CONCLUSION THAT INDUCTION IS SAFER IS BECAUSE YOU  
8 BELIEVE AFTER 20 WEEKS INDUCTION IS SAFER THAN D&E; IS THAT  
9 RIGHT?

10 A. MINE IS BASED ON MEDICAL LITERATURE, MY OPINION.

11 Q. AND THE MEDICAL LITERATURE THAT IS AVAILABLE IS ABOUT D&E;  
12 IS THAT RIGHT?

13 A. YES, IT IS.

14 Q. SO, IT'S FAIR TO SAY THAT YOUR CONCLUSION THAT INDUCTION IS  
15 SAFER IS BECAUSE YOU BELIEVE THAT AFTER 20 WEEKS D&E IS SAFER  
16 THAN INDUCTION; IS THAT CORRECT?

17 A. NO.

18 Q. WHY NOT?

19 A. YOU SAID IT BACKWARDS.

20 Q. OH, BECAUSE I SAID IT BACKWARDS? LET'S TRY IT AGAIN, THEN.

21 IS IT FAIR TO SAY THAT YOUR CONCLUSION THAT  
22 INDUCTION IS SAFER IS BECAUSE THAT YOU BELIEVE AFTER 20 WEEKS  
23 INDUCTION IS SAFER THAN D&E ABORTIONS; IS THAT CORRECT?

24 A. YES.

25 Q. IN FACT, YOU DON'T FIND INTACT D&E ANY MORE OBJECTIONABLE

1 THAN D&E, DO YOU?

2 A. WHAT DO YOU MEAN BY "OBJECTIONABLE"?

3 Q. IF YOU COULD PLEASE TURN TO YOUR DEPOSITION, PAGE 242,  
4 LINES 18 TO 20.

5 YOU WERE ASKED:

6 "DO YOU FIND D&X OR PARTIAL-BIRTH ABORTIONS  
7 MORE OBJECTIONABLE THAN D&E?"

8 AND YOU RESPONDED:

9 "NO."

10 A. YES. I DID SAY THAT.

11 Q. DO YOU BELIEVE THAT?

12 A. YES.

13 Q. NOW, MS. CLARK ASKED YOU ABOUT SEVERAL ARTICLES IN SUPPORT  
14 OF YOUR OPINION ABOUT THE SAFETY OF INDUCTION VERSUS D&E. AND  
15 ONE WAS THE EPNER ARTICLE WE ALREADY DISCUSSED. WOULD YOU  
16 AGREE THAT THE CONCLUSION REACHED BY THE AUTHORS OF THAT  
17 ARTICLE WAS ACTUALLY THAT MORTALITY RATES FOR D&E AND INDUCTION  
18 AT OR AFTER 21 WEEKS IS COMPARABLE?

19 A. THAT'S THEIR CONCLUSION THAT THEY DREW BASED ON THE DATA IN  
20 THAT TABLE.

21 Q. AND WILL YOU AGREE IN THE GRIMES STUDY THAT WE LOOKED AT IT  
22 SAYS -- I BELIEVE YOU ACTUALLY READ THIS -- THE MORTALITY RATE  
23 IS STATISTICALLY INDISTINGUISHABLE BETWEEN D&E AND INDUCTION AT  
24 THAT GESTATIONAL AGE?

25 A. THEY SAID, ACTUALLY, AT 16 WEEKS AND GREATER, IN THE GRIMES

DIANE E. SKILLMAN, OFFICIAL COURT REPORTER, USDC (415) 552-5393



1 STUDY.

2 Q. AND GIVEN THE SMALL NUMBER OF WOMEN HAVING ABORTIONS AT 21  
3 WEEKS OF GESTATION OR GREATER, CAN YOU STATE WITH ANY CERTAINTY  
4 THAT THE DIFFERENCE IN THE MORTALITY RATES THAT ARE STATED IN  
5 TABLE 3 OF THE EPNER ARTICLE ARE OF STATISTICAL SIGNIFICANCE?

6 THE COURT: WHERE IS THAT IN THE --

7 MS. KRASNOFF: I DON'T HAVE AN EXHIBIT NUMBER ON IT.

8 THE COURT: IT WAS PREVIOUSLY REFERRED TO.

9 MS. KRASNOFF: IT'S CALLED "LATE TERM ABORTION."

10 MS. CLARK: IT'S DEFENDANT'S LT A-15.

11 MS. KRASNOFF: SHE REFERRED TO TABLE 3, I BELIEVE.

12 OR MAYBE NOT.

13 I AM SORRY, IT'S TABLE 4. THAT'S ON PAGE 727, WHICH  
14 I BELIEVE SHOWS THAT MORTALITY RATE AT GREATER THAN 21 WEEKS IS  
15 11.9 FOR DILATION AND EVACUATION, AND 10.3 FOR LABOR INDUCTION.  
16 BY MS. KRASNOFF:

17 Q. AND BASED ON THE FACT THAT THE AUTHORS INCLUDE THAT THOSE  
18 RATES ARE COMPARABLE, I AM ASKING YOU WITH ANY CERTAINTY YOU  
19 CAN STATE THAT THAT IS A STATISTICALLY SIGNIFICANT DIFFERENCE.

20 A. WE COULD ACTUALLY DO THE NUMBERS AND FIND THAT IT IS  
21 BECAUSE THE N IS QUITE LARGE. THE NUMBER OF WOMEN IN THE STUDY  
22 IS NOT INSIGNIFICANT. IT IS 175,395. AND I BELIEVE IF YOU  
23 ACTUALLY DID THE T TEST IT WOULD BE STATISTICALLY SIGNIFICANT.  
24 HOWEVER, IN THIS STUDY THEY DID NOT DO THAT T TEST.

25 Q. AND YOU YOURSELF ARE NOT AN EPIDEMIOLOGIST, ARE YOU?

- 1 A. THAT IS CORRECT.
- 2 Q. YOU HAVE NO FORMAL TRAINING IN EPIDEMIOLOGY?
- 3 A. I HAVE COURSES I HAVE TAKEN, AND I HAVE TAKEN POSTGRADUATE  
4 COURSES, IN FACT, BY DR. GRIMES ON EPIDEMIOLOGY.
- 5 Q. DO YOU HAVE A MASTER'S DEGREE OR ANY OTHER DEGREE IN  
6 EPIDEMIOLOGY?
- 7 A. NO, I DO NOT.
- 8 Q. DO YOU HAVE AN APPOINTMENT IN TEACHING EPIDEMIOLOGY AT THE  
9 UNIVERSITY OF MICHIGAN?
- 10 A. NO, I DO NOT.
- 11 Q. DESPITE YOUR VIEW THAT INDUCTIONS ARE SAFER THAN D&E'S,  
12 WOULD YOU ALSO AGREE THAT THE VAST MAJORITY OF ABORTIONS  
13 PERFORMED IN THE UNITED STATES AFTER 16 WEEKS ARE SURGICAL  
14 ABORTIONS?
- 15 A. THAT IS CORRECT.
- 16 Q. AND WILL YOU AGREE THERE IS NO CONSENSUS IN THE MEDICAL  
17 COMMUNITY ABOUT WHICH PROCEDURE, D&E OR INDUCTION, IS SAFER  
18 AFTER 20 WEEKS?
- 19 A. I DON'T KNOW.
- 20 Q. DO YOU THINK THAT SOME REASONABLE PHYSICIANS MAY BELIEVE  
21 THAT THERE ARE COMPARABLE SAFETY?
- 22 A. THERE MAY BE.
- 23 Q. ONE OF THE SPECIFIC CONCERNS YOU EXPRESSED ABOUT THE SAFETY  
24 OF INTACT D&E IS ABOUT CERVICAL TRAUMA; IS THAT CORRECT?
- 25 A. YES.

1 Q. AND THOSE CONCERNS RELATE IN PART TO THE USE OF LAMINARIA;  
2 IS THAT CORRECT?

3 A. YES.

4 Q. IN PARTICULAR, YOU TESTIFIED ABOUT THE RISK OF INFECTION  
5 AND OF TRAUMA TO THE CERVIX FROM INSERTING THE LAMINARIA; IS  
6 THAT CORRECT?

7 A. YES.

8 Q. AND THOSE RISKS ARE PRESENT AT ANY TIME LAMINARIA ARE  
9 INSERTED, AREN'T THEY?

10 A. YES, THEY ARE.

11 Q. AND THOSE RISKS ARE PRESENT IN ANY D&E ABORTION, AS WELL AS  
12 ANY INTACT D&E; IS THAT CORRECT?

13 A. YES, IF LAMINARIA ARE USED, THEN IT WOULD BE.

14 Q. SO YOUR OPINIONS ABOUT THAT TRAUMA TO THE CERVIX FROM  
15 LAMINARIA WOULD APPLY EQUALLY TO D&E PROCEDURES WHERE LAMINARIA  
16 ARE USED AS THEY DO TO INTACT D&E; IS THAT CORRECT?

17 A. NO.

18 Q. WHY NOT?

19 A. BECAUSE THE INTACT D&E ACTUALLY USES MORE LAMINARIA OVER  
20 TWO DAYS, AND GENERALLY FOR REGULAR D&E IT IS JUST USED FOR ONE  
21 DAY. AND PUT IT IN ONE DAY, AND THEN THE PROCEDURE IS DONE ON  
22 THE SECOND DAY.

23 Q. AND THAT IS ONLY BASED ON THOSE FEW ARTICLES THAT YOU READ?

24 A. NO, IT IS BASED ON MY PRACTICE, TOO.

25 Q. WELL, YOU HAVE NEVER PERFORMED AN INTACT D&E, HAVE YOU?

1 A. NO.

2 Q. AND YOU HAVE NEVER TALKED TO ANY PHYSICIAN WHO HAS  
3 PERFORMED AN INTACT D&E, HAVE YOU?

4 A. NO, BUT YOU ASKED ME ABOUT D&E VERSUS INTACT D&E, UNLESS I  
5 DIDN'T UNDERSTAND YOU.

6 Q. RIGHT. AND MY POINT IS ONLY THAT YOUR UNDERSTANDING OF THE  
7 DILATION THAT OCCURS IN AN INTACT D&E IS ONLY BASED ON THE ACOG  
8 STATEMENT, THE HASKELL PAPER, WHICH YOU READ, THE MCMAHON  
9 PAPER, WHICH YOU READ. AND THERE WAS A FOURTH: SOME OF THE  
10 TESTIMONY, I BELIEVE, IN THIS CASE; IS THAT CORRECT?

11 A. YES, IT'S BASED ON THOSE THINGS.

12 Q. THE OTHER CONCERN THAT YOU --

13 THE COURT: EXCUSE ME. COULD I ASK A FOLLOW-UP  
14 QUESTION SO I MAKE SURE THAT'S YOUR OPINION?

15 WOULD YOUR OPINION BE THE SAME ABOUT RISK OF TRAUMA  
16 TO THE CERVIX IF THE INTACT PROCEDURE WAS NOT PRECEDED BY  
17 SERIAL LAMINARIA, BUT JUST BY ONE SETTING OF LAMINARIA?

18 THE WITNESS: I WOULD SAY THAT THOSE ARE TWO  
19 DIFFERENT KINDS OF THINGS TO COMPARE, BECAUSE THE SERIAL  
20 LAMINARIA ACTUALLY DILATED THE CERVIX TO A GREAT MUCH GREATER  
21 DEGREE OVER TWO DAYS THAN A SINGLE SET OF LAMINARIA.

22 THE COURT: SO THAT WOULD CHANGE YOUR OPINION?

23 THE WITNESS: YES, IT WOULD.

24 BY MS. KRASNOFF:

25 Q. AND TO FOLLOW THAT UP, IF YOU THOUGHT THERE WAS ONLY ONE

1 SET OF LAMINARIA, THAT WOULD ME THAT YOU THOUGHT IT WAS  
2 POTENTIALLY SAFER THAN IF THERE WAS SERIAL LAMINARIA; IS THAT  
3 CORRECT?

4 A. IT WOULD DEPEND ON HOW DILATED AND HOW LAMINARIA THERE  
5 WOULD BE. I AM TALKING ABOUT AVERAGES, AS I UNDERSTAND IT.

6 Q. THE OTHER CONCERN YOU EXPRESSED WAS ABOUT PULLING FETAL  
7 PARTS THROUGH THE CERVICAL OS. THAT WOULD APPLY TO A D&E,  
8 WOULD IT NOT?

9 A. SPECIFICALLY, I WAS TALKING ABOUT THE HEAD BEING A BIGGER  
10 PART THAN THE OTHER PARTS BEING PULLED THROUGH.

11 Q. BUT THE HEAD HAS TO BE PULLED THROUGH IN A D&E, DOESN'T IT?

12 A. YES, BUT IT IS DISARTICULATED AND ACTUALLY TAKEN OUT IN  
13 PIECES, WHICH IS NOT TRUE FOR A D&X.

14 Q. AND IF IN A D&E THE HEAD WERE NOT TAKEN OUT IN PIECES BUT  
15 WERE JUST REDUCED WITH FORCEPS AND BROUGHT THROUGH, THAT WOULD  
16 BE THE SAME; IS THAT CORRECT?

17 A. THE SAME AS WHAT?

18 Q. AS IN AN INTACT D&E?

19 A. THAT IS THE DESCRIPTION OF THE INTACT D&E, YES.

20 Q. NOW, WE TALKED SOME --

21 THE COURT: I AM NOT SURE. IT WASN'T CLEAR ENOUGH  
22 FOR ME, EXACTLY --

23 MS. KRASNOFF: LET'S TRY IT AGAIN, THEN.

24 THE WITNESS: YOUR HONOR, MAY I ASK COULD WE HAVE  
25 ANOTHER BREAK? OR ARE WE NOT GOING TO --

1 THE COURT: YES, WE CAN HAVE ANOTHER BREAK.  
2 AND WHY DON'T YOU REFORMULATE YOUR QUESTION --  
3 MS. KRASNOFF: AND THEN, WE WILL BREAK?  
4 THE COURT: NO, WE WILL TAKE IT AFTER THE BREAK.  
5 MS. KRASNOFF: OH, OKAY. GREAT. I UNDERSTAND.  
6 THE COURT: WE WILL TAKE A BREAK NOW.  
7 MS. KRASNOFF: THE LAST QUESTION.  
8 THE COURT: THE WITNESS NEEDS A BREAK. WE WILL TAKE  
9 A BREAK. 15 MINUTES.

10 THE WITNESS: THANK YOU, YOUR HONOR.

11 THE COURT: YOU ARE WELCOME.

12 (RECESS TAKEN AT 11:50 A.M.)

13 (PROCEEDINGS RESUMED AT 12:05 P.M.)

14 THE COURT: ALL RIGHT. NOW YOU WERE GOING TO --

15 MS. KRASNOFF: I WILL TRY THIS AGAIN.

16 BY MS. KRASNOFF:

17 Q. LET'S TRY AGAIN.

18 ONE OF THE CONCERNS YOU EXPRESSED ABOUT INTACT D&E  
19 WAS ABOUT COLLAPSING AND PULLING THE FETAL SKULL THROUGH THE  
20 CERVICAL OS; IS THAT CORRECT?

21 A. YES.

22 Q. AND IF I REPRESENTED TO YOU THAT IN A D&E THE FETUS WAS  
23 DISARTICULATED UP TO THE FETAL SKULL BUT THEN FORCEPS WERE  
24 INSERTED INTO THE UTERUS, THE FETAL SKULL WAS COLLAPSED AND  
25 REMOVED IN ONE PASS, WOULD THAT PRESENT THE SAME RISK THAT YOU

1 ARE SPEAKING OF?

2 A. AS COMPARED TO AN INTACT?

3 Q. YES.

4 A. YES.

5 Q. THERE HAS BEEN A LOT OF BACK AND FORTH ABOUT THIS, BUT I  
6 WOULD LIKE TO ASK ABOUT YOUR REVIEW ARTICLE.

7 THAT ARTICLE DOES NOT SEPARATE OUT WHAT METHOD OF  
8 ABORTION THE WOMEN HAD; IS THAT CORRECT?

9 A. THE INDIVIDUAL ARTICLES MAY HAVE SEPARATED FROM FIRST AND  
10 SECOND TRIMESTER, BUT THERE WEREN'T ENOUGH OF THEM TO BE ABLE  
11 TO DRAW CONCLUSIONS BY SEPARATING OUT BY TRIMESTER.

12 Q. SO YOUR REVIEW ARTICLE DOESN'T SEPARATE THEM OUT, DOES IT?

13 A. CORRECT.

14 Q. YOUR REVIEW ARTICLE DOESN'T LOOK AT THE GESTATIONAL AGE OF  
15 THE FETUS AT THE TIME OF THE ABORTION, DOES IT?

16 A. NOT SPECIFICALLY.

17 Q. WELL, IN FACT, WHEN IT TALKS ABOUT SAY, FOR EXAMPLE,  
18 PRE-TERM BIRTH, THERE IS NO MENTION OF METHOD OF PROCEDURE OR  
19 GESTATIONAL AGE, IS THERE, IN THE REVIEW?

20 A. NOT IN MY PAPER.

21 Q. AND SO THAT CONCLUSION, THE ARTICLE'S CONCLUSION APPLY TO  
22 ALL METHODS OF ABORTION AT ALL GESTATIONAL AGES; IS THAT  
23 CORRECT?

24 A. I WOULD SAY YOU CAN'T GENERALIZE TO ALL ABORTION METHODS AT  
25 ALL GESTATIONAL AGES NECESSARILY, BUT THE WHOLE GIST OF IT IS

1 THAT WE NEED TO BE AWARE THAT THERE ARE LONG-TERM  
2 COMPLICATIONS. AND, IN FACT, IT WOULD BE NICE TO HAVE BETTER  
3 STUDIES SO WE CAN JUST, AS YOU IMPLIED, WE CAN LOOK AT  
4 FIRST-TRIMESTER VERSUS SECOND-TRIMESTER AND WHAT ACTUAL METHOD  
5 WAS USED.

6 Q. BUT YOU DIDN'T DO THAT?

7 A. I DID NOT DO THAT.

8 Q. THE CONCLUSIONS IN YOUR ARTICLE APPLY THE WAY IT WAS  
9 WRITTEN WITH EQUAL FORCE TO ALL ABORTIONS AT ALL GESTATIONAL  
10 AGES?

11 A. I WOULD SAY YES.

12 Q. AND, IN FACT, THE MAJORITY OF THE ABORTIONS IN THE STUDIES  
13 THAT FORM THE BASIS OF YOUR REVIEW ARTICLE, THOSE LOOK AT  
14 FIRST-TRIMESTER ABORTIONS, DON'T THEY?

15 A. THEY LOOK AT A MIX, BUT MOSTLY FIRST-TRIMESTER JUST BECAUSE  
16 IT IS MORE COMMON.

17 Q. YOUR ARTICLE DID NOT LOOK SPECIFICALLY AT CERVICAL  
18 INCOMPETENCE, BUT RATHER LOOKED AT PRE-TERM BIRTH; IS THAT  
19 CORRECT?

20 A. YES. IT LOOKED AT PRE-TERM BIRTH AND LOW BIRTH WEIGHT  
21 WHICH IS A CORRELATE.

22 Q. YOU TESTIFIED ABOUT THIS ON DIRECT, BUT YOU AGREE THAT  
23 PRE-TERM BIRTH AND CERVICAL INCOMPETENCE ARE NOT THE SAME  
24 THING; IS THAT CORRECT?

25 A. THAT'S CORRECT.



1 Q. THERE ARE MANY RISK FACTORS FOR PRE-TERM BIRTH BESIDES  
2 CERVICAL INCOMPETENCE; ISN'T THAT CORRECT?

3 A. YES.

4 Q. SOME WOMEN HAVE PRE-TERM BIRTHS EVEN IF THERE ARE NO RISK  
5 FACTORS PRESENT, DON'T THEY?

6 A. YES.

7 Q. YOUR ARTICLE FOUND AN ASSOCIATION BETWEEN ABORTION AND  
8 PRE-TERM BIRTH, BUT AN ASSOCIATION IS NOT THE SAME THING AS A  
9 CAUSE; IS THAT CORRECT?

10 A. YES, THAT IS CORRECT.

11 Q. AND BECAUSE MOST OF THE ABORTIONS THAT WERE IN THE STUDIES  
12 THAT MAKE UP YOUR REVIEW ARTICLE WERE FIRST-TRIMESTER  
13 ABORTIONS, IT'S MOST LIKELY THAT THE DILATION WOULD HAVE BEEN  
14 MECHANICAL DILATION AND NOT OSMOTIC DILATION; IS THAT CORRECT?

15 A. YES.

16 Q. YOU, YOURSELF, WHEN YOU PERFORM A D&C PROCEDURE OR A VACUUM  
17 ASPIRATION TO REMOVE A DEAD FETUS --

18 THE REPORTER: I'M SORRY.

19 BY MS. KRASNOFF:

20 Q. YOU, YOURSELF, IF YOU PERFORM A D&C PROCEDURE OR A VACUUM  
21 ASPIRATION TO REMOVE A DEAD FETUS, YOU, YOURSELF, USE THE  
22 MECHANICAL DILATION; IS THAT CORRECT?

23 A. YES, I DO.

24 Q. ISN'T PURELY HYPOTHETICAL TO SAY, BASED ON THE STUDIES THAT  
25 ARE IN YOUR ARTICLE, THAT DILATION OVER A PERIOD OF HOURS OR

1 DAYS WITH OSMOTIC DILATORS IS ANY MORE DANGEROUS THAN THE  
2 DILATION FROM AN INDUCTION?

3 A. NO.

4 Q. IN FACT, AT YOUR DEPOSITION YOU TESTIFIED THAT YOUR OPINION  
5 ABOUT TRAUMA TO THE CERVIX IS BASED ON YOUR INTUITION, YOUR  
6 UNDERSTANDING OF INDUCTION PROCEDURES, AND YOUR UNDERSTANDING  
7 OF MATERNAL PHYSIOLOGY; IS THAT CORRECT?

8 A. I DON'T RECALL USING THE WORD "INTUITION," BUT IF YOU TELL  
9 ME IT IS IN THERE --

10 Q. WE CAN TAKE A LOOK.

11 IT IS PAGE 199, LINE 25.

12 199, LINE 25, THE QUESTION WAS:

13 "AND SO YOUR OPINION ON THAT," AND "THAT" BEING  
14 ABOUT THE DILATION IN COMPARISON TO AN  
15 INDUCTION VERSUS INTACT AN D&E, "YOUR OPINION  
16 ON THAT IS INTUITIVE BASED ON YOUR  
17 UNDERSTANDING OF INDUCTION PROCEDURES AND YOUR  
18 UNDERSTANDING OF THE D&X PROCEDURE?

19 AND YOUR ANSWER WAS:

20 "YES, AND MY UNDERSTANDING OF MATERNAL PHYSIOLOGY."

21 SO, IS IT CORRECT THAT YOUR OPINION ABOUT TRAUMA TO  
22 THE CERVIX IN AN INDUCTION VERSUS AN INTACT D&E IS BASED ON  
23 INTUITION, YOUR UNDERSTANDING OF INDUCTION PROCEDURES, AND YOUR  
24 UNDERSTANDING OF MATERNAL PHYSIOLOGY?

25 A. YES.

1 Q. AND ARE THOSE THINGS, INTUITION, YOUR UNDERSTANDING OF THE  
2 PROCEDURES, AND YOUR UNDERSTANDING OF MATERNAL PHYSIOLOGY, ARE  
3 THOSE THINGS SUFFICIENT BASES UPON WHICH YOU CAN OFFER YOUR  
4 OPINIONS?

5 A. JUST AS MUCH AS ABORTION PROVIDERS CAN, YES.

6 Q. IF A WOMAN DOES NOT DESIRE TO HAVE ANOTHER CHILD ARE EITHER  
7 CERVICAL INCOMPETENCE OR PRE-TERM BIRTH CONCERNS FOR HER?

8 A. YES.

9 Q. WHY IS THAT?

10 A. BECAUSE WOMEN CHANGE THEIR MINDS.

11 Q. IF THE WOMAN DOES NOT CHANGE HER MIND AND SHE KNOWS SHE  
12 DOESN'T WANT TO HAVE ANOTHER CHILD, ARE THEY CONCERNS?

13 A. IF SHE DOESN'T CHANGE HER MIND IT WOULDN'T BE, BUT WE KNOW  
14 HOW MANY TIMES THAT CAN HAPPEN.

15 Q. LET'S JUST ASK ABOUT -- IF A WOMAN DOES NOT HAVE ANOTHER  
16 CHILD, ARE CERVICAL INCOMPETENCE OR PRE-TERM BIRTH CONCERNS FOR  
17 HER?

18 A. NO.

19 Q. YOU TESTIFIED THAT ONE OF THE BASES FOR YOUR BELIEF THAT  
20 INDUCTION IS SUPERIOR IS THAT AFTER 20 WEEKS OF PREGNANCY  
21 THAT'S WHAT IS PERFORMED AT THE UNIVERSITY OF MICHIGAN; IS THAT  
22 CORRECT?

23 A. THAT'S ONE OF THE BASES, YES.

24 Q. AND YOUR OPINION IS BASED SOLELY ON A CONVERSATION YOU HAD  
25 WITH THE CHAIR OF MATERNAL FETAL MEDICINE; IS THAT RIGHT?

1 A. NO.

2 Q. WHO ELSE DID YOU SPEAK WITH?

3 A. NO ONE.

4 Q. SO, IT IS BASED ON YOUR PRACTICE AS WELL AS THAT  
5 CONVERSATION?

6 A. AND GOING TO THE M & M CONFERENCES EVERY WEEK, YES.

7 Q. YOU DIDN'T SPEAK WITH DR. JOHNSON, THE CHAIR OF YOUR  
8 DEPARTMENT, ABOUT THE ABORTION PRACTICES AT THE UNIVERSITY OF  
9 MICHIGAN IN ORDER TO PREPARE YOUR EXPERT REPORT OR OFFER THAT  
10 OPINION, DID YOU?

11 A. THAT IS CORRECT.

12 Q. NOR DID YOU ASK ANY OF THE OTHER DOCTORS AT THE UNIVERSITY  
13 OF MICHIGAN WHO PERFORM ABORTIONS WHAT GESTATIONAL AGE THEY  
14 PERFORM ABORTIONS TO, DID YOU?

15 A. THAT IS CORRECT.

16 Q. OR ANY OTHER DOCTOR AT THE UNIVERSITY AT ALL, OTHER THAN  
17 THE CHAIR OF MATERNAL FETAL MEDICINE; IS THAT CORRECT?

18 A. THAT IS CORRECT.

19 Q. AND IF I TOLD YOU THAT DR. JOHNSON TESTIFIED IN THE NEW  
20 YORK TRIAL THAT D&E'S ARE DONE UP TO 22 WEEKS AT THE UNIVERSITY  
21 OF MICHIGAN, WOULD YOU HAVE ANY REASON TO BELIEVE THAT'S NOT  
22 TRUE?

23 MS. CLARK: OBJECTION, HEARSAY.

24 THE COURT: OVERRULED.

25 THE WITNESS: NO.

1 BY MS. KRASNOFF:

2 Q. SO IF I TOLD YOU THAT HE TESTIFIED TO THAT, YOU WOULD  
3 BELIEVE IT'S TRUE?

4 A. I WOULD BELIEVE IT MIGHT BE TRUE. HE LOOKED AT ALL THE  
5 RECORDS.

6 Q. SO WOULD HE HAVE A STRONGER BASIS UPON WHICH TO INCLUDE --  
7 TO CONCLUDE TO WHAT GESTATIONAL AGE ABORTIONS ARE BEING  
8 PERFORMED AT THE UNIVERSITY OF MICHIGAN BY D&E?

9 A. YES.

10 Q. AND IF ONE OF YOUR OWN PATIENTS IS SEEKING AN ABORTION  
11 AFTER 20 WEEKS, DO YOU TELL THEM THAT D&E AND INDUCTION ARE  
12 BOTH OPTIONS AT THE UNIVERSITY OF MICHIGAN?

13 A. YES.

14 Q. IN YOUR DIRECT TESTIMONY WE TALKED ABOUT THE PICKER REPORT.

15 I BELIEVE THAT YOU RELY ON THAT REPORT FOR YOUR  
16 BELIEF THAT WOMEN DO NOT FOLLOW UP WITH THEIR ABORTION  
17 PROVIDERS; IS THAT CORRECT?

18 A. THAT IS PART OF THE BASIS OF MY OPINION, YES.

19 Q. AND JUST LOOKING AT THAT REPORT, THAT DOESN'T LOOK AT  
20 WHETHER THEY FOLLOWED UP WITH ANY HEALTH CARE PROVIDER; RATHER  
21 IT ONLY LOOKS IF THEY FOLLOWED UP IN THE CLINIC IN WHICH THEY  
22 HAD THE ABORTION; IS THAT CORRECT?

23 A. YES, THAT'S WHAT IT SAYS.

24 Q. AND IT ONLY IS A SURVEY OF CLINICS, IT DOESN'T INCLUDE  
25 HOSPITAL-BASED PRACTICES; IS THAT CORRECT?

1 A. I BELIEVE THAT IS CORRECT.

2 Q. IF I CAN ASK YOU TO FIND THE REPORT UP THERE.

3 A. I HAVE IT.

4 Q. IF I CAN ASK YOU TO LOOK AT PAGE 31 OF THE REPORT  
5 UNDERNEATH THE CHART.

6 IS IT CORRECT THAT THE REPORT ALSO CONCLUDED THAT  
7 86 PERCENT OF WOMEN REPORTED THAT A STAFF MEMBER OFFERED TO  
8 MAKE THEM AN APPOINTMENT FOR A FOLLOW-UP VISIT?

9 A. WHICH FIGURE ARE YOU REFERRING TO, PLEASE?

10 Q. RIGHT UNDER THE CHART ON PAGE 31.

11 "MOST, 86 PERCENT OF PATIENTS REPORT THAT A STAFF  
12 MEMBER OFFERED TO MAKE THEM AN APPOINTMENT FOR A FOLLOW-UP  
13 VISIT"; IS THAT CORRECT?

14 A. I MUST BE ON THE WRONG PAGE. I'M SORRY, WHAT PAGE DID YOU  
15 ASK FOR?

16 MS. CLARK: I DON'T --

17 THE WITNESS: CAN I JUST LOOK AT YOURS?

18 MS. KRASNOFF: SURE. I HAVE A COPY. AM I ON THE  
19 WRONG PAGE FOR YOU, TOO, YOUR HONOR?

20 THE COURT: I CAN'T FIND THE EXHIBIT.

21 MS. KRASNOFF: LET'S START WITH THAT.

22 MS. CLARK: THE EXHIBIT IS LTA-42.

23 THE COURT: THIS ISN'T THE SAME ONE, AT LEAST THE  
24 COVER SHEET IS NOT THE SAME ONE.

25 MS. CLARK: LET ME HAVE ANOTHER LOOK.

1 MS. KRASNOFF: I GAVE HER THE NEW ONE.

2 MS. PARKER INFORMS ME IT IS ON PAGE 33 OF THE  
3 VERSION IN THE BINDERS AND ON PAGE 31.

4 THE COURT: IT'S THE FIRST COUPLE OF SHEETS, THE  
5 COVERS -- YOU CAN GIVE THIS BACK -- THAT ARE DIFFERENT. IT IS  
6 OTHERWISE THE SAME.

7 BY MS. KRASNOFF:

8 Q. DR. SHADIGIAN, I'M SORRY ABOUT THIS CONFUSION. IT IS THE  
9 TEXT IMMEDIATELY UNDER FIGURE 22 IT APPEARS IN BOTH VERSIONS OF  
10 THE DOCUMENT.

11 DO YOU SEE THAT IT BEGINS WITH "MOST"?

12 A. YES.

13 Q. AND THIS DOCUMENT CONCLUDED THAT MOST, OR 86 PERCENT, OF  
14 PATIENTS REPORT THAT A STAFF MEMBER OFFERED TO MAKE THEM AN  
15 APPOINTMENT FOR A FOLLOW-UP VISIT; IS THAT CORRECT?

16 A. YES.

17 Q. AND GOING ON TO THE NEXT SENTENCE, IT ALSO CONCLUDED THAT  
18 NEARLY ALL, OR 97 PERCENT, OF WOMEN SAY THEY WERE TOLD WHO TO  
19 CALL IF THEY NEED MORE HELP OR HAD QUESTIONS AFTER THEY LEFT  
20 THE CLINIC; IS THAT CORRECT?

21 A. THAT'S WHAT THAT SENTENCE SAYS. YES.

22 Q. THAT IS WHAT THIS REPORT CONCLUDED; IS THAT CORRECT?

23 A. YES.

24 Q. NOW, I NEED YOU TO LOOK AT ANOTHER PORTION WHICH, OF  
25 COURSE, MIGHT CAUSE SOME PROBLEM HERE.

1 PAGE 13 OF THE REPORT, WHERE IT STARTS, "FINDINGS."  
2 IS THAT AT THE BEGINNING OF YOUR COPY AS WELL?

3 THE COURT: DO YOU HAVE THAT?

4 MS. KRASNOFF: PAGE 12 --

5 THE WITNESS: COULD I ASK WHICH COPY WE ARE USING?

6 MS. KRASNOFF: I KNOW WHAT PAGE IT IS ON BOTH. SHOW  
7 ME WHICH ONE YOU ARE LOOKING AT.

8 THE WITNESS: I HAVE YOUR COPY.

9 BY MS. KRASNOFF:

10 Q. IT'S ON PAGE 13 AT THE TOP OF THE PAGE "FINDINGS," IN CASE  
11 THE COURT HAS THE OTHER ONE. IT'S PAGE 12 IT'S THE HEADING  
12 "FINDINGS."

13 THE COURT: I HAVE IT.

14 BY MS. KRASNOFF:

15 Q. DR. SHADIGIAN, IF YOU CAN READ THE FIRST TWO PARAGRAPHS  
16 UNDER "FINDINGS" FOR ME.

17 A. (READING)

18 "OVERALL SATISFACTION WITH ABORTION CARE.  
19 ABORTION PATIENTS REPORT HIGH LEVELS OF  
20 SATISFACTION WITH THEIR CARE: 60 PERCENT OF  
21 WOMEN SAY THEIR CARE WAS EXCELLENT AND ANOTHER  
22 THIRD (38 PERCENT) SAY IT WAS VERY GOOD OR  
23 GOOD. TWO PERCENT OF WOMEN SAY THAT THEIR CARE  
24 WAS FAIR AND LESS THAN 1 PERCENT SAY IT WAS  
25 POOR. PATIENT'S OVERALL RATING OF THEIR CARE



1 DID NOT DIFFER BY A WOMAN'S AGE, RACE,  
2 INSURANCE STATUS OR LENGTH OF PREGNANCY."

3 Q. COULD YOU READ THE NEXT PARAGRAPH AS WELL?

4 A. YES.

5 "NEARLY ALL PATIENTS, 97 PERCENT, FEEL THE  
6 INFORMATION THEY RECEIVED THAT DAY WAS  
7 EXCELLENT, VERY GOOD OR GOOD. MOST  
8 (94 PERCENT) THOUGHT THE STAFF'S OVERALL  
9 ATTENTION TO THEIR PRIVACY WAS SIMILARLY  
10 EXCELLENT, VERY GOOD OR GOOD. ALL PATIENTS  
11 THOUGHT THE CLINIC WAS CLEAN, 100 PERCENT,  
12 INCLUDING EIGHT IN 10 WHO THOUGHT IT WAS VERY  
13 CLEAN 79 PERCENT."

14 Q. THANK YOU.

15 DR. SHADIGIAN, YOU, YOURSELF, WILL ONLY PERFORM AN  
16 ABORTION IF THE WOMAN IS SO SICK THAT THE ONLY WAY SHE IS GOING  
17 TO SURVIVE IS TO HAVE THE PREGNANCY ENDED; IS THAT CORRECT?

18 A. IF YOU MEAN ABORTION ON A LIVE INFANT, YES.

19 Q. YES, I DO MEAN ON A LIVE FETUS.

20 IS THAT CORRECT?

21 A. YES.

22 Q. AND YOU WOULD AGREE, WOULD YOU NOT, THAT ANY PHYSICIAN  
23 CAN'T KNOW 100 PERCENT IF SOMEONE IS GOING TO DIE OR NOT WHEN  
24 FACED WITH A VERY SICK PREGNANT WOMAN; IS THAT CORRECT?

25 A. THAT'S CORRECT.

1 Q. YOU WOULD AGREE THAT THE DECISION OF WHETHER THERE IS A  
2 THREAT TO THE WOMAN'S LIFE MUST BE LEFT TO THE PHYSICIAN'S BEST  
3 MEDICAL JUDGMENT; IS THAT CORRECT?

4 A. YES.

5 Q. YOU AGREE, DON'T YOU, THAT THE SAFEST AND MOST APPROPRIATE  
6 ABORTION PROCEDURE FOR A PARTICULAR WOMAN DEPENDS IN PART ON  
7 THE GESTATIONAL AGE OF THE FETUS AT THE TIME OF THE ABORTION;  
8 IS THAT CORRECT?

9 A. YES.

10 Q. AND YOU AGREE, DON'T YOU, THAT THE SAFEST AND MOST  
11 APPROPRIATE ABORTION PROCEDURE FOR A PARTICULAR WOMAN DEPENDS  
12 IN PART ON THAT WOMAN'S HEALTH AT THE TIME OF THE ABORTION?

13 A. YES.

14 Q. AND YOU AGREE THAT THE SAFEST AND MOST APPROPRIATE ABORTION  
15 PROCEDURE FOR A PARTICULAR WOMAN DEPENDS IN PART ON ANY MEDICAL  
16 CONTRAINDICATIONS SHE MIGHT HAVE TO A PARTICULAR PROCEDURE OR  
17 PART OF A PROCEDURE?

18 A. YES.

19 Q. AND YOU AGREE THAT THE SAFEST AND MOST APPROPRIATE ABORTION  
20 PROCEDURE FOR A PARTICULAR WOMAN DEPENDS IN PART ON HER PRIOR  
21 HISTORY OF GYNECOLOGIC SURGERY?

22 A. YES.

23 Q. AND YOU AGREE THAT THE SAFEST AND MOST APPROPRIATE ABORTION  
24 PROCEDURE FOR A PARTICULAR WOMAN DEPENDS IN PART ON THE  
25 TRAINING, SKILL, AND EXPERIENCE OF THE PHYSICIAN PERFORMING THE

- 1 ABORTION?
- 2 A. YES.
- 3 Q. AND YOU AGREE, DON'T YOU, THAT EVEN IF TWO ABORTION  
4 PROCEDURES ARE SIMILAR IN TERMS OF STATISTICAL RISKS, WHICH  
5 PROCEDURE WILL, IN FACT, BE SAFER FOR ANY PARTICULAR WOMAN  
6 DEPENDS ON HER INDIVIDUAL CIRCUMSTANCES?
- 7 A. YES.
- 8 Q. DR. SHADIGIAN, THIS IS NOT THE FIRST TIME YOU'VE TESTIFIED  
9 IN SUPPORT OF A LAW THAT REGULATES ABORTION, IS IT?
- 10 A. NO.
- 11 Q. IN FACT, YOU HAVE OFFERED SWORN TESTIMONY OF SOME SORT AND  
12 SUPPORT OF A VARIETY OF STATE LAWS THAT RELATE TO ABORTION,  
13 HAVEN'T YOU?
- 14 A. I HAVE TESTIFIED ONE TIME IN ALASKA.
- 15 Q. YOU'VE OFFERED DECLARATIONS AS WELL?
- 16 A. EXPERT REPORTS, YES.
- 17 Q. AND THOSE ARE SWORN STATEMENTS?
- 18 A. YES.
- 19 Q. AND YOU HAVE GIVEN DEPOSITION TESTIMONY AS WELL?
- 20 A. YES.
- 21 Q. AND THAT WAS UNDER OATH?
- 22 A. YES.
- 23 Q. AND SO YOU HAVE OFFERED SWORN TESTIMONY IN SUPPORT OF AN  
24 ALASKA LAW REQUIRING A MINOR TO OBTAIN PARENTAL CONSENT BEFORE  
25 AN ABORTION; IS THAT CORRECT?

1 A. YES.

2 Q. YOU'VE OFFERED SWORN TESTIMONY IN SUPPORT OF LAWS THAT  
3 REQUIRE MANDATORY DELAY BEFORE A WOMAN CAN HAVE AN ABORTION IN  
4 INDIANA, ALABAMA, AND OHIO; IS THAT CORRECT?

5 A. YES.

6 Q. AND YOU TESTIFIED IN FAVOR OF A FLORIDA LAW THAT REQUIRED A  
7 WOMAN TO RECEIVE CERTAIN STATE-MANDATED INFORMATION BEFORE SHE  
8 COULD HAVE AN ABORTION; IS THAT CORRECT?

9 A. YES.

10 Q. AND YOU'VE UNIFORMLY OFFERED YOUR OPINION IN SUPPORT OF  
11 THOSE LAWS?

12 A. IN THOSE PARTICULAR CIRCUMSTANCES, I DID. YES.

13 Q. IN ADDITION TO THE CASES WE JUST DISCUSSED, YOU'VE ALSO  
14 OFFERED YOUR OPINION IN A CASE BROUGHT AGAINST PLANNED  
15 PARENTHOOD FEDERATION OF AMERICA, WHO IS A PLAINTIFF IN THIS  
16 CASE, TRYING TO FORCE PLANNED PARENTHOOD TO INFORM WOMEN  
17 SEEKING ABORTIONS THAT ABORTION INCREASES THE RISK OF BREAST  
18 CANCER; IS THAT CORRECT?

19 A. YES.

20 Q. ARE YOU AWARE THAT BOTH THE TRIAL COURT AND THE COURT OF  
21 APPEALS DISMISSED THAT CASE?

22 A. IF YOU TELL ME THEY DID, I AM SURE THEY DID.

23 Q. IN FACT, YOU YOURSELF BELIEVE THAT HAVING AN INDUCED  
24 ABORTION INCREASES A WOMAN'S RISK OF DEVELOPING BREAST CANCER,  
25 DON'T YOU?

1 A. YES.

2 Q. ARE YOU AWARE THAT IN FEBRUARY OF 2003, THE NATIONAL CANCER  
3 INSTITUTE CONVENED A WORKSHOP OF WHAT THEY DEEMED TO BE MORE  
4 THAN 100 OF THEIR WORLD'S LEADING EXPERTS WHO STUDIED PREGNANCY  
5 AND BREAST CANCER RISKS TO LOOK AT THAT ISSUE?

6 A. YES.

7 Q. AND ARE YOU AWARE THAT THAT GROUP FOUND THAT INDUCED  
8 ABORTION IS NOT ASSOCIATED WITH AN INCREASE IN BREAST CANCER  
9 RISK?

10 A. NO.

11 Q. THEY DID FIND THAT?

12 A. THEY HAD TWO FINDINGS. ONE IS THAT THEY DIDN'T BELIEVE IN  
13 AN INDEPENDENT EFFECT, BUT THEY DID AGREE THAT THERE WAS A  
14 PROTECTIVE EFFECT THAT IS LOST WHEN A WOMAN HAS AN INDUCED  
15 ABORTION AS COMPARED TO GOING TO TERM.

16 Q. SO THEY DID NOT CONCLUDE THAT HAVING AN ABORTION DOES NOT  
17 INCREASE A WOMEN'S SUBSEQUENT RISK OF DEVELOPING BREAST CANCER?

18 A. IT'S JUST AS I JUST STATED IT.

19 MS. KRASNOFF: I AM SORRY, I DON'T HAVE ANY OTHER  
20 COPIES OF THIS.

21 IF I MAY APPROACH THE WITNESS AND REFRESH HER  
22 RECOLLECTION?

23 THE COURT: WHAT IS IT? FIRST OF ALL, LET DEFENSE  
24 COUNSEL SEE IT.

25 MS. CLARK: THAT'S FINE TO REFRESH HER RECOLLECTION.

1           YOUR HONOR, I AM GOING TO MAKE AN OBJECTION. I  
2 THINK THIS IS WELL BEYOND THE SCOPE GETTING INTO THE BREAST  
3 CANCER. I DON'T THINK THAT -- BREAST CANCER WASN'T TALKED  
4 ABOUT IN HER EXPERT REPORT, AND I DON'T BELIEVE IT CAME UP IN  
5 HER DEPOSITION.

6           THE COURT: IT CAME UP IN HER TESTIMONY. SHE IS THE  
7 ONE THAT LISTED IT AS ONE OF THE SEVEN FACTORS. THIS IS  
8 CERTAINLY FAIR CROSS-EXAMINATION.

9           YOU MAY SHOW HER THE DOCUMENT. WHETHER OR NOT IT IS  
10 ADMISSIBLE IS ANOTHER QUESTION, BUT YOU CAN CERTAINLY LOOK AT  
11 IT.

12 BY MS. KRASNOFF:

13 Q. IF I COULD ASK YOU TO LOOK -- THIS IS A "SUMMARY REPORT,  
14 EARLY REPRODUCTIVE EVENTS AND BREAST CANCER" WORKSHOP FROM THE  
15 NATIONAL CANCER INSTITUTE'S WEBSITE.

16 IF I CAN ASK YOU TO LOOK AT THE SIXTH BULLET. COULD  
17 YOU READ THAT FOR US?

18 THE COURT: READ IT TO YOURSELF AND THEN SHE'LL ASK  
19 YOU ANOTHER QUESTION.

20 THE WITNESS: AM I ALLOWED TO READ THE ENTIRE THING?

21 THE COURT: NO, NOT FOR THIS PURPOSE. IT'S ONLY  
22 BEING USED TO REFRESH YOUR RECOLLECTION WITH RESPECT TO THE  
23 QUESTION SHE ASKED YOU.

24 READ THE BULLET POINT. IF IT DOESN'T REFRESH YOUR  
25 RECOLLECTION, YOU CAN TELL US.

1 THE WITNESS: OKAY. YOU ARE ASKING FOR THE SIXTH  
2 BULLET POINT?  
3 BY MS. KRASNOFF:  
4 Q. YES.  
5 A. YES, I DID READ IT NOW.  
6 Q. AND WAS ONE OF THE CONCLUSIONS OF THAT WORKSHOP THAT  
7 INDUCED ABORTION IS NOT ASSOCIATED WITH AN INCREASE IN BREAST  
8 CANCER RISK?  
9 A. THAT'S WHAT THAT SENTENCE SAYS.  
10 Q. AND YOU BELIEVE THAT IS NOT AN OPINION EXPRESSED BY THE  
11 WORKSHOP FROM THE NATIONAL BREAST CANCER INSTITUTE?  
12 A. I DIDN'T SAY THAT.  
13 Q. SO, IT IS ONE OF THEIR OPINIONS?  
14 A. YES. IT IS NOT THEIR ONLY OPINION. AS YOU CAN SEE, THERE  
15 ARE 10 OPINIONS.  
16 Q. THAT IS ONE OF THEM; IS THAT CORRECT?  
17 A. YES.  
18 Q. ARE YOU ALSO AWARE THAT IN JUST THE PAST FEW WEEKS AN  
19 ARTICLE HAS BEEN PUBLISHED IN THE LANCET ABOUT THIS ISSUE,  
20 ABORTION AND BREAST CANCER?  
21 A. YES.  
22 Q. AND THAT ARTICLE IS ENTITLED "BREAST CANCER AND ABORTION  
23 COLLABORATIVE REANALYSIS OF DATA FROM 53 EPIDEMIOLOGIC STUDIES  
24 INCLUDING 83,000 WOMEN WITH BREAST CANCER FROM 16 COUNTRIES";  
25 IS THAT CORRECT?

1 A. I BELIEVE THAT'S THE TITLE.

2 Q. AND THAT ARTICLE SPECIFICALLY CONSIDERED THE REVIEW ARTICLE  
3 THAT YOU TALKED ABOUT TODAY, DID IT NOT?

4 A. I DON'T KNOW.

5 Q. HAVE YOU READ THE NEW ARTICLE?

6 A. I HAVE SKIMMED IT THROUGH.

7 Q. YOU DIDN'T NOTICE THAT FOOTNOTE 82 WAS YOUR ARTICLE?

8 A. I DIDN'T NOTICE THAT.

9 Q. DID YOU NOTICE THE LANCET REACHES THE OPPOSITE CONCLUSION  
10 OF YOUR ARTICLE; THAT IS, THAT PREGNANCIES THAT END AS AN  
11 INDUCED ABORTION DO NOT INCREASE A WOMAN'S RISK OF BREAST  
12 CANCER; IS THAT CORRECT?

13 A. I AM SORRY, COULD YOU READ IT AGAIN?

14 Q. DOES THE -- ARE YOU AWARE THAT THE LANCET ARTICLE REACHES  
15 THE OPPOSITE CONCLUSION OF YOUR REVIEW ARTICLE; THAT IS, THE  
16 CONCLUSION THAT PREGNANCIES THAT END AS AN INDUCED ABORTION DO  
17 NOT INCREASE THE RISK OF A WOMAN HAVING BREAST CANCER?

18 A. NO.

19 Q. THEY DO REACH THAT CONCLUSION?

20 A. I THINK THE ISSUE IS WE HAVE TWO CONCLUSIONS IN OUR PAPER,  
21 AND ONE IS ABOUT THE INDEPENDENT EFFECT OF ABORTION ON BREAST  
22 CANCER AND THE OTHER IS THE DELAY IN THE FIRST FULL-TERM BIRTH.  
23 SO THERE IS NOT JUST ONE CONCLUSION WE REACH.

24 WE HAVE A TABLE IN OUR STUDY, IF YOU WOULD LIKE ME  
25 TO GO OVER IT.



1 Q. I WOULD LIKE YOU TO LOOK AT THE LANCET ARTICLE THAT CAME  
2 OUT IN THE LAST FEW WEEKS.

3 THE COURT: DO YOU HAVE COPIES?

4 MS. KRASNOFF: I DO.

5 THE WITNESS: YOUR HONOR, I HAVEN'T HAD A CHANCE TO  
6 REVIEW THE ENTIRE ARTICLE.

7 THE COURT: I UNDERSTAND THAT AND I AM NOT GOING TO  
8 ALLOW HER TO ASK YOU ABOUT THE ENTIRE ARTICLE EITHER.

9 MS. KRASNOFF: MAY I APPROACH?

10 THE COURT: YES.

11 FOR WHAT PURPOSE ARE YOU GIVING HER THIS DOCUMENT?  
12 WHAT IS THE PURPOSE OF YOUR --

13 MS. MORRIS: SHE SAYS SHE BELIEVES IT DID NOT  
14 CONCLUDE THAT INDUCED ABORTION CAUSED AN INCREASE RISK OF  
15 BREAST CANCER. AND I WANT TO REFRESH HER RECOLLECTION OF  
16 WHETHER OR NOT IT DID DO THAT.

17 THE COURT: HAVE YOU SEEN THIS ARTICLE BEFORE?

18 THE WITNESS: I HAVE SEEN THE ARTICLE, BUT I HAVEN'T  
19 READ AND ANALYZED IT LIKE I HAVE THE OTHER ARTICLES IN MY  
20 REPORT, FOR EXAMPLE.

21 THE COURT: WE WILL SEE HOW MUCH DETAIL IS REQUESTED  
22 HERE.

23 BY MS. KRASNOFF:

24 Q. IF YOU WOULD TURN TO THE VERY LAST SENTENCE OF THE ARTICLE  
25 WHICH APPEARS ON PAGE 1,014.

1           WOULD YOU AGREE THE AUTHORS OF THIS CONCLUDE:  
2           "HENCE, THE TOTALITY OF THE WORLDWIDE  
3           EPIDEMIOLOGICAL EVIDENCE INDICATES THAT  
4           PREGNANCIES ENDING AS EITHER SPONTANEOUS OR  
5           INDUCED ABORTIONS DO NOT HAVE ADVERSE EFFECTS  
6           ON WOMEN SUBSEQUENT RISK OF DEVELOPING BREAST  
7           CANCER."

8   A.   THAT'S THE SENTENCE YOU JUST READ.  IT WAS THE LAST  
9   SENTENCE.

10  Q.   DO YOU AGREE THAT IS WHAT THIS STUDY CONCLUDED?

11  A.   THAT IS THEIR LAST SENTENCE, SO I AM GOING TO ASSUME THAT.

12           MS. KRASNOFF:  I HAVE NOTHING FURTHER, YOUR HONOR.

13           THE COURT:  REDIRECT?

14           MS. CLARK:  JUST A FEW QUESTIONS.  JUST A MOMENT.

15                           REDIRECT EXAMINATION

16  BY MS. CLARK:

17  Q.   DR. SHADIGIAN, JUST A FEW QUESTIONS.

18           ON CROSS-EXAMINATION YOU TESTIFIED ABOUT, IN THE D&X  
19  THERE BEING FEWER FETAL BONE PIECES AND FEWER INSTRUMENT  
20  PASSES.  IS THIS A SOUND BASIS ON WHICH TO CONCLUDE THAT THE  
21  D&X PROCEDURE OF ABORTION IS A SAFE ABORTION PROCEDURE?

22  A.   NO.

23  Q.   AND WHY NOT?

24  A.   BECAUSE THERE MAY BE OTHER MITIGATING FACTORS LIKE THE  
25  ADVANCE DILATION OF THE CERVIX THAT IS NECESSARY TO PERFORM THE

1 D&X PROCEDURE AS WELL AS THE TRAUMA OF PULLING THE HEAD THROUGH  
2 EVEN ALMOST INTACT, THROUGH THE CERVIX DILATING IT MORE.

3 SO THAT IS JUST AN ASSERTION AND IS NOT BASED IN ANY  
4 KIND OF STUDY.

5 Q. WHEN A WOMAN IS HAVING AN INDUCTION TERMINATION OF  
6 PREGNANCY AND SHE'S PREVIABLE, IF SHE'S AT THE HOSPITAL, ARE  
7 THE DOCTORS AND NURSES, ARE THEY ABLE TO MONITOR HER DURING THE  
8 ENTIRE TIME OF THE PROCEDURE?

9 A. YES.

10 Q. IS THAT IMPORTANT TO YOU IN YOUR CONSIDERATION OF THE  
11 SAFETY OF INDUCTION VERSUS D&E AND D&X?

12 A. YES.

13 Q. NOW, I BELIEVE YOU TESTIFIED THAT THE LEVEL OF EITHER  
14 OXYTOCIN OR THE PROSTAGLANDINS THAT YOU WOULD ADMINISTER IN A  
15 PREVIABILITY INDUCTION METHOD OF PREGNANCY TERMINATION, THAT  
16 THEY WOULD VARY AS COMPARED TO A POSTVIABILITY INDUCTION  
17 PREGNANCY TERMINATION; IS THAT CORRECT?

18 A. YES, THEY MAY.

19 Q. AND BECAUSE YOU'RE DOING THE PREVIABILITY INDUCTION -- IN  
20 SITUATIONS WHERE YOU ARE DOING THE PREVIABILITY INDUCTION  
21 METHOD, YOU WOULD BE ABLE TO USE GREATER DOSES OF OXYTOCIN, FOR  
22 EXAMPLE; ISN'T THAT CORRECT?

23 A. YES.

24 Q. AND ONE OF THE REASONS IS BECAUSE YOU WOULDN'T BE CONCERNED  
25 ABOUT WHETHER OR NOT THE FETUS COULD SURVIVE AFTER THE

- 1 PROCEDURE BECAUSE THERE WOULDN'T BE ANY WAY THAT THE FETUS  
2 COULD SURVIVE IN ANY EVENT; ISN'T THAT CORRECT?
- 3 A. THAT IS CORRECT.
- 4 Q. AND, THEREFORE, YOU CAN INCREASE THE DOSES OF THE OXYTOCIN  
5 AND THE PROSTAGLANDINS?
- 6 A. YES, YOU AN.
- 7 Q. WOULD THAT INCREASE IN THE DOSE OF THE OXYTOCIN OR THE  
8 PROSTAGLANDINS INCREASE THE SPEED AT WHICH THE INDUCTION  
9 PROCEDURE CAN BE ACCOMPLISHED START TO FINISH?
- 10 A. IT MAY MAKE IT FASTER.
- 11 Q. NOW, DR. JOHNSON HAS YOU ON HIS STAFF, DOESN'T HE?
- 12 A. YES.
- 13 Q. HE TRUSTS YOU TO CARE FOR THE PATIENTS AT THE UNIVERSITY OF  
14 MICHIGAN, DOESN'T HE?
- 15 A. YES, HE DOES.
- 16 Q. AND, DOCTOR, YOU WOULD AGREE THAT THERE IS A LOT OF  
17 CONTROVERSY IN THE MEDICAL LITERATURE ABOUT WHETHER OR NOT  
18 BREAST CANCER HAS ANY RELATION -- OR WHETHER ABORTION HAS ANY  
19 RELATION TO BREAST CANCER, WOULDN'T YOU?
- 20 A. I WOULD SAY THAT THERE ARE TWO DIFFERENT ISSUES AT HAND.  
21 ONE IS CONTROVERSIAL AND ONE IS ABSOLUTELY NOT CONTROVERSIAL.
- 22 MS. CLARK: THANK YOU. I WILL LEAVE IT AT THAT.
- 23 NO FURTHER QUESTIONS.
- 24 THE COURT: ANYTHING ELSE FROM PLAINTIFF?
- 25 MS. KRASNOFF: NO.

1 THE COURT: ALL RIGHT.

2 DR. SHADIGIAN, YOU'RE EXCUSED.

3 THE WITNESS: THANK YOU VERY MUCH, YOUR HONOR.

4 THE COURT: ALL RIGHT.

5 NOW, ARE -- YOU MAY STEP DOWN AND JUST LEAVE

6 EVERYTHING UP THERE.

7 ARE THERE ANY OTHER WITNESSES THAT WE ARE GOING TO

8 HEAR FROM TODAY?

9 MR. SIMPSON: TODAY, YOUR HONOR, NO.

10 THE COURT: SO DR. COOK WILL APPEAR TOMORROW

11 MORNING?

12 MR. SIMPSON: YES.

13 THE COURT: AND ON THURSDAY DR. ANAND?

14 MR. SIMPSON: YES.

15 THE COURT: AND DR. CHASEN ON FRIDAY IN THE MORNING

16 AND CLOSING ARGUMENTS.

17 ALL RIGHT. IS THERE ANYTHING ELSE THAT YOU ALL WISH

18 TO DISCUSS?

19 ONE THING I WOULD LIKE TO REVISIT, AND THAT IS THE

20 QUESTION OF THE STUDIES. I AM LOOKING AHEAD TO HOW I AM GOING

21 TO GO ABOUT PREPARING THE FINDINGS IN THIS CASE. WE HAVE A

22 MASSIVE AMOUNT OF INFORMATION, AND I WOULD FRANKLY PREFER TO

23 HAVE THESE STUDIES IN EVIDENCE.

24 PLAINTIFFS HAVE WITHDRAWN THEIR REQUEST, AND I'D

25 SIMPLY LIKE TO REVISIT THAT. WE WILL TALK ABOUT THE SPRANG

1 ARTICLE SEPARATELY.

2 IS THERE SOME PARTICULAR REASON WHY THE COURT COULD  
3 NOT -- SHOULD NOT ADMIT THESE?

4 MS. PARKER: LET ME ADDRESS THE TWO DREY ARTICLES.  
5 I LOOKED OVER THE TESTIMONY OF DR. DREY LAST WEEK AND IT SEEMED  
6 THAT HER TESTIMONY WAS QUITE LENGTHY ABOUT THE ARTICLES AND THE  
7 ARTICLES THEMSELVES REALLY DIDN'T ADD THAT MUCH ADDITIONAL  
8 EVIDENCE.

9 BUT IF YOUR HONOR WANTS TO ADMIT THOSE TWO INTO  
10 EVIDENCE, WE HAVE NO OBJECTION TO THAT.

11 THE COURT: THE ISSUE FOR ME IS PRIMARILY THE DATA  
12 THAT IS INCLUDED IN THE TABLES. SHE DID GIVE LENGTHY  
13 TESTIMONY, BUT BOTH SIDES HAVE ASKED A NUMBER OF WITNESSES  
14 ABOUT THOSE TABLES, AND IT'S GOING TO BE A LITTLE LOGISTICALLY  
15 DIFFICULT FOR US TO HAVE TO KEEP GOING BACK TO TRANSCRIPTS TO  
16 FIND OUT WHERE THE TABLES ARE DESCRIBED.

17 IT'S CERTAINLY MUCH EASIER TO HAVE THE INFORMATION  
18 IN A FORM THAT IF WE NEED TO, WE CAN FIND IT AND CITE TO IT AS  
19 NECESSARY.

20 MS. PARKER: WE WOULD HAVE NO OBJECTION TO THEM  
21 COMING INTO EVIDENCE. OBVIOUSLY WE ORIGINALLY MOVED TO HAVE  
22 THOSE TWO COME IN.

23 THE COURT: THERE IS NO OTHER REASON BECAUSE I  
24 CERTAINLY DON'T WANT TO --

25 MS. PARKER: WE WERE WORRIED ABOUT THE

1 CONSISTENCY -- THE CONSISTENT APPROACH ACROSS THE BOARD WITH  
2 THE DIFFERENT ARTICLES AND STUDIES.

3 THE COURT: THAT'S A SEPARATE ISSUE.

4 SINCE -- SO, WILL PLAINTIFFS RE-MOVE THOSE INTO  
5 EVIDENCE?

6 MS. PARKER: YES. WE WILL RE-MOVE THE TWO DREY  
7 ARTICLES.

8 THE COURT: THE DEFENDANTS HAVE OBJECTED ON ALL THE  
9 VARIOUS DIFFERENT GROUNDS YOU'VE INCLUDED IN YOUR PAPERS, AND  
10 EVEN THOUGH I HAVE ALREADY TOLD YOU THAT I WOULD PREFER TO HAVE  
11 THE MATTERS IN EVIDENCE, I CERTAINLY NEED TO STATE FOR THE  
12 RECORD WHETHER OR NOT I FIND THE RESIDUAL EXCEPTION APPLIES IN  
13 THE CASE, AND I DO FIND THAT THE RESIDUAL EXCEPTION APPLIES.

14 I KNOW THAT YOU ALL HAVE RELIED UPON ONE OF THE  
15 THREE CITED CASES IN THIS AREA THAT WE WERE ABLE TO FIND.  
16 THERE ARE ONLY THREE. AND I DIDN'T FIND THE TURNER DECISION  
17 THAT YOU ALL HAD RELIED UPON TO BE TOTALLY DISPOSITIVE OF THE  
18 CASE BECAUSE THAT CASE INVOLVED MEDICAL -- THE FACTS WERE  
19 DIFFERENT. IT INVOLVED MEDICAL TEXT, IT WAS IN THE CONTEXT OF  
20 A CRIMINAL CASE AND THE PROBLEM WAS THAT THERE WASN'T AN EXPERT  
21 THROUGH WHICH TO GET IN THE INFORMATION UNDER THE LEARNED  
22 TREATISE EXCEPTION.

23 AND IN THIS CASE, IT SEEMS TO ME THE LEARNED  
24 TREATISE EXCEPTION GENERALLY APPLIES TO INFORMATION WRITTEN BY  
25 SOMEONE ELSE THAT A TESTIFYING EXPERT HAS RELIED UPON IN SOME

1 WAY IN FORMING HIS OR HER OPINION.

2 WHAT WE HAVE HERE IS VERY DIFFERENT. WE HAVE  
3 INFORMATION, SCIENTIFIC AND MEDICAL INFORMATION THAT WAS  
4 ESSENTIALLY DERIVED THROUGH THE EFFORT OF THE TESTIFYING  
5 WITNESS WHO IS THE AUTHOR OR CO-AUTHOR OF THE PARTICULAR STUDY.  
6 SO I DON'T FIND THAT THE COURT'S REASONING FOR -- AND THAT IS,  
7 TO PREVENT EXCEPTION TO THE LEARNED TREATISE EXCEPTION REALLY  
8 APPLIES TO THIS KIND OF SITUATION.

9 THE TWO CASES WE WERE ABLE TO FIND IN WHICH THE TWO  
10 DISTRICT COURTS DID PERMIT THE USE OF THE RESIDUAL EXCEPTION  
11 FOR MEDICAL INFORMATION WERE MORE AKIN TO THIS CASE IN WHICH  
12 THERE WAS SOME PARTICIPATION ON THE PART OF THE TESTIFYING  
13 WITNESS IN THE PREPARATION OF THE STUDIES, AND IN THE FACT THAT  
14 THE STUDIES WERE PEER REVIEWED AND PUBLISHED IN PEER REVIEW  
15 JOURNALS.

16 SO I THINK WHEN I CONSIDER THE REQUIREMENTS OF THE  
17 RESIDUAL EXCEPTION TRUSTWORTHINESS BEING THE HALLMARK OF THE  
18 EXCEPTION, I HAVE TO FIND THAT IRRESPECTIVE OF THE OBJECTIONS  
19 WITH REGARD TO THE METHODOLOGICAL LIMITATIONS THAT THE STUDIES  
20 ARE TRUSTWORTHY BECAUSE OF THE ACTUAL AND DIRECT PARTICIPATION  
21 AND OBSERVATIONS OF THE DOCTORS.

22 ADDITIONALLY, AT LEAST WE HAVEN'T HEARD FROM  
23 DR. CHASEN, BUT AT LEAST WITH REGARD TO THE DREY STUDY, SHE WAS  
24 HERE SUBJECT TO CROSS-EXAMINATION BOTH AT LENGTH IN HER  
25 DEPOSITION AND AT TRIAL, AND THE STUDIES WERE NOT CONDUCTED IN



1 CONNECTION WITH THIS PARTICULAR LITIGATION, SO THERE IS  
2 ABSOLUTELY NO REASON NOT TO FIND THAT THEY WERE INDEED  
3 TRUSTWORTHY.

4 ONCE AGAIN, I THINK THAT THE ARGUMENTS ON THE  
5 PROBATIVE VALUE OF THOSE REALLY GO TO THE WEIGHT TO BE ACCORDED  
6 AND NOT TO WHETHER OR NOT THEY HAVE SOME PROBATIVE VALUE AND  
7 ARE ADMISSIBLE UNDER THE SECTION.

8 NEITHER SIDE REALLY ADDRESSED THE QUESTION OF  
9 WHETHER OR NOT THE GENERAL APPLICATION OF THE HEARSAY RULE ARE  
10 ADDRESSED BY THE ADMISSION OF THESE PARTICULAR DOCUMENTS, BUT I  
11 DO FIND THAT THE PRIMARY RATIONALE FOR NOT ADMITTING THEM UNDER  
12 THIS EXCEPTION, WHICH HAS TO DO WITH WHETHER OR NOT A JURY  
13 MIGHT BE OVERLY IMPRESSED WITH INFORMATION CONTAINED IN MEDICAL  
14 TEXT OR LEARNED TREATISE, DOESN'T APPLY IN THIS SITUATION.

15 AND THE TWO OTHER, I THINK MOST SIGNIFICANT REASONS  
16 THAT I WISH TO HAVE THEM IS BECAUSE, AS I INDICATED, WE NEED TO  
17 HAVE AN EASY WAY TO HANDLE ALL THIS INFORMATION THAT YOU ALL  
18 HAVE GIVEN US, AND WE NEED THE TABLES.

19 SECONDLY, I HAVE ALREADY READ ALL OF THESE REPORTS.  
20 I HAD TO READ THEM IN ORDER TO RULE ON THIS PARTICULAR  
21 OBJECTION. IT IS NOT LIKE WHEN THE COURT REACHES AN ASSESSMENT  
22 AS TO WHETHER OR NOT THEY SHOULD BE PRESENTED TO A JURY, I HAVE  
23 ALREADY READ THEM. AND TO THAT EXTENT, I SEE NO BASIS  
24 WHATSOEVER TO NOT APPLY THE RESIDUAL EXCEPTION TO THE STUDIES.

25 AND I WOULD INCLUDE THE CHASEN STUDY, ASSUMING HE IS

1 ALSO SUBJECTED TO CROSS-EXAMINATION. I KNOW HE WAS AT HIS  
2 DEPOSITION BECAUSE I BELIEVE YOU ALL SUBMITTED A COPY OF HIS  
3 DEPOSITION BEFORE THE TRIAL COMMENCED THAT I LOOKED AT, AND  
4 ASSUMING HE IS SUBJECT TO CROSS-EXAMINATION ON THE STUDY, WHICH  
5 I WOULD ANTICIPATE HE WILL BE, I SEE NO REASON WHY IT SHOULDN'T  
6 GO TO HIS AS WELL.

7 NOW, I KNOW YOU ALL HAD CONCERNS ABOUT THE SPRANG  
8 ARTICLE, SO I AM GOING TO ADMIT THE STUDIES AS EVIDENCE.

9 MS. GARTNER: FOR POINT OF CLARIFICATION, ARE YOU  
10 ADMITTING THE CHASEN STUDY AS WELL OR JUST THE DREY STUDY?

11 THE COURT: YES. I LOOKED AT ALL OF THEM ON THE  
12 BASIS OF THE PAPERS YOU SUBMITTED AND THE ARGUMENTS YOU'VE MADE  
13 AND I CAME TO THE CONCLUSION THAT THOSE THREE SHOULD COME IN  
14 FOR THE SAME REASON.

15 ALL RIGHT. NOW --

16 MS. GARTNER: ACTUALLY, I AM SORRY, YOUR HONOR. I  
17 THINK THAT IF YOU DON'T MIND, LATER TODAY WE WOULD -- I THINK  
18 THERE WERE SOME STATEMENTS IN OUR REQUEST THAT WAS FILED LAST  
19 WEEK WITH RESPECT TO THE CHASEN STUDY THAT WE DON'T ACTUALLY  
20 THINK WERE FULLY ACCURATE AND WERE DONE BECAUSE WE WERE TRYING  
21 TO BRIEF THINGS AT THE SAME TIME THAT WE ARE PREPARING  
22 WITNESSES, SO WITH YOUR HONOR'S PERMISSION WE WOULD FILE AN  
23 ERRATA TO THAT LATER TODAY WITH THE UNDERSTANDING THAT THE  
24 MOTION HAS ALREADY BEEN GRANTED WITH RESPECT TO THE CHASEN  
25 STUDY?

1 THE COURT: MAYBE I SHOULDN'T GRANT THE MOTION UNTIL  
2 I SEE THE ERRATA. I DON'T KNOW HOW SIGNIFICANT IT'S GOING TO  
3 BE.

4 IS THIS SOMETHING YOU ALL HAVE TALKED ABOUT THIS.

5 MS. GARTNER: NO. I THINK IT'S REALLY JUST TO  
6 CLARIFY. I DON'T THINK IT IS A SUBSTANTIVE CHANGE IN WHAT WAS  
7 STATED, BUT I THINK THERE WERE JUST SOME STATEMENTS IN THE  
8 BRIEF THAT COULD BE TAKEN AS -- THEY WEREN'T INTENDED THIS WAY,  
9 THEY COULD BE TAKEN AS SUGGESTING THAT THE STUDY ITSELF WOULD  
10 BE MORE RELIABLE THAN DR. CHASEN'S TESTIMONY ABOUT IT, AND WE  
11 DON'T WANT IN ANY WAY TO SUGGEST THAT THAT'S THE CASE.

12 THE COURT: I AGREE THAT THE DOCTORS' TESTIMONY  
13 ABOUT THE STUDY, EITHER CHASEN, OR DREY, OR SPRANG, THEIR  
14 TESTIMONY IS REALLY WHAT IS MOST IMPORTANT HERE. THE STUDIES,  
15 AS THEY ARE WRITTEN, ASSIST THE COURT BECAUSE IT CAPTURES ALL  
16 OF THE UNDERLYING MATERIAL IN A VERY COHERENT FASHION FOR THE  
17 COURT.

18 MY FINDING IS BASED NOT UPON THE FACT THAT THE  
19 WRITTEN MATERIALS ARE SUPERIOR IN ANY WAY TO THE OPINIONS --

20 MS. GARTNER: OKAY.

21 THE COURT: -- OF THE DOCTORS.

22 MS. GARTNER: I THINK THAT'S CLEAR ENOUGH. WE  
23 WANTED TO BE CLEAR THAT IN NO WAY DO WE THINK THE STUDY  
24 REPLACES WHAT DR. CHASEN WILL TESTIFY TO.

25 THE COURT: NO. I CERTAINLY WOULDN'T COME TO THAT

1 CONCLUSION.

2 NOW, THE SPRANG ARTICLE IS A LITTLE DIFFERENT. I  
3 INDICATED EARLIER IT WAS MY INCLINATION TO NOT ALLOW IT IN AND  
4 THAT'S BECAUSE I DON'T FIND IT TRUSTWORTHY, AS TRUSTWORTHY  
5 BECAUSE IT IS BASED, WHEN I LOOK ON HIS BIBLIOGRAPHY, THERE ARE  
6 MORE NEWSPAPER ARTICLES AND WEEKLY PERIODICALS CITED THAN THERE  
7 ARE LEARNED MEDICAL TREATISES, ALTHOUGH THERE ARE SOME OF THOSE  
8 SO BECAUSE HE DIDN'T PARTICIPATE, HE DID THE RESEARCH, HE  
9 DIDN'T ACTUALLY PARTICIPATE IN THE UNDERLYING STUDIES, I DON'T  
10 FIND THAT HIS ARTICLE IS SO TRUSTWORTHY THAT IT SHOULD FIT  
11 UNDER THE RESIDUAL EXCEPTION.

12 BUT, AS I INDICATED, AND THERE IS ONLY ONE TABLE IN  
13 HIS, AND SO THE TABLE IN HIS PARTICULAR PIECE DEALS WITH THE  
14 DIFFERENT STATUS OF THE LAW ON INTACT ABORTION FROM STATE TO  
15 STATE WHICH IS NOT AN ISSUE ABOUT WHICH I AM AT ALL CONCERNED  
16 IN TERMS OF THE ISSUES THAT I HAVE TO DECIDE HERE.

17 BUT I DO -- THE ONE THING I DID NOTE WAS THAT IT  
18 DOES APPEAR THAT CONGRESS HAS CITED VERY LIBERALLY FROM THE  
19 DOCTOR'S ARTICLE IN ITS FINDINGS, AND TO THAT EXTENT, IT MIGHT  
20 BE HELPFUL TO HAVE THAT AS PART OF THE RECORD AS WELL.

21 SO, NOTWITHSTANDING THAT YOU HAVE NOT OFFERED AN  
22 EXCEPTION THAT I THINK SQUARELY APPLIES, BECAUSE I HAVE READ  
23 IT, I HAVE READ EVERY WORD OF IT, I SEE NO REASON NOT TO ALLOW  
24 IT IN AT THIS TIME, EVEN THOUGH THERE PERHAPS MIGHT NOT BE AN  
25 EXCEPTION THAT APPLIES EXACTLY.

1                   SO I AM GOING TO ALLOW THEM ALL IN AND DECIDE WHAT  
2 WEIGHT TO GIVE THEM.

3                   MS. CLARK: YOUR HONOR, BASED ON YOUR RULING, I  
4 WOULD ALSO MOVE TO ADMIT DR. SHADIGIAN'S ARTICLE AS WELL,  
5 DEFENDANT'S A-56.

6                   IN TERMS OF RELIABILITY, SHE HAS 101 DIFFERENT  
7 REFERENCES. THEY ARE NOT OF THE NEWSPAPER TYPE, KIND OF THING,  
8 SUBSTANTIVE ARTICLES, AND I WOULD MOVE IT INTO EVIDENCE ON THE  
9 BASIS THAT IT IS RELEVANT WITH RESPECT TO THE LONG-TERM  
10 COMPLICATIONS AND THAT IT ALSO WOULD HELP THE COURT IN REACHING  
11 ITS CONCLUSIONS.

12                   THE COURT: I DON'T FIND THAT THE LONG-TERM  
13 COMPLICATIONS, GIVEN THAT THERE HAS BEEN NO DELINEATIONS  
14 BETWEEN ABORTIONS IN THE FIRST- OR SECOND-TRIMESTER OR THE  
15 METHODS USED IS AT ALL HELPFUL TO ME IN THIS REGARD.

16                   SO TO THE EXTENT I HAVE ALLOWED IN DR. SPRANG'S  
17 REPORT, EVEN THOUGH IT DOESN'T SQUARELY FIT UNDER THE RESIDUAL  
18 EXCEPTION, I JUST DON'T SEE THE PROBATIVE VALUE ON THIS ON THE  
19 ISSUES THAT I HAVE TO DECIDE.

20                   SO I CERTAINLY LISTENED TO HER TESTIMONY AND HER  
21 OPINION ON IT, IT'S PART OF THE RECORD AND TO THE EXTENT THAT  
22 OPINION ON LONG-TERM EFFECTS IS IMPORTANT, I CAN RELY UPON  
23 THAT, BUT I AM NOT GOING TO ALLOW HER REPORT IN.

24                   AND THE NUMBERS OF THOSE WILL BE IDENTIFIED. I  
25 WOULD HAVE TO LOOK THEM UP.

1                   CAN YOU PROVIDE ME WITH THE EXHIBIT NUMBERS JUST SO  
2 WE CAN KNOW?

3                   MS. GARTNER: FOR THE DREY STUDIES IT'S EXHIBIT 34,  
4 EXHIBIT 30 AND FOR THE CHASEN STUDY IT IS EXHIBIT 19.

5                   THE COURT: FOR THE SPRANG?

6                   MR. SIMPSON: SPRANG IS A-55, YOUR HONOR.

7                   THE COURT: ALL RIGHT. THOSE FOUR EXHIBITS ARE  
8 ADMITTED AT THIS TIME.

9                   ALL RIGHT. WE ARE -- UNLESS THERE IS ANYTHING ELSE,  
10 WE ARE ADJOURNED UNTIL TOMORROW MORNING AT 8:30.

11                   (PROCEEDINGS ADJOURNED AT 12:48 P.M.)

12                   THE CLERK: EXHIBITS 30, 34, 19 AND A-55 ADMITTED  
13 INTO EVIDENCE.

14

15   (PLAINTIFFS' EXHIBITS 19, 30 & 34

16   RECEIVED IN EVIDENCE)

17   (DEFENDANT'S EXHIBIT A-55

18   RECEIVED IN EVIDENCE)

19

20

21

22

23

24

25

1

2

## I N D E X

3

4 DEFENDANT'S WITNESS:

PAGE

5 SHADIGIAN, ELIZABETH

6 DIRECT EXAMINATION BY MS. CLARK 1187

7 VOIR DIRE EXAMINATION BY MS. KRASNOFF 1212

8 DIRECT EXAMINATION RESUMED BY MS. CLARK 1219

9 CROSS-EXAMINATION BY MS. KRASNOFF 1280

10 REDIRECT EXAMINATION BY MS. CLARK 1330

11

12

13 PLAINTIFFS' EXHIBITS: EVD.

14 19 1342

15 30 1342

16 34 1342

17

18 DEFENDANT'S EXHIBIT: EVD.

19 A-6 1189

20 A-55 1342

21

22

23

24

25